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 Abstract___________________________________________________________________________ 
HIV infection in sub-Saharan Africa is a major public health threat particularly for girls and women of 
reproductive age. The research presented in this thesis was conducted particularly in West Africa and 
the specific objectives are i) to estimate the prevalence of intimate partner violence according to HIV 
serological status; ii) to estimate the incidence rate of pregnancy following ART initiation; iii) to 
determine the effect of pregnancy after ART initiation on the risk of death, HIV-disease progression 
and loss to follow-up. Firstly, in Togo, According to our findings, the prevalence rates of lifetime 
physical and sexual violence (IPV) among HIV-infected women were significantly higher than 
among uninfected women (63.1 vs. 39.3%, p=0.01 and 69.7 vs. 35.3%, p=0.01, respectively). 
Secondly, Among HIV-infected West African women, the crude incidence of first pregnancy after 
ART initiation was 2.9 per 100 women-years [95% confidence interval (CI): 2.7 to 3.0] and it could be 
as high as 4.7 per 100 women-years (95% CI: 4.3 to 5.1) among women aged 25-29 years old. Finally, 
pregnancy after ART initiation appeared to reduce the risk of death or HIV-disease progression 
(Adjusted Hazard Ratio [aHR] =0.61; 95%CI: 0.40-0.92) and the risk of becoming LTFU at M48 
(aHR=0.74; 95%CI: 0.60-0.92) among West African HIV-infected women. Intimate partner violence is 
highly prevalent among HIV-infected women and it may have negative repercussions on their health 
status. Pregnancy is a common event after ART initiation and it might have repercussions on the 
health status of HIV-infected women.  The design of safe motherhood programs addressed to HIV-
infected women and its integration within HIV care services must are a public health priority in sub-
Saharan Africa.  
Résumé____________________________________________________________________________ 
En Afrique sub-Saharienne, les femmes et les filles sont particulièrement vulnérables à l’infection par 
le VIH. L’infection par le VIH est une menace importante pour la santé reproductive de cette 
population. Les études de recherche présentées dans le cadre de cette thèse ont été conduites en 
Afrique de l’Ouest et avaient pour objectifs principaux : i) Estimer la prévalence de la violence 
perpétrée par le partenaire intime selon le statut sérologique ; ii) Estimer l’incidence de grossesse 
après la mise sous traitement antirétroviral ; iii) Déterminer l’effet de la grossesse après la mise sous 
ARV sur le risque de décès, de progression de la maladie à VIH et d’être perdu de vue.  Nos résultats 
nous montrent que la prévalence de violence physique et sexuelle perpétrée par le partenaire intime 
est plus élevée auprès des femmes VIH-positives qu’auprès de celles non-infectées (63,1 vs. 39,3%, 
p=0.01 and 69,7 vs. 35,3%, p=0.01, respectivement). De plus, l’incidence brute globale de première 
grossesse après la mise sous ARV en Afrique de l’Ouest est de 2,9 par 100 femmes-années 
(IC95% :2,7 – 3,0). Auprès des jeunes femmes âgées de 25-29 ans cette incidence peut être de 4,7 
per 100 femmes-années (IC95% :4,3 – 5,1). Finalement, la grossesse après la mise sous ARV réduit 
le risque de décès ou de progression de la maladie à VIH (aHR : 0,61, CI95% : 0,40-0,92) ainsi que le 
risque de devenir perdue de vu (aHR : 0,74 ; CI95% : 0,60-0,92) des femmes ouest-africaines infectées 
par le VIH. La prévalence de violence perpétrée par le partenaire intime est très élevée auprès des 
femmes infectées par le VIH  et cela pourrait entrainer des conséquences négatives de santé de ces 
femmes. La grossesse est un évènement fréquent auprès des femmes VIH positives sous ARV qui a 
des répercussions importantes sur le statut de santé des femmes séropositives. L’intégration des 
programmes de prise en charge maternelle dans les services de prise en charge du VIH doit être 
priorisé en Afrique sub-saharienne.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Résumé en français 
Historique épidémiologique de la féminisation de l’épidémie de VIH au niveau mondial__ 
L’épidémie du virus de l’immunodéficience humaine (VIH) est considérée parmi les plus 
grandes catastrophes de santé publique de l’histoire de l’humanité. Depuis son apparition, 
75 millions de personnes ont acquis l’infection par le VIH et l’infection par ce virus a été 
responsable de 36 millions de décès au niveau mondial. Trente ans depuis le premier cas 
confirmé de VIH et malgré les grands efforts déployés pour ralentir la progression de 
l’épidémie, un nombre important de nouvelles infections sont rapportées encore chaque 
année et le VIH est encore une cause majeure de décès dans le monde. 
En 2013, Il a été estimé qu’un total de 35,3 millions de personnes vivaient avec le VIH au 
niveau mondial, et parmi elles 2,3 millions avaient nouvellement acquis l’infection au cours 
de cette année. L’Afrique sub-saharienne, hébergeant environ trois quarts de la population 
vivant avec le VIH au niveau mondial, est la région du monde la plus touchée par la 
pandémie. Ainsi, en 2013, le nombre de personnes vivant avec le VIH dans cette région du 
monde s’élevait à 23,5 millions. En Afrique sub-Saharienne, pendant cette même année, 
environ 1,6 millions de nouvelles infections par le VIH ont été diagnostiquées, soit 70% du 
total des nouvelles infections par le VIH au niveau mondial.  
Au début de l’épidémie, les hommes étaient la population la plus affectée par le VIH, 
essentiellement ceux qui entretenaient des relations sexuelles avec d’autres hommes. Puis 
le visage de l’épidémie a changé, sa propagation ne se limitant plus aux seuls homosexuels 
masculins, et la distribution par genre de l’épidémie s’est ainsi ensuite inversée à partir de la 
fin du dernier siècle. On a ainsi commencé à parler d’une féminisation de l’épidémie 
d’infection par le VIH.  
Cette féminisation de l’épidémie d’infection par le VIH était tout particulièrement marquée 
en Afrique sub-Saharienne où 60% de la population vivant avec le VIH était constituée des 
femmes. Cette prévalence était d’autant plus élevée auprès des jeunes âgées entre 15 et 24 
ans vivant avec le VIH, parmi lesquels les femmes représentaient 75%. Au début des années 
2000, les jeunes femmes africaines âgées entre 15 et 24 ans avaient une probabilité d’être 
infectée par le VIH huit fois plus élevé que n’importe quelle autre population du même âge 
au niveau mondial. L’épidémie à VIH est ainsi un problème majeur de santé publique en 
 Afrique sub-saharienne, et ce tout particulièrement pour les jeunes femmes et les femmes 
en âge de procréer. 
Contexte actuel mondial de l’épidémie d’infection à VIH___________________________ 
Au cours des dernières années, des avancées scientifiques considérables ont permis de 
contrôler puis réduire l’expansion de cette épidémie. Des réductions importantes des taux 
d’incidence ont notamment été observées dans les contextes les plus touchés par la 
pandémie. L’expansion à l’échelle universelle de l’accès aux médicaments antirétroviraux a 
permis aux personnes vivant avec le VIH d’améliorer considérablement leur espérance de 
vie, leur qualité de vie et de réduire leur infectiosité à leurs partenaires sexuels.  
Cependant et malgré tous ces avancés, l’Afrique sub-saharienne reste toujours la région du 
monde la plus touchée par l’épidémie de VIH. De même, les femmes en âge de procréer 
constituent toujours la population la plus vulnérable à acquérir ce virus dans le contexte 
africain. De plus, les femmes se trouvent au carrefour de la transmission du virus, tant étant 
les plus vulnérables à acquérir l’infection par le VIH par voie sexuelle, mais aussi tout en 
étant le véhicule de l’épidémie pédiatrique par la voie verticale.  
En termes de santé publique, les femmes enceintes infectées par le VIH ont été la cible d’un 
nombre important d’interventions préventives. Ces interventions ont été dirigées 
notamment vers la réduction du risque de transmission du VIH de la mère à l’enfant pendant 
la grossesse, autour de l’accouchement et au cours de la pratique de l’allaitement maternel. 
Néanmoins, l’effet du traitement antirétroviral sur la santé sexuelle et reproductive des 
femmes vivant avec le VIH en âge de procréer a été peu étudié, et ce tout particulièrement 
dans le contexte de l’Afrique de l’Ouest.  
Vulnérabilité des femmes face à l’infection par le VIH_______________________________ 
Les femmes ont ainsi une vulnérabilité particulièrement élevée d’acquérir l’infection par le 
VIH. Cette vulnérabilité des femmes face à l’acquisition de ce virus a été expliquée par une 
conjonction de facteurs de risque d’ordre à la fois biologique et psychosocial.  
La configuration anatomique des organes génitaux féminins ainsi que les mécanismes 
d’action des hormones sexuelles féminines sur ces organes sont des facteurs biologiques 
majeurs associés à un risque plus élevé de contracter l’infection par le VIH. 
 Certains facteurs psychosociaux comme par exemple l’éducation ont été ainsi associés à une 
vulnérabilité des femmes à acquérir l’infection par le VIH. L’accès à l’éducation permet aux 
individus de développer des capacités cognitives leur permettant de mieux saisir les 
messages préventifs et de les intégrer à leurs pratiques d’une manière plus efficace. Il a aussi 
été souligné que pour les femmes en particulier, le fait d’avoir des attentes professionnelles 
bien définies réduit le risque de rapports sexuels non protégés, tout en évitant le risque des 
grossesses non-planifiées et ainsi par ricochets le risque d’acquérir des infections 
sexuellement transmissibles (IST) tels que le VIH. 
Cependant, dans des milieux où l’accès à l’éducation n’est pas universel, les femmes sont 
parfois contraintes à s’orienter vers le mariage comme une manière d’assurer leur avenir 
et/ou leur statut social. On observe ainsi qu’en Afrique sub-saharienne, pour des raisons 
culturelles ou économiques, les femmes ont tendance à choisir des hommes plus âgés 
qu’elles. Ceci a des conséquences directes sur la dynamique d’acquisition de l’infection par 
le VIH, puisqu’il a été estimé que les femmes en couple avec des hommes âgés d’au moins 
cinq ans de plus qu’elles ont un risque plus élevé de contracter l’infection par le VIH au sein 
de leur couple. Ce risque plus élevé est expliqué d’une part par le fait que chez les hommes, 
la probabilité d’être infecté par le VIH augmente proportionnellement avec leur âge, et 
d’autre part, par la capacité limité des jeunes femmes de négocier des rapports sexuels 
protégés avec leurs partenaires plus âgés. Finalement, le déséquilibre dans les rapports de 
pouvoir, fréquemment retrouvé dans ces types de relations, peuvent même in fine inciter à 
des actes de violence envers la femme.  
Il a ainsi été estimé que, de toutes les formes de violence envers les femmes, la violence 
perpétrée par le partenaire intime est la forme la plus fréquente. Selon les résultats d’une 
enquête conduite par l’Organisation Mondiale de la Santé, les prévalences globales de 
violence physique et sexuelle perpétrée par le partenaire intime peuvent être aussi élevées 
que 61% et 59% respectivement. 
De plus, ces actes de violence perpétrés par le partenaire intime sont  associés à des 
conséquences néfastes pour la santé physique et mentale des femmes, comme par exemple 
celui de contracter l’infection par le VIH. Il a ainsi été estimé que les femmes victimes de 
 violence de la part de leur partenaire intime ont 55% plus de risque d’acquérir l’infection par 
le VIH.  
Par ailleurs, il a été suggéré que les femmes séropositives au VIH ont un risque plus élevé 
d’être victimes de violence physique et sexuelle de la part de leur partenaire intime. 
Cependant, même si un nombre important d’études ont estimé la prévalence de violence 
physique et sexuelle perpétrée par le partenaire intime en Afrique sub-saharienne, cette 
prévalence est peu connue en Afrique de l’ouest, notamment auprès des femmes infectées 
par le VIH. 
Incidence de grossesse après l’initiation du traitement antirétroviral___________________ 
L’accès universel aux antirétroviraux a amélioré considérablement le statut de santé des 
individus infectés par le VIH. Cette amélioration significative de la qualité et de l’espérance 
de vie a changé sans doute leur avis sur la procréation suite à la découverte de leur statut 
vis-à-vis de l’infection par le VIH. Les études les plus récentes montrent que, même si la 
proportion d’individus infectés par le VIH rapportant un désir positif de procréation est 
inférieure à celle des individus non-infectés, ce désir est présent et persistant, et ce tout 
particulièrement auprès des personnes sous traitement antirétroviral. Auprès des femmes 
infectées par le VIH, l’âge apparait comme un facteur majeur associé au désir positif de 
procréer. Le désir de procréation diminue proportionnellement avec l’âge biologique des 
femmes. Chez ces mêmes femmes,  le fait d’être en couple prédit le désir positif de procréer.  
La grossesse n’est pas un évènement rarement détecté auprès des femmes infectées par le 
VIH. Selon la littérature scientifique récente, même si l’incidence de grossesse auprès des 
femmes infectées par le VIH reste au global inférieure à celle observée chez les femmes non-
infectées, cet indicateur épidémiologique reste élevé auprès des femmes infectées sous 
traitement antirétroviral. De plus,  plusieurs études soulignent que cette incidence de 
grossesse après la mise sous traitement antirétroviral augmente proportionnellement avec 
le temps passé sous traitement. Ce phénomène suggère un potentiel effet positif du 
traitement antirétroviral sur les fonctions reproductives.  
L’incidence de grossesse a été documentée chez les femmes infectées par le VIH dans 
plusieurs études scientifiques menées en Afrique sub-saharienne, et les taux rapportés 
 allaient de 4,4 jusqu’à 24,6 grossesses pour 100 femmes-années. Néanmoins, en Afrique de 
l’ouest, l’incidence de grossesse auprès des femmes infectées par le VIH suite à la mise sous 
traitement ARV a été très peu documentée, et ce tout particulièrement depuis le passage à 
l’échelle des traitements antirétroviraux. .   
Mortalité maternelle et infection par le VIH______________________________________ 
Etant donné que la grossesse n’est pas un événement isolé après la mise sous traitement en 
Afrique, on peut se demander si la grossesse peut entrainer un effet négatif sur la santé des 
femmes infectées par le VIH et traitées.  
On sait déjà que l’infection par le VIH a été identifiée comme une cause majeure de 
mortalité maternelle puisque  les femmes enceintes infectées par le VIH ont huit fois plus de 
risque de décéder que leurs analogues non-infectées. Cependant, les résultats des études 
menées en Afrique sub-saharienne ayant pour objectif d’explorer l’association de la 
grossesse avec la mortalité et la progression de la maladie à VIH sont contradictoires et ne 
permettent pas de conclure à la question posée. Ainsi, certaines études menées en Afrique 
australe concluent que la grossesse suite à la mise sous traitement antirétroviral apparait 
comme un facteur protecteur contre le risque de décéder ou de  progresser dans la maladie 
à VIH, tandis que d’autres études menées en Afrique de l’est mettent en évidence un risque 
plus élevé de décéder associé à la survenue de grossesse après la mise sous traitement. 
Cette question de recherche n’a pas été explorée en Afrique de l’ouest jusqu’à présent. 
Objectifs de thèse____________________________________________________________ 
La recherche conduite dans mon parcours doctoral porte sur l’étude de la vulnérabilité de la 
femme africaine face à l’épidémie de VIH en s’intéressant notamment aux problématiques 
des violences perpétrées par le partenaire intime, de l’incidence des grossesses dans un 
contexte d’accès aux traitements antirétroviraux  et aux répercussions de la grossesse suite à 
la mise sous traitement sur la santé maternelle. Les objectifs principaux de mon parcours 
doctoral étaient donc les suivants : 
1. Estimer la prévalence de violences physiques et sexuelles perpétrées par le 
partenaire intime auprès des femmes infectées par le VIH au Togo ; 
 2. Estimer l’incidence de grossesse auprès des femmes infectées par le VIH sous 
traitement antirétroviral dans huit pays d’Afrique de l’Ouest ; 
3. Etudier l’association entre la grossesse et le risque de décès, de progression de la 
maladie à VIH et d’être perdue  de vue dans huit pays d’Afrique de l’Ouest. 
Objectif 1. Vulnérabilité des femmes face à l’infection par le VIH : Prévalence de violences 
physiques et sexuelles selon le statut sérologique VIH auprès des femmes togolaises_____ 
Nous avons conduit une étude qui a eu pour objectif d’estimer la prévalence de violences 
physiques et sexuelles auprès des femmes selon le statut sérologique du VIH. Cette étude a 
été conduite à Lomé au Togo . Nous avons enquêté un total de 454 femmes (150 femmes 
VIH négatives et 304 femmes VIH positives). Dans cette étude, la prévalence de violence 
physique et sexuelle perpétrée par le partenaire était significativement plus élevée chez les 
femmes infectées par le VIH qu’auprès des femmes non-infectées (63,1 vs. 39,3%, p=0,01 et 
69,7 vs. 35,3%, p=0,01, respectivement). De plus cette étude a montré aussi que 
indépendamment du statut sérologique VIH, un risque plus élevé de violence était associé 
avec le fait d’avoir un partenaire ayant plusieurs partenaires sexuels et avec pour les femmes 
une entrée précoce dans la vie sexuelle.  
Cette étude nous a permis de conclure en soulignant que même si la violence physique et 
sexuelle perpétrée par le partenaire intime est globalement élevée au Togo, elle est d’autant 
plus élevée auprès des femmes infectées par le VIH. Ces résultats soulèvent l’importance 
d’évaluer systématiquement le risque de violence auprès des femmes infectées par le VIH 
dans les services de prise en charge du VIH. 
Objectif 2. Incidence de grossesse suite à la mise sous traitement antirétroviral et ses 
facteurs associés dans huit pays de l’Afrique de l’Ouest. 
Cette étude a été conduite dans le cadre de la collaboration IeDEA West-Africa qui est 
conduite dans huit pays d’Afrique de l’Ouest. La population de cette étude a été constituée 
de toutes les femmes ayant moins de 50 ans à la mise sous traitement et ayant initié le 
traitement antirétroviral entre 1998 et 2011.  
Un total de 29.425 femmes VIH-positives sous traitement antirétroviral ont été incluses dans 
l’analyse et leur âge moyen était de 33 ans (IQR : 28-38) à l’inclusion. Cette population a 
contribué à 84.870 femmes-années de suivi. L’incidence brute de première grossesse était 
 de 2,9 pour 100 femmes-années (ICà95% : 2,7 – 3,0). L’incidence de grossesse auprès des 
femmes âgées en 25 à 29 ans à la mise sous traitement était de 4,7 pour 100 femmes-
années de suivi (ICà95% : 4,3 – 5,1). La probabilité de tomber enceinte au cours des quatre 
premières années de suivi était de 10,9% (ICà95%: 10,4 – 11,4) au global. Chez les femmes 
âgées entre 20 et 29 ans au moment de l’initiation du traitement antirétroviral, cette 
probabilité était de 28,4% (ICà95% : 26,3 – 30,6). 
Les résultats de cette étude nous permettent de constater que l’incidence de grossesse 
après la mise sous traitement est élevée, notamment auprès des femmes de moins de 30 
ans à la mise sous traitement. Elle souligne tout particulièrement les manques en soins de 
santé sexuelle et reproductive dans le contexte ouest-africain.   
Objectif 3. Association de la grossesse après l’initiation du traitement antirétroviral la 
rétention dans les soins, la progression de la maladie à VIH, le risque de décès et la 
réponse immunologique en Afrique de l’Ouest_____________________________________ 
Cette étude a été conduite sur une base de données rétrospective issue de la cohorte IeDEA 
West Africa. Dans l’analyse nous avons inclus toutes les femmes âgées de moins de 50 ans, 
ayant initié leur traitement antirétroviral pour leur propre santé sur une période de dix ans. 
L’effet de la grossesse (variable dépendante du temps) sur la mortalité à 48 mois de 
l’initiation du traitement, la progression de la maladie et la perte de vu a été estimé à partir 
des modèles de Cox. Pour cette première analyse toutes les femmes ayant initié un 
traitement pendant la grossesse ou présentant un stade SIDA au moment du diagnostic de 
l’infection par le VIH ont été exclues. Dans une deuxième analyse, le gain moyen de 
lymphocytes CD4 durant les 24 premiers mois après l’initiation du traitement antirétroviral a 
été estimé à partir d’un modèle linéaire mixte. 
Pour la première analyse un total de 12.851 femmes VIH positives ont été retenues, parmi 
lesquelles 864 (6,7%) ont reporté au moins une grossesse dans les 48 mois qui suivaient la 
mise sous traitement antirétroviral. Parmi les femmes étant tombées enceintes, 15,2% avait 
progressé vers un stade SIDA ou été décédées et 8.3% étaient perdues de vu. Parmi les 
femmes n’étant jamais tombées enceintes pendant la période d’étude, 12,7% avait 
progressé vers un stade SIDA ou étaient décédées et 24,8% étaient perdues de vue. Suite à 
un ajustement sur le niveau de CD4 au moment de l’initiation du traitement, l’âge, l’index de 
 masse corporel et l’hémoglobine, la grossesse réduisait le risque de progression de la 
maladie ou de décès (aHR : 0,61 ; ICà95% : 0.40-0.92) et le risque d’être perdu de vue (aHR : 
0,71 ; ICà95:0,40 -0,92). 
Pour la deuxième analyse, un total de 20.408 femmes VIH-positives ont été retenues, parmi 
lesquelles 1.561 (6,2%) avait reporté au moins une grossesse dans les 24 mois qui suivaient 
la mise sous traitement antirétroviral. Le gain moyen de lymphocytes CD4 entre la mise sous 
traitement et le vingt-quatrième mois après la mise sous traitement était significativement 
plus élevé parmi les femmes qui avaient rapporté une grossesse pendant les six premiers 
mois après la mise sous traitement par rapport à celles qui ne sont pas tombées enceintes 
au cours de la même période 
Conclusion__________________________________________________________________ 
Les résultats des études conduites dans le cadre de mon parcours doctoral m’ont permis de 
constater premièrement que la violence physique et sexuelle est un phénomène très 
répandu en Afrique de l’Ouest. Ces résultats montrent aussi que ce phénomène est d’autant 
plus fréquent auprès des femmes séropositives. Cette étude est la première étude de type 
épidémiologique menée dans la région mesurant la prévalence des violences physiques et 
sexuelles auprès des femmes séropositives. Cependant, le schéma d’étude transversal nous 
permettant de mesurer la prévalence des violences, est une limite majeure pour induire 
l’association causale de ce phénomène et l’infection par le VIH en Afrique de l’Ouest. 
J’ai pu constater également que la grossesse n’est pas un évènement rare auprès des 
femmes ouest-africaines infectées par le VIH suite à la mise sous traitement antirétroviral. 
Cette incidence augmente proportionnellement avec le temps de mise sous traitement 
antirétroviral et elle est d’autant plus élevée auprès des femmes âgées de moins de 30 ans à 
la mise sous traitement. De même, nous avons constaté que la survenue d’une grossesse 
après la mise sous traitement antirétroviral n’est pas associée à une augmentation du risque 
de décéder, de progresser dans la maladie à VIH ou d’être perdu de vue. De plus, la 
grossesse parait bien avoir des répercussions sur la réponse immunologique des femmes 
infectées par le VIH, mais ces répercussions ne semblent pas négatives. Ces études sont les 
premières menées dans la région Ouest-africaine estimant l’incidence de grossesse et les 
répercussions de celle-ci sur la santé de la femme infectée par le VIH après la mise sous 
 traitement antirétroviral. Cependant, l’interprétation de ces résultats est limitée par le fait 
que dans la base de données régional IeDEA West-Africa, les grossesses ne sont pas 
répertoriées exhaustivement et celles qui sont répertoriées ne sont pas complètement 
documentées. Au-delà de ce parcours doctoral, j’entends maintenant continuer mes 
recherches sur cette thématique, en construisant dans le cadre de mon post-doctorat une 
véritable cohorte prospective qui me permettra de limiter ces biais.  
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1. Introduction 
In the history of humanity, the epidemic of Human Immunodeficiency Virus (HIV) has been 
the most devastating health catastrophe so far. Since the beginning of the epidemic, almost 
75 million people have been infected with the HIV virus and about 36 million people have 
died of HIV worldwide(1). No region in the world has been spared, and HIV has become the 
most globalized epidemic in human history.  
Despite the massive global effort deployed to stop and hold back the progression of the 
epidemic, HIV claims still for an important number of new infections every year and remains 
one major cause of death. Current estimations point out that roughly 35.3 million people are 
living with HIV worldwide and around 2.3 million of new infections occurred during last year 
2013(2). Although the number of death has considerably declined during last years since the 
roll-out of antiretroviral therapy (ART), HIV infection is still responsible for 1.7 million deaths 
every year worldwide(2). 
Although HIV epidemic is considered major global health challenge, it has impacted deeply 
and negatively resource-limited settings. Sub-Saharan Africa, the most impoverished region 
of the world has been particularly ravaged by HIV epidemics, hosting the vast majority of 
HIV-infected individuals. Additionally to the biological factors linked to transmission, the 
deep inequality at structural, societal and individual levels were major contributors to the 
rapid and large spread of the epidemic in this region of the world. 
In the cusp of the fourth decade of its debut and despite the huge effort delivered to control 
its progression, HIV remains one major public health challenge, particularly in low-middle 
income countries and, one major barrier to achieve Millennium Development Goals within 
these contexts(3, 4). Although one of the Millennium Development Goals (Goal 6) 
specifically addresses the HIV epidemic, it is believed that an effective HIV response will also 
support the achievement of other Millennium Development Goals (3) 
During the early days, HIV epidemic was delimited to certain specific vulnerable groups of 
the population with particularly risky behaviors, such as men who have sex with men and 
injecting drugs users, but it rapidly spread out to general population. Although across the 
years HIV epidemic became generalized, during last decade, women started to hold an 
increasing burden of the epidemic, particularly in sub-Saharan Africa(5). Indeed, current 
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epidemiological estimations point out that in sub-Saharan Africa 60% of all infected 
individuals are women(6). Paramount of this is that the highest burden of HIV epidemic 
among women population is hold by girls and younger women (15 – 24 years old), who 
represent 75% of all HIV-infected women population(6). 
Moreover, women of reproductive age are located at the crossroads of HIV transmission, not 
only participating at HIV sexual transmission through heterosexual intercourses but being 
the vehicle of the vast majority of pediatric HIV infections through vertical transmission. 
Although the coverage of effective antiretroviral regimens for preventing mother-to-child 
transmission has improved in low and middle-income countries, vertical transmission of the 
virus is still a major threat for the mothers and children who do not access such 
interventions(7).  
In addition, HIV infection is recognized as a leading indirect cause of maternal and child 
mortality(5, 8). Ensuring a mother living with HIV has access to HIV treatment not only has 
benefits for her, but also for her family. Studies indicate that children whose mothers stay 
alive and healthy have a decreased risk of death regardless of the child’s HIV status(2). Thus, 
tackling HIV epidemic among women of reproductive age is recognized as a global health 
priority. There is now an urgent need for creating updated action plans aiming at eradicating 
HIV pediatric infections through a more holistic approach, targeting women health and 
motherhood in its whole spectrum. 
Since 2011, global community embraced optimistically the goal of eliminating new HIV 
pediatric infections by 2015. This goal was established within a global action plan which, 
besides preventing new HIV pediatric infections, also aims at reducing the excess of 
maternal mortality due to HIV infection(9). Based on four pronged-strategies, this global 
action plan aimed at providing the foundation from which national plans will develop, 
implement and encompass a range of HIV prevention and treatment measures for mothers 
and their children. These preventive measures are coupled with essential maternal, newborn 
and child health services as well as family planning as an integral part of countries efforts to 
achieve Millennium Development Goal 4 and 5(9, 10). 
However, more scientific knowledge is needed to correctly deliver this four-pronged 
strategy.  Together with the outstanding improvement of life expectancy owed to ART, a 
growing desire of childbearing has been documented among HIV-infected individuals. The 
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reproductive dynamics among HIV-infected women following the initiation of ART are not 
completely understood and research on these purposes is dearth. Thus, further research is 
needed in order to propose safe reproductive strategies for HIV-infected individuals willing 
to procreate.   
The research framework of this thesis will firstly introduce the epidemiological and 
psychosocial context of HIV epidemics among women. The main focus will be done on sub-
Saharan Africa and particularly West-Africa, which was the research field of the present 
work.  
Secondly, I’ll present a discussion on the subject of vulnerability to acquire HIV infection; 
focusing in particular on specific vulnerability of sub-Saharan Africa women. This section will 
be closed with an insight on gender-based violence, specifically intimate partner violence, 
which was the subject of the first peer-reviewed article I present within this doctoral 
research framework.  
The aim of the second section is to introduce the subject of sexual and reproductive health 
among HIV-infected women in sub-Saharan Africa. This chapter will start with a brief 
discussion about current public health challenges in terms of mother-to-child transmission of 
HIV, to be followed by an insight about sexual and reproductive dynamics among HIV-
infected women. The sexual and reproductive dynamics will be presented under an 
epidemiologic perspective, discussing current trends on fertility intentions among people 
living with HIV/AIDS, and incidence rates of pregnancy among HIV-infected women on ART. 
This insight will appear together with a second peer-reviewed article aiming at estimating 
incidence rates of pregnancy following ART initiation in eight West African countries. 
The last chapter of my doctoral framework will focus on repercussion of pregnancy on HIV-
infected women’s health outcomes. The aim of this chapter is to discuss the repercussion of 
pregnancy on AIDS disease progression and death among HIV-infected women. One last 
peer-reviewed scientific article related to former subject will close this chapter. 
The present doctoral research framework will be closed with the discussion of my findings 
and methodology under the perspective of existing scientific evidence. As a conclusion, I’ll 
present my post-doctoral research perspectives. 
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2. Global background of HIV epidemic  
At the end of 20st century, it was estimated that around 34.3 million people were living with 
HIV/AIDS worldwide(11). Although by this time, HIV epidemic had already reached a global 
size breadth, the burden of the epidemic varied across the regions worldwide. Roughly 70% 
of all HIV-infected individuals worldwide were living in sub-Saharan Africa, region holding 
the highest burden of the epidemic (11). Indeed, rapid spread of HIV pandemic together 
with its lethal consequences constituted a major menace in terms of global security.  In 
order to roll back HIV pandemic, the global community mobilized an unprecedented amount 
of human and economic resources. 
Ten years later of this outstanding mobilization, the epidemiologic profile of HIV epidemic is 
less grim. According to current estimations, the number of new infections has significantly 
declined within a ten years period. In 2012, there were 2.3 (1.9 – 2.7) million of new HIV 
infections worldwide, representing a decline of 33% of global incidence rate, which was of 
3.4 (3.1 – 3.7) million of new infections in 2001(7). Recent estimations show as well that the 
decline of HIV epidemic was even steeper in 25 low-and-middle income countries where the 
prevalence rate of HIV infection was of roughly 50% (2). This decline of incidence rate of HIV 
infection is undoubtedly a result of the great human, economic and political effort deployed 
worldwide against the pandemic, particularly during last decade towards slowing down the 
spread of HIV epidemic.  
Moreover, the increasing access to antiretroviral treatment has impacted positively life 
expectancy of HIV-infected individuals, reducing significantly the AIDS-related morbidity and 
mortality. In 2012, 1.6 (1.4 – 1.9) million people died from AIDS-related causes worldwide 
compared to 2.3 (2.1 – 2.6) million in 2005(7). Within a seven year period mortality rate of 
AIDS-related causes declined of roughly 30%(7).This important decline of AIDS-related 
deaths is owed to the increasing access to life-saving antiretroviral drugs.  
The important improvement of life expectancy of HIV-infected individuals owed to 
antiretroviral therapy together with the relative decline of the number of new HIV-
infections, both have provoked a slightly increase of the global HIV-epidemic. In 2012, 35.3 
(32.2 – 38.8) million people were living with HIV worldwide compared to the 30.0 (27.2 – 
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33.1) millions estimated in 2001. However, despite the impressive achievements in rolling 
back HIV pandemics at a global level, important geographic disparities remain.  
2.1. HIV epidemic in sub-Saharan Africa 
Within the last decade, several regions have got to reduce importantly the spread of HIV 
infection, stabilizing their local epidemic. Nevertheless, for sub-Saharan Africa 
epidemiological trends remained almost unchanged and as shown in figure 1, this region 
host still the vast majority of HIV-infected individuals (7). 
 
According to currents estimations, 70% of the global population infected with HIV lives in 
sub-Saharan Africa. Indeed, in 2012, 25.0 million [23.5 million – 26.6 million] people are 
living with HIV/AIDS in this region, among these 2.9 million [2.7 million – 3.3 million] are 
children (2). Although the number of new infections among adults has observed decline of 
34% since 2001; 1.6  million [1.4 million – 1.8 million]of new HIV infections occurred in sub-
Saharan Africa in 2012, representing almost three thirds of all new infections worldwide of 
these year(7, 12). 
Figure 1.  Global distribution of the number of people living with HIV/AIDS.  
(Source: AIDS info. 2013: http://www.unaids.org/es/dataanalysis/datatools/aidsinfo/) 
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In addition, although AIDS-related mortality in sub-Saharan Africa decreased of more than 
half in 2012 (1.2 million AIDS-related deaths; 95%IC: [1.1 million – 1.3 million]) compared to 
the peak of mortality observed in this region in 2005 (2.1 million AIDS-related deaths; 
95%IC:[1.8 million – 2.4 million]), the AIDS-related mortality in this region is higher than any 
other region worldwide (7, 13). Undoubtedly, the burden of HIV epidemic in sub-Saharan 
Africa is the highest worldwide 
Even though, although HIV infection seems not to discriminate gender or age and, the 
epidemic is considered generalized, at the beginning of 21st century a particular trend 
emerged. Owed to specific biologic and context-related factors, the spread of the epidemic 
started to be more aggressive among women, particularly young women and girls. This 
particular epidemiologic trend is described in the next chapter. 
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2.2. Global picture of HIV epidemic during first decade of 21st 
century: A feminized pandemic 
2.2.1. Epidemic overview 
According to epidemiologic estimations, in the early days of HIV epidemic, men largely 
outnumbered women among people living with the virus worldwide(12). However, at the 
beginning of the present century, epidemiologic trends turned drastically over and HIV 
infection started to become a real health threat for women, particularly for girls and women 
of reproductive age.  
During early 2000s, prevalence rates of HIV infection were importantly high worldwide and 
the progress of the pandemic was very aggressive. By this time, besides several countries 
that were facing epidemics confined to specific risk groups, HIV pandemic was declared 
generalized (12). However, although epidemic trends pointed out men as the most affected 
population worldwide, the proportion of females infected by HIV worldwide started to 
increase steadily(12).  
As shown in figure 2, by 2004, of the almost 36 million of adults and children living with 
HIV/AIDS worldwide, 17 million were women(14). Although the burden of HIV infection was 
slightly higher among men worldwide; nearly the half of all people infected with HIV 
between ages of 15 to 49 years old worldwide were women.  
Figure 2. Estimated number of adult (age 15 to 49) women (red) and men (black) living with 
HIV/AIDS by region from 1985 to 2003 (Source: UNAIDS/WHO 2004). 
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At the beginning of the century, even in high income countries where, the wide availability 
of antiretroviral treatment and  the implementation of effective preventive measures the 
HIV epidemic was thought to be under control, among adults, the percentage of women 
living with HIV/AIDS was rising. In North America, 25% of all people living with HIV/AIDS 
were women; this figure represented an increase of 5% of prevalence rate between 2001 
and 2003. Similarly, by this time, in Western Europe epidemiologic estimations pointed out 
that one out of four HIV-infected individuals was a women(14).  
This gender trend of HIV epidemic was even more remarkable in low-and-middle income 
settings. In Latin America 36% of all HIV-infected individuals were women and this figure was 
as high as 50% in the Caribbean(14). In South and South-East Asia, women represented more 
than a quarter of overall HIV-infected adults of this region and 40% of overall young people 
aged 15 to 24 living with HIV/AIDS (14). Moving more to the West, although somewhat 
higher, women represented a 33% of all the adult population living with HIV/AIDS in Central 
Asia and Eastern Europe(14).  
The paramount figure of this disastrous gender trend of HIV epidemic was sub-Saharan 
Africa. In Sub-Saharan Africa, setting reporting the highest epidemic burden worldwide, the 
progress of HIV epidemic among young girls and women was rampant. In 2004, nearly 60% 
of all people living with HIV/AIDS in sub-Saharan Africa were women, and 75% of infected 
individuals between ages of 15 and 24 years old were young women and girls(15). Indeed, 
HIV epidemic in sub-Saharan Africa, besides being generalized, it was also “feminized”.  
As shown in figure 3, since early nineties the number of people living with HIV in sub-
Saharan Africa started to be outnumbered by women. By early 2000s, the half of the 
population living with HIV in sub-Saharan Africa were women (16). In 2002, on average, for 
every 10 infected men there were 13 HIV-infected women in this region. This proportion was 
more pronounced in urban areas, with 14 women for every 10 men, than in rural areas, 
where this relation was of 12 women for every 10 men (14).  Alarmingly, this figure was even 
more pronounced among young people aged 15-24 years old. In South Africa for example 
among people, for every 10 men aged of 15 to 24 years old infected with HIV there were 20 
women of the same age. In Kenya and Mali, this proportion was even worse, for every 10 
men there were 45 women(14). 
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Figure 3. Estimated number of adult (age 15 to 49) women (red) and men (black) living with HIV/AIDS 
in sub-Saharan Africa over time (1985-2003). (Source: Quinn, T et al, Science 308, 1582 
(2005). UNAIDS 2004) 
HIV prevalence worldwide was indeed largely outnumbered by women and, this trend was 
particularly true for sub-Saharan Africa. In this region, women accounted already for more 
than half of the HIV infected population in certain settings and the risk of acquiring the 
infection appeared to be outstandingly high among young women. The term “gender factor” 
referring the manifest phenomenon of feminization of the HIV pandemic was used by the 
first time in 2004 by UNAIDS (14).  
Although by the end of the first decade of 21st century HIV epidemic started to reach a 
relative stability worldwide, this gender trend remained. In 2010, 34 million [31.6 – 35.2] of 
people were living with HIV/AIDS worldwide and among these 50% were women and 
girls(17). Sub-Saharan Africa was still the most affected region worldwide with an overall 
population of people living with HIV of 22.9 million. Women represented 59% of the overall 
population living with HIV in sub-Saharan Africa(17). 
20 
 
More recent estimations underscored that this gender imbalance was became still more 
pronounced among young people aged 15 – 24 years old.  By 2013, young women make up 
more than 60% of all young people living with HIV globally and in sub-Saharan Africa this 
proportion can be as high as 72% (figure 4) (9, 18-20).  
 
 
The risk of acquiring HIV infection among sub-Saharan Africa women was higher than any 
other group of women worldwide (16). Alarmingly, this risk ratio was strikingly higher among 
African girls and young women. In several sub-Saharan countries, women aged 15 to 24 
years old were three to six times more likely to be infected by HIV than men of the same age 
group (15, 21).  
Even if HIV transmission is a merely biological event, its spread does not occurs necessarily 
randomly and is profoundly influenced by the surrounding social, economic and political 
environment(14). It is well known that the higher risk of acquiring HIV infection presented by 
women resulted of a sum of biological factors and social factors (explained more in detail in 
chapter 2)(12). Biological factors are more related to women’s biological constitution but 
social factors are context-dependent and are more related to the ubiquitous gender 
disparities prevailing worldwide, particularly in low-and-middle income settings. These 
gender disparities are distributed at the structural, societal and individual levels (13). 
Figure 4. Estimated number of young people aged 15–24 living with HIV, 2009. 
(Source: UNAIDS/UNICEF 2013). 
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2.2.2. Risk of transmission 
Besides the major health risk HIV infection represents for women, there is also the known 
risk of HIV transmission to their children, carrying therefore important disastrous 
consequences for the family. The transmission of HIV from an infected mother to her child 
can occur during pregnancy, labor, delivery or breastfeeding. In the absence of any 
preventive intervention transmission rates ranges from 15 – 45%(22). This transmission rate 
can be reduced by 5% with effective biomedical interventions but their limited availability 
make of mother-to-child transmission an important mechanism fueling HIV epidemic among 
children (22). Nearly all young children newly infected with HIV are infected through mother-
to-child transmission.  
In 2005, 470 000 [430 000 – 510 000] children acquired HIV infection from their mothers 
through vertical mechanisms(22). Although during the last years a great reduction of the 
mother-to-child transmission rate of HIV has been achieved, an important number of 
children acquire HIV infection from their mothers. In 2013, 1 260 000 [1 170 000–1 360 000] 
pregnant women were living with HIV worldwide, transmission rate of HIV from mother to 
child by this year was of 16% [13 – 18%], estimated number of HIV infected children 200 000 
[170 000–230 000] worldwide, from which 89% live in sub-Saharan Africa(22). 
2.2.3. Risk of morbidity and mortality 
Recent estimations point out that HIV-infection is a source of great morbidity and mortality 
for women of reproductive age. Tuberculosis, one leading cause of death among HIV 
infected individuals is highly prevalent among HIV-infected women(23). In 2012, 160 000 
HIV-infected women died of tuberculosis, representing 50% of all TB-related deaths among 
HIV-positive people(23). It is noteworthy that almost 90% of overall HIV-associated 
tuberculosis deaths among women were in sub-Saharan Africa. Moreover, a positive 
diagnosis of tuberculosis for a HIV-positive pregnant women is associated with more than 
double the risk of mother-to-child transmission of HIV to the unborn child and increases the 
risk of maternal and infant mortality by almost 300%(23). 
Currently, HIV-infection has been pointed out as the leading indirect cause of maternal 
mortality in high prevalence settings. The fraction of maternal deaths attributable to HIV 
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infection in sub-Saharan Africa is as high as 28% (24). HIV infected women are eight times 
more likely to die of maternal causes compared to their uninfected counterparts (24).  
Finally, according to WHO health statistics, HIV infection is the leading cause of death among 
women of reproductive age worldwide, responsible of 18.6% of all deaths among this 
population(25). This proportion of HIV-related deaths among women of reproductive age is 
as high as 27.9% in low-income settings(25).  
To summarize, HIV infection is undoubtedly a major health threat for women, particularly for 
young women and girls worldwide. Despite the global size of the HIV epidemic among 
women, the burden of HIV epidemic among sub-Saharan African women and girls appeared 
to be higher than in any other setting worldwide. The risk of acquiring HIV infection for sub-
Saharan African women is higher than anywhere else worldwide. Moreover, the HIV 
pediatric epidemic is indirectly proportional to the infection rate of HIV among women of 
reproductive age. Importantly, HIV infection is an important source of morbidity for women 
of reproductive age and is the leading cause of mortality among this population worldwide. 
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2.3. Global mobilization towards rolling back HIV epidemic: 
Actions plans and strategies to roll back HIV epidemic 
released during 21st century 
As at the beginning of 21st century, the burden of HIV epidemic had reached unexpectedly 
high levels, this creating great awareness within the global community. This great awareness 
provoked an unprecedented global mobilization of global leaders and stakeholders aiming at 
designing and implementing public health strategies to roll back the rapid spread of HIV 
epidemic and provide with clinical care the growing population of people living with 
HIV/AIDS.  
Although by this time the burden of HIV epidemic was already higher among women and 
girls than any other population group, the inclusion of a gender perspective within global 
action plans happened progressively. Within the first global action plans, the gender 
perspective was included probably more as a political statement, articulated transversely 
within the different preventive and care strategies. It was by the end of the first decade of 
21st when global action plans included specific epidemiologic indicators to measure 
accurately the burden of the epidemic among women and included women-centered 
preventive and care strategies were included. 
The present section outlines the public health frameworks and global strategies to roll back 
HIV epidemic released within the last decade. These public health frameworks are outlined 
highlighting the gender perspective included within. 
2.3.1. Declaration of commitment on HIV/AIDS (UNGASS 2001) 
Alarmed by the outstandingly rapid spread of HIV epidemic worldwide and the magnitude of 
its disastrous consequences at the beginning of the century, the United Nations General 
Assembly convened a special session on HIV/AIDS. This high level meeting took place in June 
2001 in New York, and was the first-ever United Nations meeting devoted to a public health 
issue. At this meeting Heads of State and Representatives of Governments of 189 UN 
members states, issued and signed the Declaration of Commitment on HIV/AIDS (2001)(26).  
The Declaration of Commitment on HIV/AIDS (UNGASS 2001) described the extent of the 
global HIV epidemic at this moment, the effects it has had on human development, and the 
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way to overcome it. This Declaration stablished time-bound targets and deadlines, which 
allowed for measurements of government accountability (26).  
Within this declaration it was recognized as well that empowering women was one key 
strategy to reduce vulnerability to HIV infection. It was stated that in order to reduce 
effectively vulnerability of women and girls face to the epidemic, care and prevention 
programs must be reinforced including a gender dimension. This gender dimension should 
advocate for ensuring safe and secure environments, particularly for young women and girls 
and; expand effective reproductive and sexual health programs. 
2.3.2. Three by five strategy 
According to UNAIDS and WHO estimations in 2002, 6 millions of people living with HIV were 
in advanced stages of the disease, urgently needing antiretroviral therapy(12). Out of these 6 
million, 4.1 where living in sub-Saharan Africa, where health system were not strong enough 
to provide clinical care and treatment(12).  
Three years later the initiative “three by five” was adopted by the global community and 
principal objective was to improve the coverage of antiretroviral programs, increasing 
subsequently the access to antiretroviral treatment(27). This ambitious initiative stablish as 
target treating 3 million people living with HIV by 2005. The achievement of this goal was 
based on the following public health approaches: 
a. Standardized treatment protocols and simplified clinical monitoring 
b. Using existing physical infrastructure and human resources optimally 
c. Involving people living with HIV/AIDS as well as communities in designing and 
implementing programs 
d. Simplified record-keeping 
e. Minimizing costs of clinical care, including cost of drugs and diagnostics 
In order to assure the achievement of this ambitious goal covering with antiretroviral 
treatment 3 Million people living with HIV within three years, the first global financial 
mechanism was launched almost simultaneously. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria was launched by the United Nations in 2002 and its objective was 
to provide a financial aid to low-and-middle income countries to fight back the three more 
deadly illnesses by that time: HIV infection, Tuberculosis and Malaria. This global financial 
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mechanism was funded by industrialized countries and set its secretary office within The 
United Nations Organization. 
In 2003, one year after the United Nations Organization launched the Global Fund, the 
government of the United States under the mandate of President George W. Bush, launched 
the President’s Emergency Plan for AIDS Relief (PEPFAR). Committed to fight the global AIDS 
pandemic, this initiative aimed initially to increase antiretroviral treatment and clinical care 
coverage in sub-Saharan Africa. 
2.3.3. Three ones strategy  
Subsequently and in order to propose a strategy to track the targets stablished within The 
Political Declaration of UNGASS 2001, a guiding framework was proposed by global 
community.  The three ones principles was a strategy recognized by international 
organizations and national governments as the guiding principles to ensure effective 
coordination of national responses to HIV/AIDS(28).  
The three ones principles were endorsed in 2004 in Washington D.C. by UNAIDS major 
bilateral donors, UNAIDS cosponsors, other key international organizations and national 
governments. These principles challenged the growing number of strategies, committees 
and monitoring systems, which were adding confusion, increasing transaction costs for 
countries and detract from impact(29).  
The rationale behind the formulation of these three guidance principles was to ensure a 
harmonized, coordinated and country-owned response to HIV epidemic. Thus, aiming at 
reinforcing the commitment of international stakeholders to coordinate contributions to the 
HIV epidemic at the national level, the following principles were stablished(29): 
One agreed HIV/AIDS Action Framework that provides the basis for coordinating the 
work of all partners; 
One National HIV/AIDS Coordinating Authority, with a broad-based multi-sectorial 
mandate; 
One agreed HIV/AIDS country-level Monitoring and Evaluation (M&E) System.  
Later on, in 2005, leaders of the G8 countries agreed to work with WHO, UNAIDS and other 
international bodies to develop and implement wide scaled efforts to overcome HIV 
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epidemic globally, with the aim to achieve universal access to treatment combined with 
prevention and care, for all those who need it by 2010. This goal was subsequently endorsed 
by all United Nations Members States at the 2005 UN Millennium Summit, high level 
meeting gathering the largest number of world leaders in history(30).  
The values and principles of the political declaration yielded of the 2005 UN Millennium 
Summit reaffirmed that in order to advance development and roll back HIV epidemic, it was 
essential to promote the gender equality and protect human rights and fundamental 
freedom for all, in particular for women and girls (30). 
On the light of formers agreements and taking into account the significant progress rolling 
back HIV epidemic, within The General Assembly High Level Meeting of HIV/AIDS of 2006 
global community decided to assume more ambitious targets to control HIV epidemic 
spread. In 2006, the United Nations Member States agreed to work towards a broader goal 
of “Universal Access to comprehensive prevention programs, treatment, care and support” 
by 2010 to all those in need. This broader goal was stablished within the Political Declaration 
on HIV/AIDS of 2006(31). 
2.3.4. Zero strategy 
In 2010, the “Getting to Zero” strategy was launched by UNAIDS in partnership with other 
United Nations agencies and private and public sector partners. This strategy aimed at 
accelerating and advancing global progress in achieving country set targets for universal 
access to prevention, treatment, care and support, halting and reverting the spread of HIV 
epidemic, and contributing the achievement of the Millennium Development goals by 2015 
(32). The strategy was supported by three main visions, resuming the principles goals 
stablished to roll back HIV epidemic by 2015: 
1. Zero new HIV infections 
2. Zero AIDS-related deaths 
3. Zero discrimination 
It is worth to note that, The Getting to Zero strategy was probably amongst the first 
strategies encompassing the gender dimension within their global approach with gender-
specific and measurable targets(32). Amongst the goals of the third strategic direction of this 
strategy it was set out that national responses to HIV of countries committed, must address 
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comprehensively the HIV-specific needs of women and girls and advocate for a zero 
tolerance for gender-based violence, recognized as a major driver of women-specific 
vulnerability to acquire the infection(32). 
These gender-specific goals emerged from the fact that although a growing number of 
women were becoming infected, the most of the funding allocated to women issues was 
only destined to provide antiretroviral therapy to prevent mother-to-child transmission(32). 
As in most affected regions women represented 60% of all the population living with 
HIV/AIDS, it was essential to combine HIV related funding with other resources to address 
the full range of women’s vulnerability such programs for serodiscordant couples, young 
women and female sex workers and particularly to foster the change of the harmful gender 
norms and economic disempowerment(32). 
The “Getting to Zero” strategy was probably the strategy setting the pace towards a real 
comprehensive approach of HIV epidemic with a gender-specific approach, outlining clear 
and measurable goals to tackle HIV epidemic among women and girls.  
2.3.5. The Political Declaration on HIV/AIDS of 2011 
In 2011, thirty years since the first case of AIDS was identified, ten years since the landmark 
United Nations General Assembly Special Session on HIV/AIDS took place and five years since 
the 2006 High Level Meeting, where the “Universal Access commitment” was made, the 
global agenda moved towards a more sustained scale-up of national responses to HIV/AIDS. 
The Political Declaration on HIV/AIDS of 2011 claimed to an intensification of the efforts to 
eliminate HIV/AIDS(33). This political declaration was unanimously adopted by UN member 
states and the commitment was to redouble efforts to achieve a set of ten more ambitious 
goals by 2015. In alignment with the Millennium Development Goal 6: Combat HIV/AIDS, the 
targets stablished in 2011 were clear: 
1. Reduce sexual transmission of HIV by 50% 
2. Halve the transmission of HIV among people who inject drugs 
3. Eliminate HIV infections among children and reduce maternal deaths 
4. Reach 15 million people living with HIV with lifesaving antiretroviral treatment 
5. Halve tuberculosis deaths among people living with HIV 
6. Close the global AIDS resource gap 
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7. Eliminate gender inequalities and gender-based abuse and violence and 
increase the capacity of women and girls to protect themselves from HIV 
8. Eliminate HIV-related stigma, discrimination, punitive laws and practices 
9. Eliminate HIV-related restrictions on entry, stay and residence 
10. Strengthen HIV integration  
In addition, the UN member states attending to this high level meeting pledged also to close 
global resource gap for overcoming the HIV epidemic and work towards increasing funding 
to expand global and national responses to HIV/AIDS. It was recognized as well that the 
investment into the HIV response is a shared responsibility which demands a sustained 
cooperation of global community together with an in-country investment.  
Finally, it was recognized as well that to narrow the funding gap and meet funding needs, 
designing strategic investment plans was compulsory. These strategic investments plans 
must foster the creation and sourcing of innovative financing mechanisms increase the 
national ownership of HIV responses and assure that funding is aligned to national responses 
priorities and strategies. 
In summary, we observed over the last decade a positive evolution of the political 
commitment aiming at rolling back the HIV epidemic, progressively coupled with specific 
targets to tackle the spread of HIV epidemic among women and girls. This positive evolution 
of political commitment is evidenced by the inclusion of gender specific axes within the new 
generation of global action plans to tackle HIV epidemic, aligning policies, strategies and 
public health actions to scale-up HIV prevention and care programs through a gender 
equitable perspective.  
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3. Scaling-up the access to HIV care: towards the universal access 
to antiretroviral therapy in constrained-resources settings 
3.1. Contextualization 
Since introduction of antiretroviral drugs the life expectancy and the quality of life of people 
living with HIV/AIDS has dramatically improved. The great effort deployed to make available 
these drugs worldwide has been a cornerstone to reduce the burden of HIV epidemic and to 
slow down it rapid spread. In 2011, by the time United Nations released the political 
declaration claiming for an intensification of the efforts to eliminate HIV/AIDS, the access to 
antiretroviral therapy had already increased of 63% since 2009 worldwide. In low-and-
middle income countries 54% of HIV-infected individuals needing antiretroviral therapy were 
receiving it. Overall, 8 million people living with HIV/AIDS were accessing to antiretroviral 
therapy worldwide in 2011, being 2 million more than in 2009(34). 
This progressive increase of the percentage of people living with HIV/AIDS acceding to 
antiretroviral treatment was traduced in more than half a million fewer deaths in 2011 than 
in 2005 worldwide(34). Only in sub-Saharan Africa, the increasing availability of these drugs 
reduced by 32% the number of AIDS-related deaths between 2005 and 2011(34).  
In addition, the incidence rate of tuberculosis among HIV-infected individuals, the most 
deadly HIV comorbidity, has reduced importantly since the increasing availability of 
antiretroviral drugs. Indeed, TB-related deaths fell by 25% worldwide and 28% in sub-
Saharan Africa(34).  
Besides the well-known benefits of combination antiretroviral therapy on decreasing viral replication 
and improving the survival of HIV-infected persons, it has also an important preventive effect. 
Evidences of the potential preventive benefit of antiretroviral therapy are available since mid-
nineties, when it was clinically demonstrated that the administration of short courses of 
antiretroviral drugs during pregnancy and breastfeeding reduce significantly the risk of mother-to-
child transmission of HIV. This biomedical intervention was among the first showing a significant 
preventive. 
Furthermore, biomedical research explored the potential benefits of antiretroviral treatment 
in preventing sexual transmission of HIV. The preventive power of antiretroviral treatment 
was explored among uninfected individuals before and after a risk exposure to HIV infection. 
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Findings from recent studies such as iPREX and CAPRISA 004 confirmed the effectiveness of 
preexposure antiretroviral prophylaxis (PrEP) on preventing sexual transmission of HIV (35-
38).  Emergency ART, the best example of post-exposure prophylaxis, is considered the 
standard of care after occupational exposures to HIV. Although a growing number of 
countries started to offer antiretroviral therapy in cases of non-occupational exposures, it 
was more an empirical practice, its efficacy was not proven by a clinical trial (39). However, 
as former biomedical interventions are addressed to uninfected individuals and their aim is 
to reduce the risk of contracting HIV infection through a risk contact, their implementation is 
limited by ethic and economic issues. 
Thus, within this context, a novel preventive hypothesis emerged setting out that if HIV 
transmission is only possible through the contact with biological fluids (blood, genital fluids 
and breast milk) of HIV-infected individuals containing active virus then, a sustained viral 
suppression within these fluids may reduce the risk of HIV transmission, leading to a 
significant decline of new HIV-infections. This hypothesis drove the new HIV preventive 
approach of “Treatment as Prevention” (TaSP). 
Mathematical models aiming at quantifying the virtual preventive benefit of the systematic 
initiation of antiretroviral treatment following a HIV-positive test regardless clinical status, 
pointed out that theoretical positive impact of these strategy on reducing the number of 
new HIV-infections (40). In 2011, the multicountry randomized control trial HPTN 052 aiming 
at evaluating the effect of combination antiretroviral therapy on the prevention of HIV-1 
transmission among serodiscordant couples confirmed that, besides the recognized benefits 
of antiretroviral treatment on improving health status of HIV-infected individuals, it is also a 
powerful HIV preventive strategy (see box 1)(41).  
In summary, antiretroviral therapy, besides increasing importantly the life expectancy and quality of 
life of people living with HIV/AIDS, has a powerful demonstrated preventive effect, reducing 
significantly the number of new HIV infections among adults and children. Thus, in order to achieve 
the ambitious goals set out by the United Nations Declaration of 2011, a massive scale-up of HIV 
treatment, was indeed a key public health strategy. In line with these global goals, the actions to 
achieve this massive scale-up of HIV-treatment were encompassed within global action plans. 
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BOX 1. Benefits of an early initiation of antiretroviral therapy: ART as a preventive strategy  
The potential benefit of antiretroviral therapy in preventing sexual transmission of HIV has been object of 
scientific research during last years. Mathematical modeling showed that universal voluntary HIV testing 
once a year of all people older than 15 years, combined with immediate ART after diagnosis, could bring 
about a phase change in the nature of the epidemic. These model suggests that massive scale-up of 
universal voluntary testing with immediate initiation of ART could nearly stop transmission and drive HIV 
into an elimination phase in high-burden setting with 1-2 years of reaching 90% of program coverage 
(Granich et al. Lancet, 2009).  
In 2011, Cohen et al conducted a randomized control trial among 1763 serodiscordant couples aiming at 
evaluating the impact of at enrollment initiation of antiretroviral treatment –regardless clinical status -, on 
HIV-1 sexual transmission and on clinical events in infected persons versus a delayed initiation. Findings of 
this study showed, that besides the outstanding restoration of clinical status, an early initiation of 
antiretroviral treatment provides real benefits on preventing HIV sexual transmission. The risk of 
transmission of HIV-1 observed a relative reduction of 96% among early ART starters, as compared with 
delayed therapy. 
 
Figure 5. Kaplan–Meier Estimates for Partner-Linked and Any HIV-1 Transmission. Cohen et al, 2011 
On the light of these promising results, investing in expanding ART coverage might have an outstanding 
public health impact. Indeed, besides the acknowledged benefits of ART on reducing morbidity and 
mortality of HIV-infected individuals, it does have the power to reduce the number of new infections.  
 
Reference: Cohen, M. S., Y. Q. Chen, et al. (2011). "Prevention of HIV-1 infection with early antiretroviral 
therapy." N Engl J Med 365(6): 493-505. 
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3.2. Global action plan: “Treatment 2015” 
According to UNAIDS estimations, 6.6 million people in low- and middle-income countries 
were receiving treatment at the end of 2010 of the estimated 14.2 million people eligible, 
nearly the half (47%) of all the people in need of these drugs were receiving it(42). Under the 
light of these estimations, achieving the global target of reaching 15 million people with 
antiretroviral treatment was indeed a major challenge for global community; therefore an 
action plan was required to organize a global response. 
In 2013, UNAIDS joined with WHO, the US President’s Emergency Plan For AIDS Relief 
(PEPFAR), the Global Fund to Fight AIDS, tuberculosis and Malaria and other partners to 
launch the “Treatment 2015” initiative. “Treatment 2015”, is a global action plan which 
emphasizes speed in scaling up, enhanced strategic focus to intensify scale-up in key 
geographic areas and populations, and innovation in program planning and service 
delivery(7, 43). This global action plan set out a particular focus on women, advocating for 
gender equality in terms of access to care (7, 43). 
3.3. Rationale of global action plan: Treatment 2015  
Accelerating the scale up of antiretroviral therapy will drive progress across the broader AIDS 
response. It will reduce HIV-related illness and death, prevent people from acquiring HIV 
infection, address the needs of women and girls, reduce stigma and social exclusion and 
promote service integration(43). 
However, the eligibility to receive these drugs is determined by a combination of clinical and 
biological criteria. In order to establish standard criteria of ART-eligibility, the World Health 
Organization (WHO) has been collecting, evaluating and systematizing scientific evidence 
since the advent of antiretroviral treatment in resource-limited settings. These criteria are 
fundamentally based on CD4 cells measurements.  
According to WHO guidelines of 2010, all HIV individuals having <350 CD4 cell/mm3 were 
recommended to start antiretroviral treatment(44). Under this criterion, it was estimated 
that 61% (57% - 66%) of all persons eligible for HIV treatment in low-and-middle-income 
countries had obtained antiretroviral therapy in 2012(7). In settings, where the coverage 
with Antiretroviral treatment has reached levels over 80% under the 2010 WHO treatment 
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guidelines (initiate treatment at a CD4 cell count of 350 cells/mm3 , incidence of HIV-
infection has observed an important reduction (44, 45). 
The positive effect of the introduction of ART on averting new HIV infections is practically 
undeniable. In 2013, WHO guidelines on antiretroviral treatment were updated and the 
biological threshold established to initiate treatment changed. According to this last update 
of WHO guidelines treatment was recommended for all individuals having between >350 
CD4 cells/mm3 and <500 CD4 cells/mm3 regardless their clinical stage (46).  
Achieving and maintaining 80% global coverage under the 2013 guidelines would prevent 
more than 3 million additional AIDS related deaths and prevent an additional 3.5 million 
people from acquiring HIV infection through 2025, in comparison with the 2010 
guidelines(43, 45, 46). Higher reductions of new infections are expected with the full 
implementation of new WHO treatment guidelines released on 2013 (initiate antiretroviral 
treatment at 500 CD4 cells/mm3)(46). 
 
Figure 6. Impact of implementation of 2013 WHO guidelines of antiretroviral treatment use in terms    
of number of AIDS-related deaths averted. (Source: UNAIDS, 2011). 
 
Besides de important benefits of antiretroviral treatment increasing life expectancy and 
improving quality of life of HIV infected individuals, may contribute importantly with 
economic development of the most severely affected countries. Scaling up antiretroviral 
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therapy fosters future economic growth, strengthening and preserving the health and well-
being of adolescents and young adults which are the most important work force.  
3.4. Current status of universal access to antiretroviral 
treatment: 15 Million by 2015 
At the time the global action plan “Treatment 2015” was launched in 2012 around 9.7 
million people living with HIV/AIDS were accessing to antiretroviral treatment in low-and-
middle-income countries(42, 43). Under WHO guidelines of 2010, 61% of all HIV-infected 
individuals eligible for antiretroviral treatment where accessing to these live saving drugs 
and 34% under WHO guidelines of 2013(34). 
According to currents global estimations, the number of people living with HIV receiving 
antiretroviral treatment observed an important increase. In 2013, 12.9 million HIV-infected 
individuals were accessing to treatment meaning an increase of 3.2 million individuals within 
one year(34). These estimations seem to be optimistic as the proportion of people living 
with HIV covered by antiretroviral programs represents 86% of 15 million targeted. 
In sub-Saharan Africa, setting with highest prevalence rates of HIV-infection, increasing 
coverage of antiretroviral programs is a major public health challenge. Although currents 
trends are somewhat encouraging, important gaps in terms of access to antiretroviral 
therapy persist in sub-Saharan Africa. The breadth of these gaps is changeable and as shown 
Figure 7. Percentage of all people living with HIV receiving ART worldwide. 
              (Source: UNAIDS/AIDS info) 
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in figure 7, the percentage of people living with HIV/AIDS receiving antiretroviral drugs varies 
importantly worldwide. The proportion of adults living with HIV/AIDS eligible for and 
receiving antiretroviral treatment in sub-Saharan Africa is amongst the lowest worldwide. 
Indeed, in at least 14 countries at the south of the Sahara, 80% or more of people who were 
estimated to be eligible for treatment under the 2013 WHO guidelines were not receiving 
antiretroviral therapy at the end of 2012(47). Additionally, this gap appeared to be deeper in 
Western and Central Africa where only around 20% of all HIV-infected people eligible for 
antiretroviral treatment are currently receiving it (47).  
In southern and eastern Africa, although coverage appeared to be higher this gap represents 
around 40% of HIV-infected people eligible for antiretroviral treatment who have not yet 
started(47). Currently, antiretroviral programs of an important number of sub-Saharan 
countries have barely achieved a 40% of coverage (20% – 39%). Given that women 
constitute more than half of the population living with HIV in sub-Saharan Africa, the 
expected massive increase of the coverage of antiretroviral programs will be undoubtedly 
outnumbered by women. 
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4. Mother to child transmission of HIV 
By 2010 an estimated 390 000 [340 000–450 000] children became newly infected with HIV 
worldwide (42). The vast majority of these children acquired the infection from their 
mothers during pregnancy or postpartum through breastfeeding. This number represents an 
important drop of new HIV pediatric infections from 2002, year where pediatric infections 
reached a peak of 560 000 (340 000 – 450 000)(42). For most of high income countries, the 
elimination of new HIV pediatric infections is practically a reality. In United States for 
example the proportion of new HIV infections among children fell by 93% within a ten years 
period (1992 – 2005)(48). Despite this important drop of the number of newly HIV-infected 
children, the target of elimination of new HIV pediatric infections faces still important public 
health challenges. 
For a growing number of resource-limited settings, the elimination of new HIV pediatric 
infections is not anymore utopic. By 2011, the prevention of mother-to-child transmission 
programs of several low-and-middle income countries started achieving 80% of 
coverage(42). Botswana was an outstanding example, were the percentage of infants who 
are born HIV-positive to mothers living with the virus declined from 21% in 2003 to 4% in 
2010(42). Likewise, several other southern and eastern Africa countries have successfully 
achieved universal access to prevent new HIV pediatric infections(42). Indeed, the goal of 
taking to zero new HIV pediatric infections was almost a reality for an important number of 
countries.  
However, the pediatric epidemic was principally concentrated within 22 countries which 
were hosting 90% of all pregnant women living with HIV and in need of clinical care in 2012 
(42). Among these 22 countries, besides India, all were located in sub-Saharan Africa: 
Angola, Botswana, Burundi, Cameroon, Chad, Côte, d’Ivoire, Democratic Republic of the 
Congo, Ethiopia, Ghana, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, 
South Africa, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe(42).  
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4.1. Coverage of HIV testing services for pregnant women. 
In 2009, the proportion of pregnant women in low-and-middle income countries who 
received an HIV test was as low as 26%(6). The limited integration of HIV services within 
antenatal care services is major barrier to the early detection of HIV-infected pregnant 
women and therefore a primary limitation to implement preventive strategies during 
pregnancy. Offering an HIV test and counseling was not systematic within antenatal services 
and in consequence, the initiation of prophylactic treatment was delayed, increasing 
therefore the risk of HIV transmission.  
In 2009, 53% of all HIV-infected pregnant women in low-and-middle income countries 
received antiretroviral medication to prevent mother-to-child transmission of HIV during 
pregnancy and/or postpartum(6). Moreover, for those HIV-infected mothers accessing 
preventive antiretroviral strategies, the distribution of antiretroviral regimens varied 
importantly, particularly among the 22 prioritized countries. Although trends were shifting, 
the overall proportion of HIV-infected mother who were receiving a three-drug regimen was 
less than 10% (figure 8). The benefits of a global shifting to a three-drugs regimens would 
provoke an immediate drop in the number of new HIV infections among children(42) 
Figure 8. Distribution of antiretroviral regimens to prevent new HIV infections among children: 22 
priority countries, 2004–2010 
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These former structural and operational obstacles, together with the high epidemic burden 
held by women of reproductive age and the large access gap to family planning estimated in 
these settings, constituted major menaces to the achieve the full elimination of new HIV 
pediatric infections. As a consequence, an updated global action plan encompassing 
effective evidence-based strategies targeting these obstacles was urgently needed.  
4.2. Global plan towards elimination of new HIV infections among 
children by 2015 and keeping their mothers alive 
4.2.1. Concept and rationale of the global action plan 
In 2011, the global community embraced a new challenging goal aiming at eliminating new 
HIV infections among children and reducing AIDS-maternal deaths by 2015. This ambitious 
goal was included within the Global Action Plan Towards Elimination of New HIV Infections 
among Children by 2015 and Keeping their Mothers Alive launched in 2011 by UNAIDS (9). 
This global action plan lies on a more comprehensive public health approach targeting 
women, maternal and child health in it whole spectrum. On the one hand, the public health 
strategy proposed by this plan aims at reducing the incidence of HIV infection among women 
of reproductive age and preventing unintended pregnancies, narrowing the gap of unmet 
needs for family planning. On the other hand, this strategy aims at increasing the coverage 
of preventive programs and providing women with ART to reduce AIDS-related morbidity 
and mortality and prevent the vertical transmission of HIV. Although this global action plan is 
addressed to all resource-limited settings, the 22 countries holding the highest prevalence 
rates of HIV among pregnant women are the priority(9).  
The goals of this action plan are consistent with the current global development priorities. 
The framework of this global action plan is in alignment with four of the Millennium 
Development Goals (MDG), where HIV is holding back progress. Firstly, preventing new HIV 
infections among women of reproductive age, fostering the access to HIV prevention and 
treatment services, delivering sexual and reproductive health services and involving HIV-
positive mothers as key partners to deliver this plan contributes directly with MDG 3, which 
claims for gender equality and women empowerment.  
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Secondly, as HIV is considered a major cause of maternal and child mortality, providing them 
with appropriate health care services and treatment to prevent new HIV pediatric infections 
and to treat those mothers and children already infected have undoubtedly a positive 
impact in the progress of MDG4 and MDG5, aiming at the reduction of child mortality and 
improving maternal health respectively(49).  
Finally and very importantly, this global plan contributes outstandingly with the achievement 
of MDG6, combating HIV/AIDS, preventing its spread among women of reproductive age and 
children, providing treatment and care for mother living with HIV/AIDS and reducing AIDS-
related morbidity and mortality among this population. 
4.2.2. Configuration of the global action plan 
As shown in figure 9, this global action plan is constituted by two global targets which are 
expected to be achieved through a four-pronged strategy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Configuration of the Global Plan of Elimination of New HIV Infections among 
Children and keeping their mothers alive (source: UNAIDS 2011). 
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In order to assess the progress towards the global goal of this action plan, each prong 
includes a comprehensive package of items to be tracked. 
1. Global target 1: Reducing by 90% all new pediatric infections/ Reduce AIDS-related 
infant deaths by >50%. 
Three prongs are designated to measure the achievement of this goal. Preventing new HIV 
pediatric infections in primary based on reducing the spread of HIV infection among women 
of reproductive age (prong 1) and preventing unintended pregnancies (prong 2). Together 
with the third prong which aims at actively preventing HIV transmission through the 
provision of appropriate care and treatment to pregnant women living with HIV, these three 
first prongs are expected to reduce new HIV pediatric infections to the expected levels. 
2. Global target 2: reduce by 50% the number of AIDS-related maternal deaths 
As a part of the public health approach, to measure this goal, the indicator will capture a 
broader package of HIV and maternal, newborn and child health services (prong 4). This 
global action plan presents an unprecedented opportunity to tackle Millennium 
development objectives 5 and 6 specifically(50). In addition, this target is in line with the 
goals set out in the Countdown to 2015 initiative for maternal, newborn and child 
survival(49).  
Besides preserving mother’s lives is a legitimate action on its own; the impact of keeping 
children alive and free of HIV infection will be limited if their mothers are no longer there to 
take care of them. The indicator is the number of HIV-related deaths among women who 
were either pregnant or gave birth in the preceding six weeks. 
4.2.3. When to start ART during pregnancy 
ARV drugs are used for pregnant and breastfeeding women infected with HIV primarily for 
the mother’s health and to prevent the exposed child from becoming infected. Besides these 
health benefits, it may also offer benefits on preventing the sexual transmission of HIV.  
Concerning the therapeutic management of pregnant women living with HIV and their 
children, this action plan is in line with the updated WHO guidelines about prophylactic ART 
regimes released in 2013. The preventive strategy proposed by the global plan of elimination 
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is based on a triple antiretroviral therapy for all HIV-infected pregnant women regardless 
their clinical status.  
Before 2010, recommended prophylactic regimens during pregnancy and postpartum were 
based on short-course of antiretrovirals, starting during pregnancy and continued until 
several weeks of postpartum. From 2010, WHO PMTCT guidelines stated that lifelong ART 
was only recommended for pregnant women living with HIV meeting eligibility criteria for 
treatment (based on the 2010 eligibility criteria of CD4 counts ≤350 cells/mm3 or presence 
of WHO clinical stage 3 or 4 disease) (44). For HIV-infected pregnant women not meeting 
treatment eligibility criteria, two prophylactic strategies were recommended: 
1.  Option A, AZT for the mother during pregnancy, single-dose NVP (sd-NVP) plus AZT 
and 3TC for the mother at delivery and continued for a week postpartum; this was 
coupled with daily NVP given to the infant throughout breastfeeding exposure(44)  
2. Option B, triple ARV drugs for the mother during pregnancy and throughout 
breastfeeding. Prophylaxis was recommended to start as early as 14 weeks of 
gestation, and both prophylaxis options included four to six weeks of peripartum NVP 
or AZT for the infant, regardless of whether the mother was breastfeeding(44). 
Although these two prophylactic regimens do offer a benefit in terms of preventing HIV 
transmission from the HIV-infected mother to her child, several operational barriers limited 
their optimal efficacy. Although available data continue to show that the Option A and 
Option B prophylactic regimens have similar efficacy in clinical trial context, the complexities 
of Option A have been an impediment to scaling up PMTCT in many countries(46). These 
complexities include different treatment and prophylactic regimens; the requirement for 
CD4 cells measurement to determine treatment eligibility and type of regimen; changing 
antepartum intrapartum postpartum regimens; the need for an additional postpartum ARV 
“tail” in mothers; and extended NVP prophylaxis in infants.  
In order to achieve the global goal of elimination of new HIV infections among children, 
WHO guidelines about prophylactic therapies to be used during pregnancy and postpartum 
evolved. In 2011, Malawi implemented a new approach of lifelong ART for all pregnant and 
breastfeeding women with HIV regardless of CD4 count or clinical stage, commonly referred 
to as “Option B+”(51). WHO issued a programmatic update in April 2012, outlining some of 
the operational advantages of Option B and the emerging strategy of Option B+(52). 
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In 2013, for programmatic and operational reasons, Option A was no longer recommended 
and current WHO guidelines recommend that all pregnant and breastfeeding women with 
HIV should initiate triple ARV  during the period of risk of mother-to-child transmission and 
continue lifelong antiretroviral treatment, regardless CD4 count or clinical stage(46). 
Although the recommendation of Option B+ is based on moderate-quality scientific 
evidence, it was suggested to offer an important number of operational benefits. 
Public health benefits of Option B+:  
1. Covering pregnant women living with HIV with antiretroviral therapy reduce 
significantly AIDS-related maternal mortality.  
2. As an important number of pregnant women report to be in a stable couple, ART 
initiation offers protection from HIV transmission.  
3. ART initiation will protect current and future children against the acquisition of HIV 
infection from their HIV-infected mother through vertical mechanisms.  
In addition, Option B+ provides as well structural benefits for health systems. The same 
simplified ARV regimen administered to all pregnant women (regardless of clinical eligibility) 
and continued during pregnancy and labor and postpartum is easy to deliver. The optimized 
first-line fixed-dose combination regimen can be harmonized with guidelines for ART in non-
pregnant adults. Finally, Option B+ ensures that immunocompromised women who do not 
have access to CD4 testing receive appropriate ART without delay. 
To accelerate the rapid global scaling up of ART and PMTCT in resource-limited settings, 
ensure equitable access to ART for pregnant women and achieve the global goal of 
eliminating new pediatric infections and keeping mothers alive, recommendations now need 
to be further simplified, standardized and harmonized however.  
4.2.4. Progress status of global plan implementation 
Current estimations show that the implementation of the global action plan of elimination of 
new HIV infections among children and keeping their mothers alive started to yield 
encouraging but entirely satisfactory results. According to estimations of UNAIDS, 240 000 
(210 000 – 280 000) children became newly infected worldwide in 2013, down from 580 000 
(530 000 – 640 000) in 2001, this represents an impressive decline of 58%(34).  
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This important reduction of new HIV pediatrics infections has been partly owed to the great 
progress observed by the programs for prevention of mother to child transmission. The 
coverage of such programs (excluding the less effective sd-Nevirapine regimen) increased 
from 57% (51 – 64%) in 2011 to 62% (57 – 70%) in 2012(7). Owed to this modest increased 
coverage rate, more than 670 000 new HIV pediatric infections were prevented between 
2009 and 2012. 
In 2013, two years after this global action plan was launched, great achievements have been 
documented among the 22 prioritized countries. Among prioritized countries at least seven 
high-burden countries reduced by 50% the estimated number of new pediatric HIV 
infections from 2009 levels (Botswana, Ethiopia, Ghana, Malawi, Namibia, Zambia and 
Zimbabwe)  and four more (Mozambique, South Africa, Uganda and the United Republic of 
Tanzania) fall out very short to achieve this goal(19). Moreover, the transition from the use 
of sd-Nevirapine as primary antiretroviral preventive option for pregnant women living with 
HIV, to more effective antiretroviral regimens is a real for all priority countries(19). 
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BOX 2. Scaling-up of mother-to-child transmission of HIV prevention programs: Malawi and the 
successful story of the Option B+ 
According to 2010 WHO guidelines, for pregnant women living with HIV, the eligibility for a lifelong 
antiretroviral treatment or a short-course preventive antiretroviral regimen depended on biological and clinical 
criteria. To determine this eligibility to one or another regimen all pregnant women must realize at least one 
CD4 cell count.  
In 2011, in Malawi, East-African country with a generalized HIV epidemic was facing an important challenge 
scaling up their in-country mother-to-child transmission of HIV prevention program. The limited local capacity 
to carry out CD4 cell count was a major barrier to prevent mother-to-child transmission of HIV.  Thus, in the 
third quarter of 2011, the Malawi Ministry of Health implemented an innovative approach – Option B+ -. This 
approach called so by the Ministry of Health postulated that all HIV-infected pregnant and breastfeeding 
women are eligible for lifelong antiretroviral therapy (ART) regardless CD4 count or clinical stage. 
Implementation of Option B+ resulted in a 748% increase in the number of pregnant and breastfeeding women 
starting ART, from 1,257 in the second quarter of 2011 (representing 5% of all new ART initiations) to 10,663 in 
the third quarter of 2012 (35% of all new ART initiations).figure 10 
 
Figure 10. Number of new antiretroviral treatment (ART) initiations among pregnant and breastfeeding women, 
and percentage of all new ART initiations attributed to this population — Malawi, 2008–2012. 
Of the women starting ART in the third quarter of 2011 (the first quarter of Option B+ implementation) who did 
not transfer care during follow up, 77% continue to receive ART at 12 months. This rate is similar to the 80% 12-
month ART retention rate observed among adults who initiated ART in the second quarter of 2011 (the last 
quarter before Option B+ implementation). 
 
 
Reference: Center for Disease Control.(2013). Impact of an innovative approach to prevent mother-to-child 
transmission of HIV-Malawi, July 2011-September 2012. Atlanta, GA, Morbidity and Mortality 
Weekly Report (MMWR). 
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5. Research Rationale 
Since the last decade, women have been holding the higher burden of HIV epidemic. Current 
and past global action plans to roll back HIV-epidemic have established that the promotion 
of gender equality and the eradication of gender-based violence are capital strategies to 
reduce the spread of HIV epidemic among women.  
Although the extent of gender-based violence and, particularly intimate partner violence in 
sub-Saharan Africa has been subject to a growing amount of scientific research, this topic 
has been poorly documented in the West African region. The first question we address is to 
what extent HIV-infected women are victims of gender-based violence, particularly intimate 
partner physical and sexual violence: What is the prevalence rate of intimate partner 
physical and sexual violence among HIV-infected and HIV-uninfected Togolese women? 
This question has been poorly addressed in the West African region and I believe it is one 
major input to scale-up the comprehensive HIV-care services. 
Secondly, and in line with the goals set out by the global plan of elimination of new pediatric 
HIV infections and keeping their mothers alive, there is an urgent need to provide quality 
clinical care to HIV-infected pregnant women, including sexual and reproductive health 
services. The advent of ART has improved outstandingly the health status of HIV-infected 
women and pregnancy is not anymore an uncommon event among this population. 
However, although the incidence rate of pregnancy has been estimated across different 
settings in sub-Saharan Africa, this epidemiologic parameter has been poorly documented in 
the West African Region. Thus the second research question of this research framework is: 
what is the incidence rate of pregnancy among HIV-infected women on ART in the West 
African region? 
Finally, current scientific evidence suggests that pregnancy might represent an important 
health risk for HIV-infected women. Several studies conducted in sub-Saharan Africa have 
addressed this question but its conclusions are not definitive. As these studies have been 
mostly conducted in East and Southern Africa but, this question have been poorly explored 
in the West African region. The third research question of this research framework is then: Is 
pregnancy associated with a higher risk of death, HIV-disease progression or loss to follow-
up among HIV-infected women on ART in West Africa? 
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6. Research context: The West African region 
6.1. Demographic profile 
The West African region is constituted by the 17 more occidental states of the sub-Saharan 
Africa: Benin, Burkina Faso, Ghana, Guinea, Guinea-Bissau, Côte d’Ivoire, Liberia, Mali, 
Mauritania, Niger, Nigeria, Senegal, Serra Leone and Togo and the Islands of Cape Verde and 
Saint Helena which are overseas territories (figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The West African region is confined to an area of 5,112,903 km2; corresponding to one fifth 
of the African continent. Limited by the Atlantic Ocean to the West and, by the Saharan 
dessert to the East and North-East, West Africa is composed of a semi-arid terrain known as 
Sahel, transitional zone of the Sahara at the north and a belt of tropical forest to the south 
next to the littoral of the Gulf of Guinea.  
Overall, this region accounts for a population of 320 347 000 inhabitants, representing 30% 
of the whole African population. Nigeria is the seventh most populous country worldwide 
and accounts for more than a half of the whole west African population. 
Figure 11. Geographic localization and constitution of the West African Region. 
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According to WHO estimations in 2013, the mean life expectancy at birth in the region is 
57.2 years, being slightly higher among women(53). The lowest life expectancy is reported 
by Sierra Leone with 46 years old, whereas in Cabo Verde the overall life expectancy is of 74 
years old, the highest of the region(53).  
Similarly to other African regions, there are an important number of vernacular languages in 
West Africa but the official languages of the West African states are French, English and 
Portuguese. Islam is the most practiced religious cult within the region, followed by 
Christianity. Although not necessarily official, the animism as a form of cult is commonly 
practiced within certain West African societies.  
6.2. Government system and structures 
Excepting five countries (Nigeria, Ghana, Guinea Bissau, Liberia and Sierra Leone), the vast 
majority of the West African territory belonged to what was called the “French West Africa” 
constituted by the ancient colonies of the French empire in the African continent. At the end 
of the last century, all countries of the West African region had achieved their political and 
economic independence and ever since they have become democratic republics, leaded by a 
national head of state, elected periodically through citizen participation processes.  
In order to promote the economy integration of the west African region and foster the 
regional collaboration for development, The Economic Community of West African States -
ECOWAS- (in French: Communauté économique des États de l'Afrique de l'Ouest – CEDEAO-), 
founded in 1975 through the Treaty of Lagos, having as main goal the achievement of 
collective self-sufficiency for its member states by creating a single large trading bloc 
through an economic and trading union(54). Ever since ECOWAS is considered one the pillars 
of the African Economic Community, serving as well as a peacekeeping force for the region 
operating in three languages: French, English and Portuguese(54). 
In addition and consistently with the objectives of ECOWAS, the West African Economic and 
Monetary Union (UEMOA from the French: Union Economique et Monétaire Ouest 
Africaine), is a trade bloc of countries composed of an economic union with a monetary 
union aiming at achieving the economic integration(55). This trade bloc was founded in 1994 
with the aim of promoting economic integration among countries that share the CFA franc 
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as a common currency (Senegal, Benin, Burkina Faso, Côte d’Ivoire, Mali, Niger, Togo and 
Guinea-Bissau)(55).  
Since its foundation, the UEMOA has achieved the successful implementation of an effective 
regional surveillance system in order to track the regional economic progress. Together with 
ECOWAS, UEMOA is currently developing a common strategic-action plan on trade 
liberalization which is expected to turn positively over the economy of the region(54, 55). 
6.3. Key economic sectors 
The economy of the region is basically supported by two principal activities: exploitation of 
mineral resources and agriculture. West Africa hosts one the 10th largest oil field of the 
world located in Nigeria, which is the 12th largest producer of petroleum in the world and 
the 8th largest exporter(56). Indeed, Nigeria leads the petroleum industry in the sub-Saharan 
region with proven oil reserve of between 16 to 22 billion barrels(56). 
Similarly, the West African region is reach in other precious minerals such as gold and 
diamonds. Ghana, with a production of 102 metric tons of gold per year is the 7th largest 
producer of gold worldwide and 2nd largest of Africa, behind South Africa(56). Mali is as well 
an important gold producer and is considered the third largest in the African continent(56). 
In addition, Sierra Leone is considered amongst the principal diamond deposits of the world. 
The second most important economic activity of the region is agriculture with the culture of 
cacao, coffee and cotton(57). The cacao industry is leaded by Côte d’Ivoire, with an annual 
production of roughly 1.5 million tons, the first world producer of this seed(57). Côte d’Ivoire 
is as well amongst the most important producers of coffee worldwide. The production of 
cotton is one major activity in the Sahel countries such as Mali and Burkina Faso (57). The 
production of cereals and other vegetables such as rice, millet, corn, sorghum and peanuts 
are important key sectors of the economic activities of the region (57). 
The industry of telecommunications and technology is rapidly gaining place within the West 
Africa economic sector, particularly during last years. Nigeria is leading this industry with one 
of the fastest growing telecommunications markets in the world, basing the major emerging 
market operator in their country and owing several outer-space satellite units(56). Indeed, 
Nigeria is the country observing the most impressive and fastest economic growth within the 
region (56). 
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However, besides the impressive economic success of Nigeria, the vast majority of the 
countries of the West African region are categorized as resource-limited countries, with a 
human development index below the 150th rank (58). Besides Ghana, country classified as 
medium human development country, the rest of the countries of the region are classified 
as low human development countries (58). 
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6.4. HIV epidemic in West Africa 
Although HIV infection is highly prevalent across the sub-Saharan Africa region, the 
distribution of the epidemic varies across the different sub-regions of the continent. Since 
the early days, sub-Saharan Africa HIV epidemic has been pointed out as generalized, 
meaning that HIV spreads throughout the general population rather than being confined to 
populations at higher risk, such as sex workers and their clients, men who have sex with 
other men or injecting drugs users. Moreover, it has long been recognized that in most 
countries HIV infection level are higher in urban than in rural areas(14). 
In contrast with the high prevalence levels of HIV infection in southern Africa – highest 
worldwide -, prevalence levels of HIV infection in West Africa is sensibly lower and, varies in 
scale and intensity comparing to other sub-Saharan regions (figure 16) (13). In 2005, national 
adult HIV prevalence didn’t exceed 10% in any West African country(13). West Africa has 
been pointed out systematically as the region accounting for the lowest prevalence rates of 
HIV infection in sub-Saharan Africa (figure 12).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Prevalence of HIV infection in the African continent  
 (Source: UNAIDS, AIDS info. 2013) 
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Regional Estimations during mid-twenties described HIV epidemic within West-African 
region as diverse and changeable (14). In 2004, the prevalence rate of HIV infection in 
several West African settings was of roughly 2%, keeping a relatively stable epidemiological 
pattern for almost all 13 countries within the West African region. During late twenties, HIV 
prevalence within West African sub-region appeared to be much lower than any other sub-
Saharan region, finding a relative stability among general population(3, 59, 60). 
Although HIV prevalence in West Africa is much lower than anywhere else in the sub-
Saharan region, West Africa hosted several serious national epidemics. Nigeria, accounting 
for a total population of more than 160 million inhabitants, one of the most populous 
countries in the world, is been hosting a very serious epidemic since early twenties. In 2003, 
it was estimated that between 3.2 and 3.6 million people were infected with HIV in 
Nigeria(14). HIV prevalence ranged from 2.3% in the littoral zone to 7% in the north central 
region among pregnant women (13, 14). Although prevalence rates kept importantly high 
levels, Nigerian HIV epidemic started to find a relative stabilization at mid-twenties(3). 
However, Nigeria has still the largest epidemic in the West African sub-region and third 
largest worldwide, only preceded by India and South Africa(3, 59, 60). 
Likewise, available data from Côte d’Ivoire suggested that although the breadth of the 
national HIV epidemic was smaller than in Nigeria, this West African country faces a serious 
epidemic. In 2003, prevalence rates levels of HIV infection in Côte d’Ivoire was as high as 7% 
(range: 4.9–10%)(14). Moreover, epidemiologic surveillance data revealed that HIV 
prevalence among pregnant women was as high as 10% and 5% in rural and urban settings, 
respectively (59). However, the difficulties on gathering epidemiologic data during the civil 
conflict faced by the country during mid-twenties, limits the reliability of these estimations, 
suggesting an underestimation of the real size of the national HIV epidemic(59). According to 
UNAIDS estimations, since 2005, the national HIV epidemic in Côte d’Ivoire found a relative 
stability with a discreet trend to decline. In 2006, prevalence rate of HIV infection among 
adults observed an important decline of 3% compared to 7% estimated in 2003(13). In 2007, 
estimations of HIV surveillance among pregnant women indicated that prevalence rate 
among adult population declined substantially in urban settings, falling from 10% in 2001 to 
6.9% in 2005(3, 60). By the end of the decade, prevalence rate of HIV infection among adults 
declined roughly by the half going from 7% in 2003 to 3.7% in 2009(61). 
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Besides, Nigeria and Cote d’Ivoire, the rest of the countries seemed to maintain a relatively 
stable HIV epidemic during the first decade of the century. Epidemiological estimations of 
the West African region showed almost systematically low prevalence rates among adults of 
general population(3, 13, 14, 16, 59-61). With the exception of Togo, country which during 
early twenties reported an HIV prevalence rate of roughly 4% among adult general 
population, the rest of the countries of the region rarely exceeded a prevalence rate of 
2%(59).  
In addition, it is important to highlight the particular profile of HIV epidemic in Senegal, 
country which has been systematically reporting the lowest prevalence rate of the region 
since early twenties and one of the lowest in sub-Saharan Africa (3, 13, 14, 16, 59-61). 
Prevalence rates of HIV infection among adults of general population in Senegal have never 
exceeded 2% across the first decade of the century, reaching rates even below 1%, being the 
lowest of 0.7% in 2006(60). Senegal is the only country in West African region achieving a 
successful and sustained control of HIV epidemic among adults of general population during 
last decade. 
6.5. HIV-2 Epidemic 
One particular characteristic of the West African HIV epidemic worth to note is the presence 
of HIV-2 virus. In the late eighties, the prevalence rate of HIV-2 in the region was >1% among 
the countries of the region(62). These early prevalence rates of HIV-2 have been declining in 
several West African countries during last years (63-65). The lower size of HIV-2 epidemic 
has been suggested to be owed to its less efficient transmission rates compared to HIV-1 
(66). 
Although this virus was more commonly found in the West African region, further 
epidemiologic assessments point out that HIV-2 has been detected in countries historically 
attached with West Africa. For example, Portugal where HIV-2 is responsible of 4.2% of all 
Portuguese in-country AIDS cases (67). In France, out of all new HIV-infections diagnosed 
between 2003 and 2006, 1.8% were owed to HIV-2(68). Later on, HIV-2 has been also found 
in other former Portuguese colonies in Africa and worldwide such as Angola, Mozambique, 
and Brazil. HIV-2 has been also identified In India, particularly in Goa and Maharashtra, 
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regions having previous attachments to Portugal(66). Presently, HIV-2 has been also 
identified in the United States or in Europe but mostly among west African immigrants(66). 
HIV-2 shares the same mode of transmission of HIV-1, unprotected sexual intercourses, 
exposure to blood or other biological contagious materials (needles), and mother-to-child 
transmission. However, scientific evidence shows that infectivity of HIV-2 through any form 
of transmission path is quite lower than HIV-1 (69-71).  
The infection with HIV-2 does not provide immunological protection against contracting HIV-
1 and in West-Africa it has been estimated that 0.3% to 1% are dually infected with both 
HIV-1 and HIV-2(72). HIV-1/2 coinfected patients observed a similar mortality rates as HIV-1 
monoinfected patients(73). As the therapeutic regimen of both HIV infections differs, 
treating coinfected patients is an important clinical challenge. 
In addition, HIV-2 infection is characterized by longer asymptomatic period and AIDS 
progression is slower than HIV-1 infection (74-76). Likewise, although HIV-2 disease is very 
similar to HIV-1 disease, the progression of HIV-2 disease is highly variable. While some HIV-
2-infected patient progress in their disease in the same way HIV-1-infected patients, others 
progress more slowly, reaching longer asymptomatic periods (77, 78).  
To conclude, West Africa has been the region less severely affected by HIV epidemic in sub-
Saharan Africa and as anywhere else worldwide the HIV epidemic is composed of two 
different types of virus: HIV-1 and HIV-2. Current prevalence rates of HIV infections among 
adults of general population are less than 2% in most of the countries(2, 6). According to 
recent epidemic estimations, HIV infection rates among the general population are declining 
and as the number of new infections is decreasing progressively, prevalence rates seems to 
find a relative stability in general population(6, 18). However, Nigeria and Côte d’Ivoire are 
the two west African countries hosting serious national epidemics with prevalence rates of 
roughly 4% in general population, far higher than anywhere else in the region(6).  
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Figure 13. IeDEA Network by regions. (Source: IeDEA. 2014. http://www.iedea.org/) 
7. Research platform: International Epidemiologic Databases 
to Evaluate AIDS – IeDEA Network 
The IeDEA network is an international research consortium established in 2005 by the 
National Institute of Allergy and Infectious Diseases to provide a rich resource for globally 
diverse HIV/AIDS data. Sites in various regions throughout the world collaborate to collect 
and define key variables, harmonize data, and implement methodology to effectively pool 
data as a cost-effective means of generating large data sets to address the high priority 
research questions and streamline HIV/AIDS research.  The NICHD Pediatric, Adolescent, and 
Maternal AIDS (PAMA) Branch has co-funded the IeDEA since 2006, providing support to 
allow the inclusion of patient data on infants, children, adolescents, and pregnant women. 
The National Cancer Institute (NCI), Office of HIV and AIDS Malignancy (OHAM) has provided 
funding for IeDEA since 2007. This funding supports the collection/analyses of data on 
cancer, one of the leading co-morbidities of HIV/AIDS. 
IeDEA collects HIV/AIDS data from seven international regional data centers, including four 
in Africa, and one each in the Asia-Pacific region, the Central/South America/Caribbean 
region, and North America (figure 13). This type of data and resource pooling allows 
researchers to address unique and evolving research questions that individual cohorts are 
unable to answer. 
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7.1. IeDEA West Africa regional network 
The WADA (West African Data Base on Antiretroviral Therapy) Collaboration is a unique 
collaboration among cohorts in West Africa with a mission to conduct hypothesis-driven 
epidemiological research on the prognosis and outcome of HIV type 1 and 2 infected people, 
including adults, pregnant mothers and children.  Participating countries are Benin, Burkina 
Faso, Cote d’Ivoire, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo. The collaboration 
aims at focusing on scientific questions requiring a large sample size. Activities have been 
focusing initially on cross-sectional analyses of existing data, a comprehensive examination 
of the available data in terms of completeness of core items at baseline and during follow-
up, and the development of instruments to standardize, harmonize and improve data 
collection across sites. 
The research agenda then focused on the following four areas: programmatic issues (access 
to antiretroviral treatment and losses to follow up); monitoring and outcomes of treatment 
in adults, children, and pregnant women; clinical response, with a special interest for 
tuberculosis, opportunistic infections, immune reconstitution syndrome and hepatitis B co-
infection; care of HIV-2 infection. A total of 17 cohorts in six major cities in six West African 
counties – each ongoing and with their own internal governance structure and financial 
support- have agreed to participate, contributing to more than 5,000 HIV-infected children 
and 60,000 adults at the end of 2012.  
The regional coordinating center is located in Bordeaux, France. This university team has 
long lasting experience in epidemiological HIV cohort research in West Africa, with an office 
in Abidjan, Cote d’Ivoire.  It also has extensive experience with international collaborations 
of this kind including the Ghent Group on HIV in Women and Children and the ART-LINC 
Collaboration. Data are collected from affiliated cohorts every year and once merged into a 
main WADA database, data extracts are made for the various projects and analyses. This 
process is repeated annually allowing for the analysis of the most contemporary data 
collected in the affiliated cohorts.  WADA is an unprecedented undertaking in West Africa, 
with a unique design, led by investigators with extensive experience that will advance the 
public health knowledge required to better understand and treat HIV-infected persons of all 
ages, genders and backgrounds in sub-Saharan Africa, the continent with the largest unmet 
needs but with on-going rapid and massive roll-out of HIV treatment programs. 
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8. Drivers of HIV infection among women of reproductive 
age in sub-Saharan Africa 
As shown previously, HIV-infection is highly prevalent among women in sub-Saharan Africa, 
particularly among girls and young women of reproductive age. This phenomenon started to 
be noticed during early twenties where prevalence rates among this population began to 
increase rapidly across the region.  
Understanding this particular vulnerability of women to acquire HIV infection in sub-Saharan 
Africa gained rapidly in public health relevance since early twenties. Aiming at rolling back 
the progression of HIV epidemic, in particular among girls and women, existing scientific 
evidence aimed principally at measuring the magnitude of the phenomenon within sub-
Saharan contexts and, on the other hand determining the different factors probably 
explaining the rapid spread of HIV epidemic among women in these contexts. In order to 
reduce the rapid spread of HIV-infection among girls and women, these scientific results 
have provided stakeholders and policymakers with sufficient information to design and 
implement preventive strategies aiming at tackling women’s-specific high vulnerability 
towards HIV-infection. 
This chapter will firstly present a brief insight of several factors explaining women’s 
vulnerability to acquire HIV infection. The following insight does not pretend to be 
exhaustive about all existing scientific evidence explaining causality and associated factors of 
the burden of HIV disease women’s are presently shouldering. The content of this section 
will recapitulate several major biological and psychosocial factors explaining women 
vulnerability to acquire HIV infection, with a special focus on sub-Saharan Africa.  
The present section will be closed with a peer-reviewed article published within this doctoral 
research framework aiming at estimating the prevalence of intimate partner physical and 
sexual violence among women according to HIV status in Lomé, Togo. 
 
 
 
58 
 
8.1. Vulnerability of women to contract HIV-infection 
Current findings point out that the particular vulnerability of girls and women to acquire HIV 
infection is owed in part to several women-specific biological factors and in part to several 
other socio-cultural context-specific factors. Biological factors referred to specificities of 
women anatomy and physiology that in some extent favor the entrance of the virus into 
women body. In addition to those women’s structural and functional specificities, other 
associated factors, more related to socio-cultural dynamics of African context which 
conditioned risk perception and preventive attitudes has been identified as well. Moreover, 
the possibility of interactions between these different factors has also been suggested. 
Indeed, gender differences in terms of HIV infection acquisition goes from primary biological 
sex-specific structures and functions to socio-cultural gender roles and attitudes assigned to 
women and men defining their social interactions. Taking into account all these factors, 
African women appeared to be at a higher risk of HIV infection than their male counterparts 
regardless their socioeconomic and psychosocial status. 
8.2. Biological factors associated with women’s vulnerability to 
acquire HIV infection 
8.2.1. Anatomic structure of women genitalia 
The anatomical configuration of women genitalia has been pointed out as the major 
biological factor defining women higher risk of contracting HIV infections. Together with 
several sexual practices, these feminine anatomical particularities are important biological 
drivers of women’s higher risk of contracting HIV infection through a sexual intercourse. 
The larger surface of the vagina increases significantly the exposure to infected semen 
and/or seminal fluids. Additionally, the mucosal barrier of the vagina is constituted of a 
fragile tissue which can be easily damaged during sexual intercourse, increasing the risk of 
infection. This vaginal fragility is particularly true for girls, who haven’t fully completed their 
reproductive development(79). Moreover, young women on early stages of physical 
development are more likely to present an anatomical modification known as cervical 
ectopy –hormone-induced protrusion of more fragile endocervical columnar epithelium to 
the cervical portion of the vagina -, leading to a larger more susceptible surface to HIV 
infection(80-82).  
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8.2.2. Presence of foreign microorganism in the vaginal environment 
The presence of other sexually transmitted diseases or other foreign microorganisms in the 
surface of the vagina increases significantly the risk of HIV transmission from men to women. 
Sexually transmitted infections causing ulcers and/or the inflammation produce by these 
conditions increase importantly the efficiency of HIV transmission by increasing both the 
infectiousness of and the susceptibility to HIV infection (83, 84).  The infection with candida 
albicans or trichomona vaginalis may increase the risk of HIV acquisition through cytokines-
related inflammatory mechanisms and immune cells impairments possibly increasing 
susceptibility to acquire HIV infection (85, 86) 
On the other hand, vaginal bacterial flora seems to play an important role in women 
vulnerability to contract HIV infection. Alterations of the delicate biological balance of these 
microorganisms and vaginal environment may lead to an increased risk of HIV acquisition. 
Bacterial vaginosis, condition characterized by an imbalance in the ecology of normal vaginal 
flora, has been consistently associated with an increased risk of HIV infection(87). Bacterial 
vaginosis is highly prevalent among women in sub-Saharan Africa and is frequently owed to 
practices and products commonly used by this population to clean and/or change vaginal 
texture and that may lead to a significant loss of lactobacilli or provoke a disruption of the 
epithelium increasing biological susceptibility to acquire HIV infection(88, 89). 
Moreover, seminal fluids are important reservoirs of HIV and major vectors of sexual 
transmission which are associated with HIV transmission. During acute HIV infection and late 
stages of HIV disease, seminal viral load increases significantly, increasing proportionally risk 
of HIV transmission from HIV-infected men to women (90, 91).  
8.2.3. Female hormones metabolism: The case of hormonal 
contraception 
Meeting women need for family planning is central to achieve three of the United Nations 
MDGs – Improving maternal health, reducing child mortality and combating HIV/AIDS – and 
contributes directly or indirectly to efforts to achieve all the eight goals(92, 93). Family 
planning provides women with a large range of benefits, improving health, schooling and 
economic outcomes (94-96). One important short term benefit of safe and effective family 
planning services helps to prevent unintended pregnancies, reducing the number of 
abortions, and lower the incidence of pregnancy-related deaths and disability(92, 94).  
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Despite the enormous health and socioeconomic benefits of family planning, recent 
scientific evidence suggests that certain methods might be probably associated with the risk 
of acquiring HIV infection (97-99). However, this evidence is not conclusive and whether 
various types of hormonal contraception affect the risk of HIV acquisition remains critical 
question for women’s health, principally in populations where HIV is common(100).    
Research studies conducted in non-human primates aiming at understanding plausible 
mechanisms explaining the potential higher risk of HIV acquisition associated with hormonal 
contraception have suggested several biological hypotheses. Hormonal contraception may 
probably induce modifications of the configuration of vaginal wall; thinning epithelium layers 
and thus facilitating virus entrance (101-106). Moreover, it has been also suggested that 
vaginal normal microbiota is sensible to hormonal changes and vaginal flora imbalances are 
probably associated with higher risk of HIV acquisition (87, 101, 107, 108). Finally, female 
sexual hormones are major modulators of vaginal in situ immune response, probably 
increasing the number and the activity of HIV-target cells present in the vaginal 
epithelium(99, 101, 109-111). It has been suggested that these structural and functional 
changes favoring a higher risk of HIV-acquisition are more progesterone-related than 
estrogen-related (101). 
On the light of these findings, a growing number of research studies have been exploring 
these hypotheses among humans. Owed to methodological limitations, findings of these 
studies are inconclusive. As no scientific evidence was definitive around the whether 
hormonal contraception increased or not the risk of HIV infection, in 2012, WHO convened a 
group of experts to review epidemiological, biological, and other data on this issue(112). This 
group concluded by consensus that WHO should recommend no restriction on use of any 
method of hormonal contraception for women at high risk of HIV(112). However, the group 
added a clarification that, because of the inconclusive nature of the evidence relating to 
progestin-only injectables, women at high risk for HIV who choose progestin-only injectables 
should be strongly advised to always use male or female condoms and to take other HIV 
preventive measures(112). 
Following this high level expert meeting more recent assessments of current emerging 
evidence on this concern established that although uncertainty persists regarding whether 
an association exists between hormonal contraception and the risk of HIV acquisition; 
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current evidence points out that DMPA (depot medroxyprogesterone acetate) but not NET-
EN (norethisterone oenanthate) or COC (combined oral contraceptives pills) use increased 
women's risk of HIV(113). No data have suggested significantly increased risk of HIV 
acquisition with use of implants, though data were limited (114). No data are available on 
the relationship between use of contraceptive patches, rings, or hormonal intrauterine 
devices and risk of HIV acquisition (114). Thus according to recent guidelines,  all women 
choosing progestin-only injectable contraceptives such as DMPA or NET-EN should be 
informed of the current uncertainty regarding whether use of these methods increases risk 
of HIV acquisition, and like all women at risk of HIV, should be empowered to access and use 
condoms and other HIV preventative measures(114). Randomized clinical trials are now 
required to conclusively determine whether HC, especially DMPA, increases the risk of HIV 
acquisition compared to alternative contraceptive methods (113). 
To summarize, compared to men, anatomic configuration and physiology of women increase 
their vulnerability to acquire HIV infection. Vaginal larger surface and the particular fragility 
of the epithelial tissue covering vaginal walls are effective entry ports to the virus. 
Alterations of vaginal normal bacterial flora or the presence of pathological microorganisms 
may lead to immunological changes probably favoring susceptibility to HIV infection. Vaginal 
tissue is particularly sensible to hormonal activity, which provoke modifications in the 
epithelial tissue configuration leading to a higher permeability and thus facilitating virus 
entry. Although these factors increase independently women vulnerability to acquire HIV 
infection, their interaction with some other context-related sociodemographic factors and 
psychosocial phenomenon needs to be taken into account. 
 
 
 
 
 
 
 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 3. Association of modern contraceptive methods with an increased risk of HIV infection 
The role of hormonal contraception increasing the risk of HIV acquisition has been the object of an 
important number of research studies. Despite the important amount of scientific evidence exploring 
and explaining the association of hormonal contraception with an increased risk of becoming HIV-
infected none of them is conclusive.  
In order to formulate accurate and ethicaly correct public health recommendations on the use of 
contraceptive methods several assessments of current scientific literature has been conducted. With 
this aim Polis C et al, conducted a systematic review of existing scientific literature which aimed at 
updating previous existing systematic reviews on hormonal contraception and HIV acquisition in 
women, incorporating new epidemiological evidence published between December 2011 and January 
2014. Whether specific methods of hormonal contraception influence a woman’s risk of HIV 
acquisition was the primary goal of this systematic review. This systematic review was conducted 
independently of the WHO guidance development process and served as an input to the deliberation 
of expert group meeting. 
Within this systematic review, 22 original research papers were retained as informatives. Consistently 
with previous reviews, present available evidence suggests that HIV risk acquisition is not increased 
by oral contraception. However, although the association between injectable contraceptives and HIV 
risk remain uncertain and inconclusive, new published analyses are consistent with prior scientific 
evidence suggesting that the use of DMPA lead to a moderate increase of HIV risk acquisition (figure 
14).  
 
Figure 14. A) Use of injectable contraceptives and HIV acquisition. Error bars show 95% CIs. B) Use of oral 
contraceptives and HIV acquisition. Error bars show 95% CIs. (Source: Polis, C et al, 2014). 
On the light of these findings, current guidelines on the use of Hormonal contraception recommend 
that women choosing progesting-only injectable contraceptives should be informed of the current 
uncertainty regarding whether use of these methods is associated with an increased risk of HIV 
acquisition, and similar to all women at risk of HIV, should be empowered to access and use condoms 
and other HIV preventive measures.  
Reference: Polis, C. B., S. J. Phillips, et al. (2014). "Hormonal contraceptive methods and risk of HIV acquisition in 
women: a systematic review of epidemiological evidence." Contraception 90(4): 360-390. 
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8.3. Socio-demographic and psychosocial factors driving HIV 
epidemic among women 
The existing literature describes an important number of socio-cultural and psychosocial 
factors probably explaining the special vulnerability of women to acquire HIV infection. 
Within this chapter I will make a point on the socio-demographic and psychosocial factors 
most commonly studied. The order on which the following factors are presented is more 
sequential rather than hierarchical.  
8.3.1. The role of education in the context of HIV epidemic 
Besides being a fundamental right of all human beings, education is critical process to 
develop both societies and individuals. Education ends generational cycles of poverty and 
disease, providing foundations for sustainable development(115). A quality basic education 
equips women and men with the necessary knowledge and skills they need to adopt healthy 
lifestyles, make healthy choices about their sexual behavior and take an active role in social, 
economic and political decision-making; attenuating the potentially devastating effect of HIV 
epidemic(115, 116). 
Given the relevant role played by education in terms of human development, achieving 
universal primary education under gender equitable norms has been set out as a part of the 
MDGs(93). Since this goal has been embraced by the global community in the year 2000, 
great progress in terms of educational enrolment and attainment has been achieved. In 
terms of access to education, the achievement have been particularly remarkable in 
developing regions where school enrolment rate grew from 83% in 2000 to 90% in 2011(93). 
It is worth to note that, within this period the number of children out of school declined 
strikingly of roughly the half, 102 Million in 2000 to 57 Million in 2011(93).  
However, although the global picture seems to be encouraging, important regional 
disparities remain. Recent estimations point out that more than half of out-of-school 
children live in sub-Saharan Africa(93). Although the school attendance rate among 
schooling-age children increased of roughly 20% within the last ten years in this region, 
around one quart of the children of schooling age remained out of school in this setting(93). 
Unsurprisingly, up to date literacy rate in sub-Saharan Africa was of 59%, the lowest 
worldwide(117)  
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Figure 15. Youth literacy rate by region and by sex, 1990 and 2011 (Percentage)  
     (Source: The Millennium Development Goals Report 2013) 
Moreover, former data also underscored the fact that, with few exceptions, in all regions 
women literacy rates were lower than male literacy rates(93, 117). Presently, women 
represents two thirds of illiterate adults worldwide(93, 117). These differences appeared to 
be more pronounced in sub-Saharan Africa where literacy rates among women barely 
exceed 50% whereas among men this rate is almost 30% higher(93) (figure 15).  
 
According to the Global Gender Gap report, sub-Saharan Africa is the region presenting the 
higher gender gap in terms of educational attainment subindex, with four countries form the 
region being part of the five lowest performing countries on that subindex, and with thirteen 
countries out of the bottom 20 countries on the literacy rate indicator(118). 
8.3.1.1. Education as a determinant of HIV infection rate among women 
The lack of education in terms of quantity and quality has been well documented as a major 
driver of vulnerability to acquire HIV infection(116). This is particularly true for contexts 
where access to school education is still far to be universal. 
School education, besides being a strategic gateway to introduce knowledge on HIV 
prevention; it also favors the development of cognitive skills favoring the adoption of safe 
sexual behaviors. The effect of education on behavior change can be measured in terms of 
school attendance but also in terms of school attainment (116). 
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8.3.1.2. The effect of educational attainment in reducing the risk of 
acquiring HIV infection among women 
Several pathways have been suggested through which educational attainment may reduce 
the risk of HIV acquisition. Firstly, current literature suggests that more educated women are 
more likely to be exposed to HIV preventive intervention probably increasing safe sexual 
practices and behaviors (119). Moreover, more educated women are probably more likely to 
understand the causal relationship between sexual behaviors and HIV acquisition and this 
understanding probably increase proportionally to school years (120). This means that 
educated women get to understand more clearly and in a practical way the transmission 
dynamic of HIV transmission, how to prevent themselves of contracting the infection and 
adopting more conscious preventive sexual practices(116, 120). Indeed, more educated 
women are more likely to negotiate safer sex(121), initiate a discussion about family 
planning with her intimate partner(122) and feel more self-confident about their sexual 
relationships and practices(123). 
Similarly, school attainment plays an important role in terms of developing social networks, 
which are strongly associated with social norms and individual behavior(116). Among 
women, sexual faithfulness and practices are significantly related to the number of network 
partners who also share this same attitudes and practices(124). This suggests that more 
educated women will tend more significantly to be surrounded by individual of a similar 
level, probably assuming safer sex practices and therefore having a reduced risk of HIV 
infection compared to those having a lower level of education(124). In addition, the fact of 
belonging to a well-functioning social group reduces the risk to become HIV infected by 1.5 
times among women (125).  
Finally, women attaining higher levels of education tend to delay sexual debut and marriage 
as well(126). Although staying single and probably sexually active for longer period have 
been suggested as a potential risk factor for more educated women, this fact is probably 
compensated by the greater knowledge in terms of HIV prevention this population has (116, 
126).  
Indeed, according to literature women with at least primary education were more likely to 
report condom use when compared with their counterpart who didn’t reach primary level 
(116, 120). Similarly, women with secondary education were less likely to report having had 
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unprotected casual sex and more likely to delay sexual debut (127). Figure 16 explains the 
mechanisms through which educational attainment reduce the risk of acquiring HIV infection 
among women. 
 
Figure 16. Pathways for the effect of educational attainment on HIV infection.  
    (Source: Jukes et al, AIDS, 2008) 
 
8.3.1.3. The effect of educational attendance in reducing the risk of 
acquiring HIV infection among women 
On the other hand, the mere fact of attending school regardless level of attainment has 
showed several repercussions in terms of prevention of HIV infection. The mechanisms 
explaining these repercussions are distinct from the consequences of increased educational 
attainment discussed above (ref) 
Compared with out-of-school young individuals, school pupils have smaller sexual networks, 
which may reduce the number of potential risk sexual exposures (128). Although often there 
were no differences in terms of HIV knowledge or access to HIV prevention materials 
between students and non-students, it has been suggested that students have less risky 
sexual behaviors and fewer sexual partners than non-students, and this was particularly true 
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for young school girls (116, 128). Moreover, students attending school have a stronger 
motivation to avoid consequences of unprotected sex (both pregnancy and HIV infection) 
when compared to their out-of-school peers (116, 128). 
In addition, keeping young girls in schools has been pointed out as a strategy to reduce 
teenage pregnancy rate which is a reliable indicator of unprotected sexual intercourses(129). 
Indeed, school girls are 1.5 less likely to have a child, which amounts to nearly a 10% 
decrease in the childbearing rate for teenagers(129). Moreover, findings of a study 
conducted in South Africa aiming at comparing sexual behavior between teenaged students 
and out-of-school teenagers showed up that students tends to have a lower number of 
sexual partners. Among young women attending to school, a small number reported having 
sexual partners more than three years older than themselves, having sex more than five 
times with a partner, and having unprotected sex during the past year(129). These findings 
suggest that keeping girls in school leads to a reduction in unprotected sex and a reduction 
in the number of partners which are major risk factors to acquire HIV infection(129). 
To summarize, education reduces effectively vulnerability of young people to acquire HIV 
infection through multiple mechanisms. Increasing the knowledge of young people in terms 
of prevention, developing skills to adopt preventive measures and behavior, and providing 
healthier networks are some of the ways through which education reduce young people 
vulnerability to HIV. Education exerts a HIV preventive effect among young women through 
two pathways, one measured in terms of education attainment and the other in terms of 
education attendance. Although both pathways exert a similar effect, they work through 
different mechanisms. In conclusion, keeping girls in the school and helping them to attain 
higher levels of education, besides providing them with skills and tools that will improve 
their socioeconomic status, will help them on taking better reproductive decisions and 
reducing their risk of acquiring HIV infection. 
8.3.2. Age disparate relationships 
In settings where poverty is highly prevalent and education lacks of quality, marriage 
concurs with school attendance and attainment as an alternative pathway to assure 
women’s basic needs (116). In these settings, age-mixing in sexual relationships between 
younger women an older men are not uncommon as older men are frequently wealthier 
than their younger counterpart and therefore more up to take in charge women needs. 
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Unfortunately, findings of research studies in sub-Saharan Africa underscore the fact that 
HIV infection is more prevalent among older men and this age-disparate relationships are 
probably one of the sources of the disproportionate rate of HIV between young women and 
young men (11, 12, 14, 130, 131). This assumption is underpinned by comparison of age-
adjusted HIV prevalence data (130) and mathematic modelling (132). 
Commonly, for young women, the more important drivers to get involved in a sexual 
relationship are emotional and material support whereas for boys these drivers are more 
likely related to social status, not necessarily linked to an economic position (133, 134). 
These particular drivers observed among young women are probably taking them to be 
more interested in older men, engaging into so called age-disparate relationships because 
older men would probably be more likely to fulfill their emotional and material needs (135). 
Age-disparate relationship, as defined in the literature refers to a gap between partners of 
five years or more, larger gaps have been classified as intergenerational or cross-
generational relationships(135).  
The age asymmetries between heterosexual couples have been found to be associated with 
unsafe sexual behavior, low condom use and therefore an increased risk of HIV infection, 
particularly among younger women(135, 136). Adolescent’s relationship dynamics are 
characterized by unequal decision-making between partners, lack or poor communication 
about sexual matters, lack of anticipation of sex and gender-based differences in the 
motivation to become sexually involved (133). Moreover, it has been suggested that the 
larger the age difference the greater the association with unsafe sexual practices and HIV 
infection (135, 137-139). Moreover, these findings suggest as well that for every year’s 
increase in the age difference between partners there was a 28% increase in the odds of 
having unprotected sex(135, 140). 
In sub-Saharan Africa, several factors have been identified within age-disparate relationships 
that increase the risk of sexually transmitted infections and HIV. Within age-disparate 
relationships, younger women tend to report a lower risk perception(135). Women in these 
settings often see older men as “safe” partners because to them, older men appear to be 
less reckless, more wishful to be in stable relationships and, more responsible and caring for 
the relationship (135, 141, 142).  
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Moreover, in sub-Saharan Africa women are often more concerned about the risk of 
becoming pregnant than of acquiring sexually transmitted infections or HIV (135, 143, 144). 
In addition, age disparities and economic dependence often compromise women’s capacities 
to negotiate safer sex. For a young women, insisting into the adoption of safe sex practices 
with older partners is often see as a menace to their economic goals in the relationship(135, 
137-139, 141, 145). 
According to literature, the reasons explaining why age-disparate relationships between 
young women and older men are common in sub-Saharan Africa have been suggested to be 
also context-dependent. Indeed, although the common denominator among young women 
in a relationship with older men is mostly a matter of economic benefit, the use of this extra 
income differs whether we explore rural or urban settings. 
8.3.2.1. Context-related drivers of age-disparate relationships: in rural 
settings 
The high levels of poverty and the respect of traditional gender roles and attitudes 
characterizing sub-Saharan Africa rural settings are major drivers of age-disparate and 
intergenerational relationships among women and men. The lack of access to health 
services, education and employment; together with the weak economy of rural settings 
often push girls into age-disparate relationships basically incited by the potential economic 
benefits(146-149). It is not uncommon in these settings that young women used the 
material benefit offered by older men to cover their basic needs such as schooling, food and 
clothing (150, 151). Moreover, it has been suggested that young girls are often encouraged 
by their parents to get involved in relationships with older employed men as a way to get 
money and fulfill other household necessities(135). 
Owed to the generalized precarious economic situation of rural settings in sub-Saharan 
Africa, for young women, marriage and motherhood are somewhat effective ways to assure 
their future socioeconomic security (135). Often young women engage in casual 
relationships with older men rather than to stablish with them to acquire resources to 
improve their desirability to potential younger husbands (135). In other words, resources 
provided by older men help young women to attract and maintain a relationship with 
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younger men, hopping this will lead to marriage and this is a legitimate manner to assure 
marriage within certain sub-Saharan Africa societies(144, 149). 
Finally and not less important, in rural settings, often young women behavior is 
predominantly ruled by traditional gender norms. Young rural women are often expected to 
be obedient and dutiful as a way to show respect towards older men. These attitudes are 
frequently associated to a higher risk of coercion and sexual violence by older men to 
engage in sex(135). 
8.3.2.2. Context-related drivers of age-disparate relationships: in urban 
settings 
In urban settings, economic benefit is also the major driver for young women to engage into 
age-disparate relationships with older men, these material benefits are often seen as an 
additional income to enjoy luxury and status (135). Among urban girls, material gain is the 
most commonly cited factor motivating they to engage in relationships with older men 
(135). The second most cited reason is having fun, which is often associated with glamour 
and the enjoyment of lifestyle consistent with urban context (135). For young women in 
urban settings, the probability of having their basic needs covered is higher thus economic 
benefits provided by older partners are mostly received as an accessory income to buy 
luxury and commodities(135). Moreover, in urban settings, young girls believe that agreeing 
to engage in unprotected sexual intercourses with an old partner assures a greater economic 
benefit (152, 153). 
Besides economic benefits, for urban young women attracting and maintaining relationships 
with one or several older wealthy men has also been considered as a mark of cleverness 
(135, 149). Engaging into a relationship with an older-wealthy man is for young women a 
mean to achieve goals of personal, familiar and societal success (135). Media has been 
pointed out as responsible in part of the new self-image young women build of themselves 
and their beliefs around wealth and success(135). In urban settings, women engaging in age-
disparate relationships often perceived themselves as modern empowered women without 
sexual constraint and great achievers(135). In addition, it is suggested as well that, as in rural 
settings, families often encourage young women to pursuit this kind of relationships as a 
mark of personal realization and life success(135).  
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Anyhow these relationships lead to an exchange of favors in which younger women are not 
often able to correctly negotiate safe sex practices. Furthermore, several studies have 
demonstrated a proportional relationship between the benefit and safe-sex practices. The 
larger the economic transfer of the older partner the less likely is the woman to negotiate 
safe sex practices(135). 
8.3.2.3. Cultural roots of age-disparate relationships 
In sub-Saharan Africa is not uncommon to consider girls to be ready for courtship and 
marriage soon after attaining sexual maturity(135). In order to assure young girls future, 
being wealth and older than the girl are much appreciated characteristics for a future 
husband(135). Moreover, older wealthy men are supposed to assume better the authority 
and family responsibilities(135). 
 Furthermore, in several African settings girls are often encouraged by their family to marry 
older men and are aware about the potential difficulties that getting involved with men of 
similar ages may bring with(135). It is supposed that couples of similar age are not destined 
to last and short age differences might lead to marriage instability(135). On the other hand, 
for men in African societies, getting involved with young women is a symbol of virility and 
vindicates masculinity as defined in these contexts. Moreover, older men often prefer young 
women because of their presumably higher fertility(135). 
In sub-Saharan Africa, age-disparate relationships are often based on 
reciprocal/transactional interactions within the couple, strengthened by the traditional 
gender roles and norms of these societies and maintaining the interdependence system. This 
interdependence system prescribes for men that demonstration of love, commitment and 
appreciation for sex is in measure of material giving. On the other hand for women, cultural 
norms prescribe that their worth as women, mother and sexual partner is validated and 
compensated by material goods. In other words, for women offering sex “for free” is 
synonym of lack of dignity and self-respect. 
The potential economic contribution of older partner is, in some cases used to fulfill basic 
needs in poor-contexts or, in less-unequitable contexts, just to enjoy a more relaxed and 
luxurious status. Young women, fearing losing this extra income lose their capacity to 
negotiate safer sex, believing that acceding to unsafe sexual practices will increase the 
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material reward. Moreover, in certain contexts, besides the economic benefits women 
receive by older partners, engaging such relationships is a symbol of success. Anyhow, 
whatever the motivation is, engaging in age-disparate relationships is a major risk factor for 
women to acquire HIV infection. This higher risk of acquiring HIV infection within this kind of 
relationships is explained in part by the higher probability of older men to be infected with 
HIV and by the limited capacity of young women to negotiate safe sex practices with older 
partners. To conclude it cannot be excluded the potential risk of physical and sexual violence 
young women may face when they don’t agree with the expected gender norms and 
attitudes they are expected. 
8.4. Gender-based violence: Intimate partner violence 
8.4.1. Global background of intimate partner violence 
Since the beginning of the century, gender-based violence has been recognized by the global 
community as the most ubiquitous and serious form of human rights violation worldwide 
(154-158). It is estimated that one in every five women faces some form of violence during 
her lifetime, in some cases leading to serious injury or death(157). Around 150 million girls 
under the age of 18 have experienced some form of sexual violence worldwide, with many 
never disclosing their traumatic experience(159). Moreover, violence against women is 
associated with complex social conditions such as poverty, lack of education, gender 
inequality, child mortality, maternal ill-health and HIV/AIDS (157). Therefore, within the 
Millennium Declaration, violence against women is recognized as a major threat to social 
and economic development(160).  
Amongst all forms of violence against women, intimate partner violence is the most 
common and universal form of violence experienced by women and includes physical, 
sexual, and emotional abuse and controlling behaviors by an intimate partner(161-163). The 
World Health Organization has proposed the following definitions in order to aid research 
and programming to correctly identify an measure violent acts perpetrated against women 
(161): 
1. Intimate partner violence (also called “domestic” violence) is any self-reported 
experience of one or more acts of physical and/or sexual violence perpetrated by a 
current or former partner since the age of 15 years. 
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a) Physical violence means a woman has been slapped, or had something thrown at 
her; pushed, shoved, or had her hair pulled; hit with a fist or something else that 
could hurt; choked or burnt; threatened with or had a weapon used against her. 
b) Sexual violence means a woman has been physically forced to have sexual 
intercourse; had sexual intercourse because she was afraid of what her partner 
might do; or forced to do something sexual she found degrading or humiliating.  
Though recognized as a serious and pervasive problem, emotional violence does not yet 
have a widely accepted definition, but includes, for example, being humiliated or belittled; 
being scared or intimidated purposefully (161).  
An important number of population-based surveys have measured the prevalence rates of 
intimate partner violence; one notable survey among these is the WHO multi-country study 
on women’s health and domestic violence against women. This survey collected data on 
intimate partner violence of around 24 000 women in 10 culturally and geographically 
diverse countries around the world. Findings of this population-based survey showed that in 
almost all settings where this study took place, women were more at risk of violence by an 
intimate partner than from any other perpetrator (162) (figure 17). 
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Figure 17. Frequency distribution of partner and non-partner physical or sexual violence, or both, for 
women reporting such abuse since the age of 15 years, by site (Source: Garcia-Moreno et 
al. Lancet 2006). 
In addition, according to this large population-based survey, global prevalence rates of 
physical and sexual violence could be as high has 61% and 59% respectively (162). Currently, 
according to the World Health Organization estimations, about one in three women 
experience physical and/or sexual violence by an intimate partner (159). In order to guide 
preventive interventions, current research has explored as well factors associated with this 
phenomenon.   
8.4.2. Factors associated with intimate partner violence 
The ecological model is the most broadly used model to understand violence, this model 
proposes that violence results of factors operating at four different levels: individual, 
relationship, community and societal. Some risk factors are systematically identified across 
studies regardless the setting whereas other factors are more contexts specific and vary 
among and within countries(156, 157, 161). 
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There are two categories of individual factors associated with intimate partner violence. In 
the first category are the factors associated with a man’s increased likelihood of committing 
violence against his female partner and the most frequently cited factors are young age, low 
level of education, witnessing or experiencing violence as a child, harmful use of alcohol and 
drugs, personality disorders, acceptance of violence, past history of abusing partners(161). 
On the other hand, the second category is constituted by the factors associated with a 
woman’s increased likelihood of experiencing violence by her partner, within this category 
the most commonly cited factors are: low level of education, exposure to violence between 
parents, sexual abuse during childhood, acceptance of violence and exposure to other forms 
of prior abuse(161). 
Relationship-related factors with intimate partner violence, which is the next level are 
conflict or dissatisfaction in the relationship, male dominance in the family, economic stress, 
man’s concurrent relationships, disparity in educational attainment (161). 
 At the community and societal level, the following factors have been found associated with 
an increased risk of intimate partner violence: gender inequitable social norms, poverty, low 
social and economic status of women, weak legal sanctions against IPV within marriage, lack 
of women’s civil rights, including restrictive or inequitable divorce and marriage laws, weak 
community sanctions against domestic violence, broad social acceptance of violence as a 
way to resolve conflict and armed conflict and high levels of general violence in society(161). 
8.4.3. Consequences of intimate partner violence 
Intimate partner violence has important acute and chronic repercussions on women’s 
mental and physical health (5, 161, 164). In order to explain the mechanism through which 
intimate partner violence may lead to adverse health outcomes several pathways have been 
suggested(161) (figure 18). 
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Figure 18. Pathways and health effects on intimate partner violence. (Source: WHO, 2013) 
 
Women suffering of abuse report higher level of depression, anxiety and phobias than their 
counterparts who have never been victim of abuse(161). According to findings of the WHO 
multi-country study, women who had experienced physical or sexual violence reported 
significantly higher levels of emotional distress, thoughts of suicide, and attempted suicide 
than those who had not experience violence(161, 162). Likewise, intimate partner violence 
has been also linked to mental and behavioral disorders such as alcohol and drugs abuse, 
eating and sleeping disorders, poor self-esteem, smoking and unsafe sexual behavior(161, 
162). 
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Moreover, injuries resulting from physical violence can be important sources of handicap 
and disabilities for women victims (161). In the WHO multi-country study, the prevalence 
rate of injury among women who had ever been physically abused by their intimate partner 
could be as high as 55%(162). It is worth to note that, violent acts during pregnancy account 
for an important proportion of maternal and child mortality, often unrecognized (161, 162). 
Intimate partner violence has as well harmful repercussions in sexual and reproductive 
health including unintended pregnancies, abortions and unsafe abortions and sexually 
transmitted diseases including HIV(161). The increased risk of acquiring sexually transmitted 
diseases can be directly associated with coerced sexual intercourses within marriage or 
indirectly, as women victims of intimate partner physical and sexual violence, are unable to 
successfully negotiate contraceptive or condom use with their partner(161, 162, 165) 
8.4.4. HIV infection: cause and consequence of violence intimate 
partner violence  
Since early nineties, findings of cross-sectional assessments conducted in Africa and South 
Asia underscore the fact that women victims of physical and/or sexual violence from male 
intimate partners were more likely to have prevalent sexually transmitted infections, 
including HIV(165-171). In these settings, intimate partner violence increased the odds of 
being HIV-infected by almost three times and by about ten times among women under 30 
years old(165, 168, 170).  
Indeed, women experiencing intimate partner violence were 55% more likely to become 
infected by HIV (172, 173).  This risk appeared to increase proportionally to the severity of 
this violence (174, 175). The odds were even higher for women who had also experienced 
sexual abuse in childhood. Those women were 2.5 times more likely to be HIV-positive than 
women who had never experienced any intimate partner violence nor any childhood sexual 
abuse(173). The national prevalence of forced first sex among adolescent girls younger than 
15 years ranges between 11% and 45% globally(173). In South Africa nearly one in seven 
cases of people acquiring HIV infection could have been prevented if the women had not 
been subjected to physical or sexual abuse(173). 
More recently, longitudinal research affirmed that young women who had experienced 
either intimate partner violence and/or high levels of gender inequality in their couple 
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relationships presented an elevated risk of acquiring HIV (174, 175). These findings suggest a 
strong causal link between intimate partner violence and HIV infection acquisition(176). 
Several pathways explaining the mechanisms through which intimate partner violence 
increases the risk of HIV acquisition among women victims have been proposed. Firstly, 
perpetrators of violence are generally considered more likely to be HIV infected because of 
links observed between violence perpetration, high-risk sex and the use of alcohol and 
drugs(176). Two main pathways explaining how victims of violence become infected by HIV 
are proposed. The first pathway is through direct transmission from an infected perpetrator 
of violence and the second pathway is more related to an increased long term HIV 
vulnerability resulting from experiences of violence (176) (figure 19). 
 
 
 
 
 
 
 
 
 
 
Furthermore, current research point out as well that intimate partner violence is highly 
prevalent among HIV-positive women. Findings of several studies suggest that women are 
more likely to experience intimate partner violence if they are known to be living with HIV 
(165, 173).  This increased likelihood of HIV-positive women to be victims of intimate partner 
violence is regardless geographic location and socioeconomic status. In a study conducted by 
Dhairyawan et al in United Kingdom findings showed that more than the half of HIV-positive 
Figure 19. Illustration of pathways from gender inequality and high-risk masculinity to 
increased HIV risk among survivors of violence. (Source: Dunkel et al, Am J 
Reprod Immunol, 2013) 
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women interviewed reported that they had experienced intimate partner violence, one in 
every seven had experienced it within the past two months alone(177). Findings of this study 
also underscored that women reported increased violence following their HIV diagnosis or 
disclosure (173, 177). Likewise, findings of a large study conducted by Silverman et al in India 
showed that prevalence rates of HIV infection were significantly higher among married 
Indian women experiencing both physical and sexual violence from husbands compared to 
those not experiencing intimate partner violence (0.73% vs 0.19%; adjusted OR, 3.92; 95% 
CI, 1.41-10.94; P = .01)(170). The People Living with HIV Stigma Index shows that women 
living with HIV in the Asia-Pacific region are more likely than men living with HIV in the same 
region to be the target of verbal abuse and physical violence as a direct result of their HIV 
status(178). 
To summarize this section, we retain that intimate partner violence is the most frequent 
form of violence women face. Although intimate partner violence is highly prevalent 
worldwide, it appeared to be higher in low-and-middle income settings. Intimate partner 
violence has been associated with important negative health consequences and important 
risk factor to acquire HIV infection. Moreover, among women, an HIV positive status has 
been associated with a higher risk of being victim of intimate partner violence. Although the 
prevalence rate of intimate partner physical and sexual violence has been documented in 
several sub-Saharan African settings, this indicator is scarcely documented in the West 
African region. Scientific findings of the following peer-reviewed article are amongst the first 
published reporting prevalence rates of intimate partner physical and sexual violence in the 
West African region. 
 
 
 
 
 
 
80 
 
Burgos-Soto, J. et al. (2014). "Intimate partner sexual and physical violence 
among women in Togo, West Africa: prevalence, associated factors, and the 
specific role of HIV infection." Glob Health Action 7: 23456. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENDER AND HEALTH
Intimate partner sexual and physical violence among
women in Togo, West Africa: Prevalence, associated
factors, and the specific role of HIV infection
Juan Burgos-Soto1,2*, Joanna Orne-Gliemann1,2, Gae¨lle Encrenaz3,
Akouda Patassi4, Aurore Woronowski5, Benjamin Kariyiare5,
Annette K. Lawson-Evi6, Vale´riane Leroy1,2, Franc¸ois Dabis1,2,
Didier K. Ekouevi1,5 and Renaud Becquet1,2
1INSERM, Centre INSERM U897 ‘Epide´miologie et Biostatistique’, Bordeaux, France; 2Universite´ de
Bordeaux, Institut de Sante´ Publique Epide´miologie De´veloppement (ISPED), Bordeaux, France;
3COMPTRASEC, CNRS UMR 5114, Pessac, France; 4Service des maladies infectieuses, Centre
Hospitalier Universitaire Sylvanus Olympio, Lome´, Togo; 5De´partement de Sante´ Publique, Faculte´
mixte de me´decine et pharmacie, Lome´, Togo; 6Service de pe´diatrie, Centre Hospitalier Universitaire
Sylvanus Olympio, Lome´, Togo
Background: A substantial proportion of newly diagnosed HIV infections in sub-Saharan Africa occur within
serodiscordant cohabiting heterosexual couples. Intimate partner violence is a major concern for couple-
oriented HIV preventive approaches. This study aimed at estimating the prevalence and associated factors of
intimate partner physical and sexual violence among HIV-infected and -uninfected women in Togo. We also
described the severity and consequences of this violence as well as care-seeking behaviors of women exposed to
intimate partner violence.
Methods: A cross-sectional survey was conducted between May and July 2011 within Sylvanus Olympio
University Hospital in Lome´. HIV-infected women attending HIV care and uninfected women attending
postnatal care and/or children immunization visits were interviewed. Intimate partner physical and sexual
violence and controlling behaviors were assessed using an adapted version of the WHOMulti-country study on
Women’s Health and Life Events questionnaire.
Results: Overall, 150 HIV-uninfected and 304 HIV-infected women accepted to be interviewed. The prevalence
rates of lifetime physical and sexual violence among HIV-infected women were significantly higher than among
uninfected women (63.1 vs. 39.3%, pB0.01 and 69.7 vs. 35.3%, pB0.01, respectively). Forty-two percent of the
women reported having ever had physical injuries as a consequence of intimate partner violence. Among
injured women, only one-third had ever disclosed real causes of injuries to medical staff and none of them had
been referred to local organizations to receive appropriate psychological support. Regardless of HIV status
and after adjustment on potential confounders, the risk of intimate partner physical and sexual violence was
strongly and significantly associated with male partner multi-partnership and early start of sexual life. Among
uninfected women, physical violence was significantly associated with gender submissive attitudes.
Discussion and conclusions: The prevalence rates of both lifetime physical and sexual violence were very high
among HIV-uninfected women and even higher among HIV-infected women recruited in health facilities in this
West African country. Screening for intimate partner violence should be systematic in health-care settings, and
specifically within HIV care services. At a time of increased investments in couple-oriented HIV prevention
interventions, further longitudinal research to better understanding of HIV-serodiscordant couple dynamics in
terms of intimate partner violence is needed.
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A
ccording to the World Health Organization
(WHO), intimate partner violence is defined as
the behavior, within an intimate relationship, that
causes physical, sexual, or psychological harm or suffering
(1). Several population-based surveys have reported that
among all forms of violence against women, intimate
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partner violence is the most prevalent and it is considered
the most common human rights violation hitherto (2, 3).
Although there is still insufficient consensus on the
operational definition and measurement of intimate
partner violence, available estimations of lifetime preva-
lence of intimate partner violence vary from 15 to
71% worldwide, with the highest rates documented in
resource-constrained settings (4). Intimate partner vio-
lence is associated with poor health outcomes among
victims and is therefore a major public health issue (57).
Besides its dramatic physical and mental consequences,
intimate partner violence has also been identified as an
important risk factor for sexually transmitted diseases
acquisition and particularly HIV infection (8). Intimate
partner violence and HIV infection are linked by a very
complex association, including diverse pathways. An
increased risk of HIV transmission within abusive rela-
tionships and a greater likelihood of acquisition of HIV
infection by violent husbands have been reported (8, 9).
Acts derived from intimate partner violence, such as co-
erced sexual intercourse, during which women are unable
to protect themselves from transmission, place women at
direct risk of HIV infection (10).
Sub-Saharan Africa is the region reporting the highest
epidemiological burden of HIV worldwide, with women
accounting for 58% of newly acquired HIV infections
(11). Furthermore, HIV infection in these settings spreads
principally through heterosexual transmission and a sub-
stantial proportion of newly diagnosed infections occur in
HIV-discordant cohabiting couples in which only one
person is living with HIV (12). HIV prevention interven-
tions aiming at protecting both couple members are thus
a public health priority to reduce HIV incidence in these
regions and several approaches have been already pro-
posed (1014). In spite of their proven efficacy, the chal-
lenges in implementing couple-oriented HIV preventive
approaches are tremendous, and most importantly be-
cause they are based on mutual disclosure of HIV serol-
ogical status (1417). Intimate partner violence as one
important consequence of HIV serological disclosure
is thus one major limit of couple-oriented HIV preventive
approaches and understanding its magnitude, dynamics,
and factors associated are a prerequisite to the roll out
of these couple strategies (1, 10, 12, 13).
In Togo, a West African country with an estimated
prevalence rate of HIV infection of 3.4% nationwide and a
predominantly heterosexual epidemic (11), intimate part-
ner violence among women and its association with HIV
infection has never been studied so far using a quantitative
methodological approach, to the best of our knowledge.
Moreover, data on intimate partner violence according
to serological status in the West African region are very
scarce, although it is needed to improve the scaling-up of
HIV prevention, care, and treatment programs. This study
aimed at estimating the prevalence and associated factors
of intimate partner physical and sexual violence among
HIV-infected and -uninfected women of childbearing age
attending a clinical facility in Togo. We also described the
severity and consequences of this violence as well as care-
seeking behaviors of women exposed to intimate partner
violence.
Methods
Study design and population
This project was an international collaboration between
the INSERM (National Institute of Health and Medical
Research) Research Centre U897 based in Bordeaux
(France), the Sylvanus Olympio University Hospital in
Lome´, and the non-governmental organization Espoir
Vie Togo, one leading organization providing care and
psychological support to people living with HIV/AIDS
in Togo.
A cross-sectional survey was conducted between
May and July 2011 within the Lome´ University Hospital.
The study population was constituted by volunteer
participants attending clinical services in the hospital.
HIV-infected women attending regular HIV care visits
constituted the first group. Women attending postnatal
care and/or children immunization visits, and who had
been diagnosed HIV-uninfected during their last preg-
nancy, constituted the second group. For these two study
groups, women aged at least 18 years, declaring having
a current intimate partner or having ever had one, were
eligible to recruitment.
Study procedures
The survey was conducted in three stages. The first
preparatory phase consisted of a methodological work-
shop between Togolese and French researchers to discuss
the study design, validate the survey instruments, and
address relevant ethical issues. A local team of four
psychologists was recruited to adapt concepts described
in the questionnaires to the local context, train inter-
viewers on the study tool, ethical and privacy terms,
and supervise data collection.
Second, a pilot study was carried out to test the
acceptability, adequacy, and understandability of the
recruitment procedures and questionnaire. Survey feasi-
bility data and interviewer’s observations were integrated
within the final survey procedures and tools.
Finally, every working day during the study period,
each eligible woman was systematically asked to partici-
pate in the survey and to provide signed informed consent
to be sequentially enrolled. Trained female health-care
staff administered the questionnaire during a 20-min
face-to-face interview in a private room.
All interviews were carried out in French, and all
participants were provided information about local sup-
port services dedicated to women experiencing intimate
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partner violence. HIV-infected women were informed
about the psychological support available at Espoir vie
Togo.
The study protocol was approved by the National Ethic
Committee of the Ministry of Health of Togo (N80125/
2011/MS/CAB/DGS/DPLET/CBRS). Written informed
consent was obtained from all participants; and all data
collection tools were strictly anonymous.
Intimate partner physical and sexual violence
assessment
Our questionnaire assessing intimate partner physical
and sexual violence and controlling behaviors was largely
inspired by the WHO Multi-Country Study on Women’s
Health and Life Events questionnaire (version 10) (4,
18, 19).
All women participating in the survey were asked about
their life experience on specific acts of physical and sexual
violence induced by their intimate partner. Physical vio-
lence was defined as the use of physical force causing
bodily harm (1). Within the survey, women were also
asked about physical consequences of physical violent acts
induced by an intimate partner, as well as help-seeking
behaviors. Sexual violence was defined as any situation
where women faced forced or coerced sexual act or at-
titude (1). Prevalence of physical/sexual violence was
estimated as the proportion of women declaring having
been exposed to any kind of physical or sexual violent act
by their current intimate partner or any previous partner.
Additionally, we explored attitudes toward partner
controlling behaviors that we summarized in six state-
ments, illustrating different gender submissive situations
to which women were asked to agree or not. We developed
a scoring system to define a ‘submission index’ summar-
izing women’s attitudes toward partner controlling beha-
viors based on the sum of the number of positive answers
to six questions detailed in Table 1.
We also documented women’s sociodemographic char-
acteristics (age, instruction level, and contraceptive use),
data on the women’s partner (alcohol consumption and
frequency of involvement in fights) and couple relation-
ships (polygamy and concurrent relationship), women’s
employment and financial autonomy (having a financial
autonomy to support herself and household without
her partner for at least 1 month), and the modalities of
women’s entry in sexual life (conditions and age at first
sexual intercourse). We also investigated women’s mental
health (loss of interest, suicidal thoughts, and suicidal
attempts) and the history of non-partner violence (physi-
cal violence after 15 years and sexual violence before and
after 15 years).
Statistical analysis
Sociodemographical and psychosocial characteristics
of women and partners were described and compared
between HIV-infected and -uninfected women. Maternal
age was dichotomized into two categories with a cut-off
defined by the median in the overall population (e.g. 33
years). Age of first sexual intercourse was dichotomized
into two categories with a cut-off defined by the age
at sexual majority in Togo (e.g. 18 years). The prevalence
of lifetime physical and sexual violence was estimated
separately among HIV-infected and -uninfected women
and also compared between the two groups. Chi-square
tests were performed to determine statistically significant
differences. Sociodemographic and behavioral factors
associated with lifetime physical and sexual violence in
both groups were then assessed using logistic regression.
Both univariate and multivariate analyses were carried
out. Variables found to be statistically associated with in-
timate partner violence with a p-value of B0.25 were
included in the multivariable model. To select the final
adjusted model presented in this paper, we used a back-
ward elimination method using a p-value of 0.05 (20).
Adjusted odds ratios (aORs) were estimated using multi-
ple logistic regression modeling and statistical signifi-
cance was considered at the 5% level. Statistical analyses
were generated using SAS software (version 9.2 for
Windows, Copyright 2013 for SAS Institute Inc., Cary,
NC, USA).
Results
Overall, 454 women attending the Sylvanus Olympio
University Hospital were informed about the study and
screened for eligibility; all of them accepted to be
interviewed and were included in the study. One hundred
and fifty women were HIV-negative and 304 were HIV-
positive.
Study population characteristics
Sociodemographical and behavioral characteristics of
women in both groups are described in Table 1 and
summarized as follows.
Concerning women’s sociodemographic profile and
financial autonomy, HIV-infected women were signifi-
cantly older than uninfected women (35 [3237] and 30
[2934] years old in median [interquartile range], respec-
tively, pB0.01). The proportion of HIV-uninfected women
having completed at least primary education was signifi-
cantly higher than among HIV-positive women (94.7 vs.
83.9%, p0.01). HIV-infected women were significantly
more likely than uninfected women to report some degree
of financial autonomy (56 vs. 39.3%, pB0.001). HIV-
uninfected women were more likely to be using a contra-
ceptive method at the time of the survey than HIV-infected
women (64.7 vs. 42.1%, p50.001).
Concerning modalities of entry to sexual life, the
proportion of women having entered sexual life before
the age of 18 was higher among HIV-infected than HIV-
negative women (62.8 vs. 58.0%, p0.32). HIV-infected
women were significantly more likely to start sexual life
Violence & HIV in Togo
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Table 1. Characteristics of women interviewed according to their HIV status: Lome´, Togo, MayJuly 2011
HIV uninfected
(N150)
HIV infected
(N304)
n % N % p
Women’s sociodemographic profile
Age
]33 y/o 55 36.7 185 60.9 B0.01
B33 y/o 95 63.3 119 39.1
Instruction level
Not instructed 8 5.3 49 16.1 0.01
At least primary level 142 94.7 255 83.9
Contraceptive methoda
Yes 97 64.7 128 42.1 B0.01
No 53 35.3 176 57.9
Financial autonomy
Employment
Yes 103 68.7 242 79.6 0.01
No 47 31.3 62 20.4
Financial autonomy to support herselfb
Yes 59 39.3 170 56.0 B0.01
No 91 60.7 134 44.0
Modalities of entry to sexual life
Age of first sexual intercourse
]18 y/o 63 42.0 113 37.2 0.32
B18 y/o 87 58.0 191 62.8
Conditions of first sexual intercourse
Consented 121 80.7 209 69.4 0.01
Coerced 29 19.3 92 30.6
Women’s mental health
Loss of interestc
Yes 103 68.7 225 74.0 0.23
No 47 31.3 79 26.0
Suicidal thoughtsd
Yes 36 24.0 157 51.6 B0.01
No 114 76.0 147 48.4
Suicidal attemptsd
Yes 8 5.3 23 7.6 0.37
No 142 94.7 281 92.4
Partners profile
Polygamous
Yes 19 12.7 138 45.4 B0.01
No 131 87.3 166 54.6
Concurrent relationships
Yes 52 34.7 203 66.8 B0.01
No 98 65.3 101 33.2
Alcohol consumption
Never/occasionally 85 56.7 125 41.0 0.01
Frequently 65 43.3 179 59.0
Frequently involved in fights/riots
Yes 11 7.3 65 21.4 B0.01
No 139 92.7 239 78.6
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through a first forced sexual intercourse than uninfected
ones (30.6 vs. 19.3%, p0.01).
Concerning partner’s profile characteristics, HIV-
infected women were more likely to live within polyga-
mous households than uninfected women (45.4 vs. 12.7%,
pB0.001) and to declare that their partner had concurrent
relationships out of the household (66.8 vs. 34.7%,
pB0.001). Reported rates of partner alcohol consumption
(59.0 vs. 43.3%, p0.01) and partner involvement in fights
and riots (21.4 vs. 7.3%, pB0.001) were more frequent
among HIV-infected women than uninfected women.
Concerning women’s mental health, suicidal thoughts
during the past 12 months were significantly more
frequent among HIV-infected women than among the
uninfected ones (51.6 vs. 24.0%, pB0.001). The propor-
tion of HIV-infected women reporting loss of interest
Table 1 (Continued )
HIV uninfected
(N150)
HIV infected
(N304)
n % N % p
History of non-partner violence
Physical violence after 15 y/o
Yes 60 40.0 200 65.8 B0.01
No 90 60.0 104 34.2
Sexual violence after 15 y/o
Yes 1 0.7 11 3.6 0.06
No 149 99.3 293 96.4
Sexual violence before 15 y/o
Yes 6 4.0 41 13.5 0.01
No 144 96.0 263 86.5
Controlling behaviors and submission index
A good wife obeys her partner,
even if she does not agree with him
Yes 113 75.3 278 91.5 B0.01
No 37 24.67 26 8.55
It is important that a man shows
his wife who is the boss?
Yes 104 69.3 240 78.9 0.02
No 46 30.7 64 21.0
A woman may have the freedom to choose
her friends, even if her partner does not agree?
Yes 19 12.7 49 16.1 0.33
No 131 87.3 255 83.8
Satisfying her husband’s sexual desire even
if she does not want to is a women’s duty?
Yes 46 30.7 151 49.7 B0.01
No 104 69.3 153 50.3
If a man abuses his wife, people around
must intervene?
Yes 122 81.3 240 78.8
No 28 18.6 64 21.1
A man must strike his wife if he considers
this necessary?
Yes 49 32.7 174 57.2 B0.01
No 101 67.3 130 42.7
Submission index
Median 3 4 B0.01
aUse of any contraceptive method at the moment of the survey.
bHaving a financial autonomy to support herself and household without her partner for at least 1 month.
cDuring at least two weeks over the last 12 months.
dAt least once over the last 12 months.
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(74.0 vs. 68.7%; p0.23) and suicidal attempts (7.6 vs.
5.3%, p0.37) during the past 12 months tended to be
higher than among uninfected ones but differences were
not statistically significant.
Finally, HIV-infected women were slightly more likely
to agree to submissive statements than HIV-uninfected
women (scoring of 4/6 and 3/6, respectively; pB0.001).
Intimate partner violence: prevalence, severity, and
care-seeking behaviors
As detailed in Table 2, the prevalence rate of lifetime
physical violence among HIV-infected women was 63.1%
(95% CI: 57.568.4), significantly higher than among
uninfected women (39.3%; 95% CI: 31.146.8; pB0.01).
Similarly, HIV-infected women reported a significantly
higher prevalence rate of lifetime sexual violence com-
pared to the uninfected ones (69.7%; 95% CI: 63.874.1 vs.
35.3%; 95% CI: 27.342.6; pB0.01). The lifetime pre-
valence rate of both types of violence combined (physical
and sexual violence) was 51.6% (95% CI: 45.356.6)
among HIV-infected women and significantly higher than
among uninfected women (18.6%; 95% CI: 11.824.1;
pB0.01; Table 2).
HIV-infected women were more likely to report a
history of physical violence after the age of 15 than
HIV-uninfected women (65.8 vs. 40.0%; pB0.001) and
the frequency of sexual violence during childhood (before
15 years old) was 13.5% among HIV-infected versus
4.0% among uninfected ones (p0.01; Table 1).
Among women ever victims of intimate partner physical
violence (n251), 194 (77.2%) reported physical injuries
as a consequence of this violence (Table 3). Most com-
monly reported injuries were scratches and bruises
(80.9%), dislocation and sprains (62.9%), eardrums rup-
ture and black eyes (54.6%), penetration injuries and deep
cuts (28.9%), and gashes and bites (20.1), although less
commonly reported were burns (5.7%), fractures (4.6%),
and broken tooth (1.6%). There were no differences
between the type of injuries reported by HIV-infected
and -uninfected women (data not shown).
Among the 194 women reporting being injured by
intimate partner violence, 160 (82.4%) reported needing
medical care for their injuries. From those needing medical
care, 93 (58.1%) received medical care and 14 (7.2%) were
even hospitalized. Among injured women in care, 49
(52.6%) disclosed real causes of injuries to medical staff
and none of them was referred to local organizations
to receive appropriate psychological support (Table 3).
Factors associated with physical violence
The only common factor associated with a history of inti-
mate partner physical violence regardless of women’s sero-
logical status was having a partner maintaining concurrent
relationships out of the household (HIV-uninfected: aOR:
2.5; 95% CI: 1.15.5; p0.02, and HIV infected: aOR:
2.2; 95% CI: 1.33.6; pB0.001). Otherwise, the profile of
HIV-infected and HIV-negative women reporting intimate
partner physical violence was different (Table 4).
Among women’s sociodemographic and sexual char-
acteristics, age was associated with physical violence only
for HIV-uninfected women (33 years old or below vs. older
than 33 years: aOR: 0.4; 95% CI: 0.20.9; p0.02), and
education level only for HIV-infected women (at least
primary level vs. never attended school: aOR: 2.0; 95%
CI: 1.04.2; p0.05). Uninfected women not using any
contraceptive method at the time of the survey were more
likely to be victims of intimate partner physical violence
(aOR: 2.3; 95% CI: 1.05.0; p0.04). Among uninfected
women, the odds of intimate partner sexual violence were
significantly higher among those reporting a first coerced
sexual intercourse (aOR: 2.6; 95% CI: 1.16.6; p0.04).
In terms of women’s mental health status, having ever
attempted suicide was strongly associated with a history
of intimate partner physical violence, for HIV-infected
women only (aOR: 4.5; 95% CI: 1.315.9; p0.02). In
the univariate analysis, loss of interest during at least
Table 2. Lifetime prevalence rates of intimate partner violence (physical, sexual, and both types of violence) among women,
according to their HIV status: Lome´, Togo, MayJuly 2011
HIV uninfected,
N150
HIV infected,
N304
n % 95% CI n % 95% CI
Any form of physical violence
Yes 59 39.3 31.146.8 192 63.2 57.568.4
No 91 60.7 52.167.8 112 36.8 30.641.3
Any form of sexual violence
Yes 53 35.3 27.342.6 212 69.7 63.874.1
No 97 64.7 56.371.6 92 30.3 24.835.1
Any form of physical and sexual violence combined
Yes 28 18.7 11.824.1 157 51.6 45.356.6
No 122 81.3 74.787.2 147 48.4 42.353.6
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two weeks (OR: 2.9; 95% CI: 1.74.9; pB0.001) and
having had suicidal thought at least once over the last
12 months (OR: 1.7; 95% CI: 1.12.8; p0.02) were also
associated with having experienced intimate physical
violence among HIV-infected women.
Factors associated with sexual violence
As detailed in Table 5, starting sexual life before the age
of 18 appeared to be the only common factor associated
with intimate partner sexual violence among both HIV-
infected and -uninfected women (HIV-infected women:
aOR: 2.3; 95% CI: 1.14.9; p0.01, and uninfected
women: aOR: 2.3; 95% CI: 1.24.4; p0.03).
Otherwise, the profile of women reporting intimate
partner sexual violence differed according to HIV serolo-
gical status. HIV-uninfected women reporting having
partners maintaining concurrent relationships out of house-
hold were more likely to report intimate partner sexual
violence (aOR: 2.4; 95% CI: 1.14.9; p0.02). For
HIV-infected women, intimate partner sexual violence
was associated with reporting suicidal thoughts (aOR:
1.9; 95% CI: 1.23.4; p0.01), having partners who were
involved in fights and/or riots with other men (aOR:
2.6; 95% CI: 1.25.5; p0.01), and reporting a higher
submission index (aOR: 1.6; 95% CI: 1.22.0; pB0.001).
Discussion
We reported here on the prevalence of lifetime intimate
partner physical and sexual violence according to HIV
status among women recruited in health facilities in
Togo. Our main finding is that the prevalence rates of
both lifetime physical and sexual violence in 2011 were
very high among HIV-uninfected women and even higher
among HIV-infected women in this West African country.
The prevalence rates we documented among uninfected
women are similar to those estimated using the same
methodology within population-based surveys from East
Africa, both in terms of physical violence (3249%) and
sexual violence (2358%) (4). On the contrary, more than
half (63.1%) of the HIV-infected women in Togo reported
lifetime intimate partner physical violence, which is almost
twice as high than among uninfected women interviewed
(39.3%) and much higher than the rates observed among
HIV-infected women in Nigeria (6%) (21), or in eastern
Africa (17%) (22). In terms of lifetime intimate partner
sexual violence, the prevalence rate we documented among
HIV-infected women in Togo (69.7%) is twice the rate of
that among uninfected women and considerably higher
than among other reported estimations in Africa, such as
in Uganda (12%) (22). We reported here as well that more
than half (51.6%) of the HIV-infected women had been
victims of both types of violence, while this proportion
was 18.6% among uninfected women.
Bruises were overall the most frequent injuries reported
among African women victims of physical violence (23),
but the proportion of Togolese women reporting serious
and disabling injuries such as dislocations (62.9%) and
deep cuts (28.9%) is alarming. The severity of the con-
sequences of intimate partner violence is often under-
estimated. Indeed, in our study, a substantial proportion
of women reported needing medical care after being
severely injured, but only a few actually accessed medical
care and, if they did, they rarely disclosed the real causes
of their injuries. Finally, none of the injured women in
our sample had been referred to existing organizations
providing psychological support. These findings suggest
that case detection of intimate partner violence should be
systematically done by medical staff, and particularly
Table 3. Distribution of physical injuries and care-seeking cascade reported by women victims of physical violence: Lome´, Togo,
MayJuly 2011
N %
Number of physically injured women among those victims of physical violence (n251) 194 77.2
Types of physical injuries reported (n194)
Scratches, hematomas 157 80.9
Dislocation, sprains 122 62.9
Eardrums rupture, black eyes 106 54.6
Penetration injuries, deep cuts, gashes 56 28.9
Bites 39 20.1
Burns 11 5.7
Fractures, broken bones 9 4.6
Broken teeth 3 1.6
Hospitalizations 14 7.2
Number of injured women needing medical care after being injured (n194) 160 82.4
Number of injured women having received medical care when injured (n160) 93 58.1
Number of women that told medical personnel the real cause of injuries (n93) 49 52.6
Number of women referred to a dedicated support group (n49) 0 0.0
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Table 4. Factors associated with intimate partner physical violence according to their HIV status: Lome´, Togo, MayJuly 2011
HIV uninfected HIV infected
OR 95% CI p aOR 95% CI p OR 95% CI p aOR 95% CI p
Women’s sociodemographic profile
Age
33 y/o 1 1 1
B33 y/o 2.02 0.994.09 0.05 0.39 0.170.88 0.02 0.93 0.581.50 0.78
Education
Not instructed 1 1 1
At least primary level 1.58 0.386.58 0.53 1.99 0.993.99 0.05 2.05 1.004.19 0.05
Contraceptive methodsa
Yes 1 1 1
No 1.65 0.833.27 0.15 2.28 1.035.01 0.04 1.05 0.651.68 0.84
Modalities of entry to sexual life
Age of first sexual intercourse
18 y/o 1 1 1
B18 y/o 0.45 0.220.89 0.02 0.48 0.211.03 0.06 0.77 0.471.24 0.28
Conditions of first sexual
intercourse
Consented 1 1 1
Coerced 2.67 1.166.10 0.02 2.65 1.066.58 0.04 1.74 1.022.95 0.04
Mental health
Loss of interestb
No 1 1
Yes 1.07 0.522.16 0.86 2.90 1.714.91 B0.0001
Suicidal thoughtsc
No 1 1
Yes 1.53 0.723.27 0.27 1.75 1.092.80 0.02
Suicidal attemptsc
No 1 1 1
Yes 2.72 0.6211.82 0.18 4.22 1.2214.54 0.02 4.53 1.2915.91 0.02
Partners profile
Polygamous
No 1 1
Yes 1.86 0.704.89 0.21 1.48 0.922.37 0.1
Concurrent relationships
No 1 1 1 1
Yes 2.86 1.425.73 0 2.51 1.135.52 0.02 2.37 1.453.88 0 2.21 1.333.65 B0.001
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Table 4 (Continued )
HIV uninfected HIV infected
OR 95% CI p aOR 95% CI p OR 95% CI p aOR 95% CI p
Alcohol consumption
Never/occasionally 1 1 1
Frequently 2.08 1.064.05 0.03 1.74 0.813.71 0.15 1.68 1.042.69 0.03
Involved in fights/riots
No 1 1
Yes 4.6 1.1618.12 0.03 2.06 1.103.82 0.02
History of non-partner violence
Physical violence after 15 y/o
No 1 1 1
Yes 0.93 0.471.82 0.84 1.51 0.932.46 0.09 1.54 0.922.56 0.1
Sexual violence after 15 y/od
Yes 1
No 1.58 0.416.07 0.51
Sexual violence before 15 y/o
No 1 1
Yes 8.33 0.9473.22 0.06 1.7 0.813.54 0.16
Financial autonomy
Employment
No 1 1
Yes 0.64 0.311.28 0.21 0.93 0.511.66 0.8
Financial autonomy to support
herselfe
No 1 1
Yes 0.77 0.391.51 0.45 0.92 0.571.47 0.74
Submission index
1.18 0.891.53 0.24 1.33 0.971.80 0.07 1.13 0.911.39 0.28
aUse of any contraceptive method at the moment of the survey.
bDuring at least two weeks for the last 12 months.
cAt least once during last 12 months.
dNot enough subjects for the analysis among uninfected women.
eHaving a financial autonomy to support herself and household without her partner for at least 1 month.
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Table 5. Factors associated with intimate partner sexual violence according to their HIV status: Lome´, Togo, MayJuly 2011
HIV-uninfected HIV-infected
OR 95% CI p aOR 95% CI p OR 95% CI p aOR 95% CI p
Women’s sociodemographic profile
Age
33 y/o 1 1
B33 y/o 0.93 0.461.86 0.84 0.68 0.411.11 0.13
Education
Not instructed 1 1
At least primary level 1.1 0.254.81 0.9 1.41 0.692.86 0.34
Contraceptive methodsa
Yes 1 1
No 0.7 0.341.43 0.33 1.23 0.752.01 0.41
Modalities of entry to sexual life
Age of first sexual intercourse
18 y/o 1 1 1 1
B18 y/o 2.84 1.375.89 0.01 2.31 1.084.92 0.03 1.78 1.082.93 0.02 2.28 1.194.37 0.01
Conditions of first sexual
intercourse
Consented 1 1 1
Coerced 2.34 1.025.33 0.04 2.18 0.925.18 0.08 2.87 1.545.34 B0.001
Mental health
Loss of interestb
No 1 1
Yes 1.93 0.894.14 0.09 7.51 4.2613.24 B0.001
Suicidal thoughtsc
No 1 1 1
Yes 1.67 0.773.57 0.19 2.21 1.333.64 0 1.98 1.163.38 0.01
Suicidal attemptsc
No 1 1
Yes 1.9 0.457.91 0.38 3.09 0.8910.66 0.07
Partners profile
Polygamous
No 1 1
Yes 1.08 0.392.92 0.88 1.54 0.932.53 0.09
Concurrent relationships
No 1 1 1
Yes 2.63 1.305.30 0.01 2.38 1.144.94 0.02 2.67 1.604.44 B0.001
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Table 5 (Continued )
HIV-uninfected HIV-infected
OR 95% CI p aOR 95% CI p OR 95% CI p aOR 95% CI p
Alcohol consumption
Never/occasionally 1 1
Frequently 0.7 0.351.38 0.31 1.58 0.962.59 0.07
Involved in fights/riots
No 1 1 1
Yes 2.35 0.688.09 0.18 2.87 1.395.93 B0.001 2.6 1.235.51 0.01
History of non-partner violence
Physical violence after 15 y/o
No 1 1
Yes 0.46 0.220.93 0.03 2.84 1.704.72 B0.001
Sexual violence after 15 y/od
Yes 1
No 4.51 0.5635.71 0.15
Sexual violence before 15 y/o
No 1 1
Yes 3.88 0.6821.91 0.13 2.83 1.146.99 0.02
Financial autonomye
Employment
No 1 1
Yes 0.64 0.311.29 0.21 1.35 0.742.43 0.32
Financial autonomy to support
herselfa
No 1 1
Yes 0.68 0.321.39 0.29 0.7 0.421.15 0.16
Submission index
1.05 0.801.37 0.72 1.66 1.302.10 B0.001 1.58 1.232.03 B0.001
aUse of any contraceptive method at the moment of the survey.
bDuring at least two weeks for the last 12 months.
cAt least once during last 12 months.
dNot enough subjects for the analysis among uninfected women.
eHaving a financial autonomy to support herself and household without her partner for at least 1 month.
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within HIV care services. Clinical care evaluation check-
lists could include items related to physical and sexual
violence to actively detect intimate partner violence. In
addition, to ensure adequate case management, medical
staff should be sensitized about intimate partner violence
and consequences management and should be able to refer
women to the appropriate supporting structures.
Although the prevalence of physical and sexual vio-
lence varied according to the HIV status among women
of our sample, we identified three associated factors that
are common to both groups. Reported partner multiple
concurrent relationships were associated with higher rates
of physical and sexual intimate partner violence regardless
of serological status. Other African studies have reported
similar findings, whereby women whose partner had sev-
eral female partners were more likely to report sexual
intimate partner violence and women suspecting their
partner’s infidelity were at higher risk of any kind of
violent act perpetrated by their male partner (12, 2426).
In Tanzania and South Africa, men acknowledging
having multiple female partners confessed that being
questioned about their fidelity could trigger physical and
sexual violent acts against their female partner (27, 28).
Gender norms in many African cultures expect masculine
men to be in control of women, and this control can take
the form of sexual multi-partnership and violent acts.
On the other hand, the prevailing ideal of femininity in
such contexts may prevent women from refusing these
sociocultural patterns, and on the contrary seems to pro-
mote the acceptance of this behavior, increasing their risk
of contracting HIV infection through sexual assaults (29).
Multi-partnership, mostly among men, is an increasing
HIV risk behavior in West African countries and the need
to intensify behavior change efforts have been already
pointed out (11). We believe that such efforts should focus
on tackling masculinity construction, fostering women’s
respect, and reducing gender inequality, all of which
should be part of a comprehensive HIV behavior change
preventive package.
We observed that starting sexual life before 18 years old
was very frequent and appeared to be a risk factor of
intimate partner violence for all women, regardless of their
serological status. The high proportion of HIV-infected
women experiencing a first forced sexual intercourse in
our study is consistent with findings in South Africa (30).
Since sexual abuse most often means unprotected sexual
intercourse, these women may have been at the same time
exposed to the risk of contracting HIV infection since
very early ages and led into the vicious cycle of intimate
partner violence (31). Age-appropriate sexuality educa-
tion contributes to more responsible sexual behavior;
nevertheless, gaps in basic knowledge about HIV and its
transmission among young men and women remain
important challenges (11). Sexuality education should be
considered as a gateway to prevent HIV infection through
a change of traditional gender norms based on fostering
responsible and respectful sexual behaviors as early as
possible in life.
Finally, prevailing submissive attitudes among Togolese
women, expressed by an overall high acceptance of partner
controlling behaviors and high submission index score,
were associated with intimate partner violence, principally
among HIV-infected women. Many women fearing in-
timate partner violence, even when aware of an HIV risk,
may feel powerless to discuss infidelity, condom use, and
HIV testing with their male partner (31). Renewed efforts
are needed to foster women empowerment, including
negotiation skills for safe-sexual practices addressed to
women victims of intimate partner violence.
Several limits to our study need to be acknowledged.
First, intimate partner violence may be a very sensitive
subject for women and data collection was based on past
experiences. We thus should not rule out a potential recall
bias. To reduce information bias, however, interviewers
were trained before conducting the survey and interviews
were carried out in a private office. Further, due to the
cross-sectional design of our study, we were not able
to demonstrate a causal link between HIV infection
and intimate partner violence or to explore the dynamic
among these factors; however, our findings may have
confirmed some of the factors to target when aiming at
preventing intimate partner violence within clinical care
services. Moreover, we did not present data on intimate
partner psychological violence, as this would have required
a thorough psychological assessment that could not
be performed at the time of the survey. Finally, our study
was conducted among a specific population of women
attending a hospital facility in Lome´, and having been
tested for HIV at least once in their life; thus, our results
are not representative of all women in Togo.
One of the main strengths of our study, however, is its
contribution to the pool of data available on intimate
partner violence, data that can be compared to other
settings as it was based on the use of WHOMulti-Country
Study on Women’s Health and Life Events questionnaire.
Our study highlights that intimate partner violence is a
true public health issue in Togo, with a high social burden
and severe health consequences on women, and especially
among HIV-infected women. Our findings argue, in par-
ticular, for systematic case detecting of intimate partner
violence  as well as any form of violence  within HIV
services, to provide adequate medical care to women in
need and to advise them about help-seeking strategies.
Taking into account the high rate of HIV-discordant
stable couples in sub-Saharan Africa, couple-oriented in-
terventions are a priority among primary HIV preventive
strategies (13), and because intimate partner violence,
highly prevalent in West African contexts and one
important consequence of HIV serological disclosure
among HIV-infected women, is a major barrier to the
Juan Burgos-Soto et al.
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acceptability of such approaches (12, 13), the assessment
of intimate partner violence should be included in couple-
oriented HIV preventive strategies.
Finally, tackling cultural representations and the social
construction of masculinity and traditional gender norms
in sub-Saharan African contexts is an important chal-
lenge to achieve behavior change in terms of sexual health
and must be addressed from adolescent ages. Further
longitudinal research is needed to understand HIV-
serodiscordant couple dynamics with regard to intimate
partner violence in African contexts and thus improve the
acceptability and efficacy of couple-oriented HIV pre-
ventive interventions. Intimate partner violence, being
highly prevalent in resource-constrained settings and a
major public health concern, global health policies must
turn more firmly to this issue.
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9. Reproductive health of HIV-infected women of 
reproductive age in sub-Saharan Africa: a public health 
challenge. 
9.1. Restoration of reproductive functions among HIV-infected 
individuals 
The advent of antiretroviral therapies in resource-limited settings has considerably improved 
both the life expectancy and quality of life of people living with HIV and AIDS. The dramatic 
reduction of AIDS-related morbidity and mortality owed to the rapid roll-out of antiretroviral 
drugs in resources-limited settings has significantly contributed to the restoration of physical 
and social functions of HIV-infected individuals. Current literature suggests as well that this 
outstanding improvement of health status has also restored fertility functions among HIV-
infected population, leading to a greater desire to bear children.  
Although HIV diagnosis has been hypothesized to be associated with an increased desire to 
cease childbearing (179); after ART initiation, many HIV-infected individuals choose to have 
children (180, 181). However, for HIV-infected individuals, choosing to procreate and having 
children implies potential health life-threatening challenges, particularly for HIV-infected 
women (182). 
For serodiscordant couples desiring to procreate, engaging in unprotected sexual 
intercourses could become a major health threat as they increase the risk of transmitting 
HIV to uninfected partner (182). Indeed, current epidemiologic estimations point out that 
serodiscordant couples play an important role in maintaining global HIV epidemic. According 
to epidemiologic surveys, it is not uncommon that HIV-infected individuals engage in 
serodiscordant couples in sub-Saharan Africa: in settings with concentrated epidemics 0 to 
6% of all couples are serodiscordant, while in settings with generalized epidemics this 
proportion goes from 9 to 17% (183, 184). In high prevalence settings, more than half of HIV-
infected individuals have an uninfected partner; in settings with lower prevalence rates, this 
proportion may be as high as 75%(184). Estimations of a mathematic models showed that 
29% (10 – 52%) of all new HIV infections occurred in serodiscordant couples(185). Although 
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recent sounding scientific evidence point out the great benefit of antiretroviral treatment in 
preventing HIV transmission (41), serodiscordant couples contributes substantially to the 
overall burden of disease(183). 
For HIV-concordant couples, unprotected sexual intercourses may represent an important 
health risk as well. It has been established that infections with more than one strain of HIV-1 
– dual infection – do occur(182). The term dual infection refers to the acquisition of two 
separate viral strains during primary infection or well a superinfection, which is the 
acquisition of one or more different viral strains after sero-conversion(186). Superinfection 
might lead to the acquisition of drug-resistant strains (187, 188) and it has been associated 
with an accelerated disease progression (189, 190). 
Importantly, for an HIV-infected woman, besides de potential risk of transmitting the virus to 
her child; becoming pregnant without the appropriate clinical management might lead to 
important risks for her own health as well. HIV infection is one leading cause of maternal 
mortality in resource-limited settings (24, 191). In addition, although pregnancy at ART 
initiation has not been associated with higher risk of impaired virological responses(192); it 
is suspected that pregnancy after ART initiation, increases modestly the relative and 
absolute risk of virologic failure(193). Indeed, for HIV-affected couples, choosing to 
procreate represents a major challenge, particularly in resource-limited settings. 
In the light of these important health risks, the increasing will of childbearing observed 
among HIV-infected individuals coupled with the increasing rates of pregnancy, particularly 
post-ART initiation are subjects of major public health concern. The measure of procreation 
desires of HIV-infected individuals and the identification of its potential predicting factors 
are important inputs in order to design strategies aiming at correctly fulfill reproductive 
needs of people living with HIV, reducing simultaneously the potential risk of HIV 
transmission and, the pregnancy-related health risks for HIV-infected women(194). In 
addition, estimating the incidence rates of pregnancy following ART initiation might be very 
useful in order to design strategies of safe motherhood tailored to HIV-infected women of 
reproductive age.  
Firstly, within this chapter, I will present an insight about current knowledge in terms of 
measure of procreation desires among HIV-infected individuals, particularly after ART 
initiation. This insight includes findings of studies aiming at measuring to what extent HIV-
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infected individuals are willing to procreate and what factors are potentially influencing this 
decision among this population.  
The second section of this chapter summarizes findings of different studies which have 
provided the measure of the incidence rate of pregnancy among HIV-infected women as 
primary or secondary outcome. This section will be listing and describing different factors 
associated to incidence rate of pregnancy as described in literature. Finally, to close this 
chapter, the second peer reviewed scientific article of this research framework will be 
presented. This article aimed at estimating incidence rate of pregnancy among HIV-infected 
women post-ART initiation within eight West-African countries. 
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9.2. Fertility intentions and desire of procreation among HIV-infected 
individuals 
The second prong of the Global Plan of Elimination of New HIV infection among children and 
keeping their mothers alive aims at reducing the unmet needs of family planning to zero 
among women of reproductive age as a preventive strategy of mother to child transmission 
of HIV. To effectively narrow the gaps in terms of unfulfilled reproductive health needs, 
understanding the reproductive dynamics of individuals of reproductive age is one first step 
to achieve this goal, and this is particularly important in settings of high HIV prevalence and 
high fertility rates. 
In addition, it has been hypothesized that a HIV positive diagnosis may influence 
reproductive decision making, changing probably the plans of procreation of affected 
individuals. These changes are suspected associated to their self-perception of health status 
and their knowledge in terms of HIV-related health risks associated with pregnancy and 
postpartum. However, with the advent of antiretroviral treatment, particularly in high HIV 
prevalence settings; the patterns in terms of child bearing desires among HIV-infected 
individuals are suspected to be changing. 
In order to better understand reproductive behaviors and patterns among HIV-infected 
individuals the measure of the desires and intentions of procreation among this population 
is one first step. Estimating to what extent HIV-infected individuals are willing to procreate is 
one key first input to correctly design public health strategies aiming at integrating family 
planning services within HIV care. Moreover, understanding reproductive dynamics of HIV 
affected individuals will provide health care staff with key information about how address 
correctly reproductive health issues of this population.  
Over the last decade, a growing body of scientific evidence estimating patterns and 
explaining trends of procreation desires among HIV-infected population has been published 
worldwide. In addition, these scientific assessments have also documented biological and 
psychosocial factors associated with the desires and intentions of childbearing among HIV-
affected individuals. The aim of the following section is to present and discuss findings of 
current scientific evidence aiming at estimating procreation desires and intentions among 
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HIV-affected individuals and the associated biological and psychosocial factors to this 
outcome.  
9.2.1. Fertility intentions among HIV-infected individuals in high-
income settings: North America and Europe. 
Studies conducted in North America and Europe pointed out that in average 30% of HIV-
infected individuals reported a positive desire of having children in a near future.  Findings of 
Chen et al within a cross-sectional study based in a national-size population sample of the 
United States, pointed out that 28% of HIV-positive heterosexual or bisexual HIV-infected 
men and 29% of HIV-positive women who receive medical care desired children in the 
future(195). Similar findings were reported by further studies conducted in the United 
States. Cross-sectional studies conducted among HIV-infected women in this same setting 
pointed out that the positive desire of procreation was present in more than 20% of the HIV-
infected women interviewed(196, 197).  
In contrast, the desire of childbearing among HIV infected women in Canada was somewhat 
more heterogeneous. Findings of Loufty et al. showed that 69% (95% CI, 64%-73%) of HIV-
infected women in Ontario stated positively that they would like to give birth in the future 
and 57% (95% CI, 53%-62%) intended to give birth in the future (198). On the other hand, 
according to findings of Oglivie et al in this same setting the proportion of women indicating 
a positive intention to have children was of 26%. 
Findings of European studies didn’t differ sensibly of those of North America. In France, 33% 
of HIV-infected women and 20% of HIV-infected men reported expecting to have a child in 
the future(199). In Switzerland, the proportion of HIV-infected individuals reporting a 
positive desire of child bear was higher than in France. Findings of a cross-sectional study 
conducted within a Swiss cohort of HIV-infected individuals showed that 45% of women and 
38% of men expressed a positive desire for children in the future(200). 
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9.2.2. Fertility intentions among HIV-infected individuals in low-and-
middle-income settings of high prevalence rate of HIV: Sub-
Saharan Africa. 
In sub-Saharan Africa, the assessment of reproductive intentions among HIV-infected 
individuals started more recently than in high-income settings. The studies included in this 
review assess fertility intentions in two different ways: 1) Interviewing HIV-infected men and 
women individually, 2) interviewing HIV-affected couples whether they are serodiscordant 
or both HIV-infected.  
A cross sectional study conducted within a sub-urban clinical care service by Oladapo et al in 
urban Nigeria showed that the proportion of HIV-infected individuals reporting a positive 
desire of childbearing was as high as 63%. Moreover, this study reported as well that 71.5% 
of men and 94% of women who desired procreate intended to have two or more children 
within a near future(201). Contrasting with former findings, a more recent study conducted 
in rural Nigeria showed that the proportion of HIV-infected individuals desiring a child within 
a near future was sensibly lower than in urban or peri-urban setting. Olowookere et al 
reported that 27% of women and 17% of men in rural Nigeria reported a positive desire to 
have more children in a near future (202). 
Contrasting with West Africa, findings from East Africa appeared to be different. According 
to findings of Nakayiwa et al in Uganda, although 42% of participants of the study were 
sexually active and 33% were engaging in pregnancy risk behaviors, only 18% expressed a 
positive desire of having children(203). Consistently with these findings, a larger study 
conducted among Ugandan HIV-infected men and women showed that 14% of all 
participants wanted to have more children (180). In Tanzania, although more than half of 
HIV-infected individuals reported being actively engaged in unprotected sexual practices, the 
positive desire for a child or additional child, was expressed only by 37% of all participants 
(40% of males and 36% of females)(204). 
Later on, findings of a study conducted by Myers et al in South Africa revealed that the 
desire of child bearing among HIV-infected individuals was sensibly different. Indeed, this 
cross-sectional study aiming at estimating the prevalence and determinants of fertility 
intentions of HIV-infected women and men receiving antiretroviral therapy in rural South 
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Africa pointed out that only 29% of the interviewed individuals stated that they wanted to 
have children in the future. Furthermore, in this study the proportion of men reporting a 
positive desire of childbearing was slightly higher than the proportion of women (36% versus 
26%)(205). In contrast, findings of Cooper et al showed that the proportion of HIV-infected 
individuals on ART reporting a positive desire of childbearing was slightly higher in urban 
Cape Town, South Africa. Indeed, in this cross-sectional study conducted in urban clinical 
care setting, 57% men and 45% of HIV-infected women reported being open to the 
possibility of having a child(181). 
9.2.3. Fertility intentions among HIV-affected couples in low-and-
middle-income settings of high prevalence rate of HIV: Sub-
Saharan Africa. 
As in sub-Saharan Africa an important number of HIV-infected individuals reported being in 
couple, the desire of childbearing is maybe influenced by this fact, and several studies have 
therefore estimated this outcome among HIV-affected couples. Beyeza-Kashesya J et al 
estimate the proportion of positives intentions of childbearing among HIV-affected sero-
disclosed couples in Uganda. Findings of this study showed that more than a half (59%) 
desired to have children in the future(206). A larger study exploring the same question and 
comparing HIV-infected couples with uninfected peers found out that HIV positive 
individuals were more likely to want no more children compared to their HIV negative peers 
(with adjusted odds ratios of 4.9 (95% CI 2.7–8.9) for men and 7.4 (95% CI 3.2–16.7) for 
women)(179). Moreover, findings of this study showed as well that the desire of stop 
childbearing was higher among concordant HIV-positive couples 27/38 (71%) and lowest 
among concordant HIV-negative couples 325/1260 (26%)(179). 
Findings of a similar study conducted in Kenya and Uganda investigating fertility intentions 
among serodiscordant couples were not so different. In Kenya and Uganda 36% of HIV-
infected women and 28% of HIV-infected men reported a positive will of childbearing. For 
the majority of couples (76%), HIV uninfected partners were in agreement with the fertility 
intentions of their HIV infected partners: for 314 couples (55%), both members did not want 
more children, whereas for 121 couples (21%), both members desired additional children. 
One hundred thirty-six couples (24%) had discordant fertility intentions, the majority of 
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which (74%) were couples in which the HIV-1 uninfected male partner desired additional 
children but their HIV-1 infected female partner did not(207).  
9.3. Predictors of the positive desire of procreation among HIV-infected 
individuals 
According to findings of the studies included in this literature review the factors defining the 
will of childbearing among HIV-infected men and women can be grouped in the following 
categories: Biologic factors, psychosocial factors and HIV-related clinical factors. 
9.3.1. Biological factors associated with the desire of procreation 
among people living with HIV. 
Biological age is one major factor found almost systematically significantly associated with 
the positive desire of childbearing (180, 201-203, 205, 208). Unsurprisingly, fertility 
intentions decreased proportionally to biological age, particularly for women. Therefore, 
older women (>35 years old) were almost systematically less likely to report a positive desire 
of childbearing. For example, in Nigeria, women between 15 and 34 years old are almost 3 
times (aOR: 2.94; 95%IC: 1.31 – 6.64) more likely to report a positive desire of childbearing 
than their older counterparts (202). 
One biological factor associated with HIV-infection hypothesized associated with 
childbearing desires among HIV-infected individuals is the knowledge of HIV serological 
status. Findings of Dube et al in Malawi pointed out that the knowledge of HIV positive 
status is associated with an increased reported desire to cease childbearing(179). Findings of 
Dube et al, also underscored the fact that although the awareness of an HIV positive status 
reduce de desire of childbearing, among the study population the proportion of HIV-infected 
individuals using any contraceptive methods was very low in this setting(179). 
In addition, a study conducted in Uganda among women of reproductive age attending to 
antenatal clinics regardless their serological status showed similar findings. Within this study 
all women attending to antenatal clinics were surveyed on their fertility intentions and 
received an anonymous HIV test. HIV-positive women reported a lower fertility intentions 
than their HIV-negative counterparts [age-adjusted RF = 0.83, 95% confidence interval (CI): 
0.75–0.93](208).  
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A second important factor hypothesized associated with reported childbearing desires is 
antiretroviral treatment. It has been suggested that, besides the known effect of ART on 
restoring health status of HIV-infected individuals, it may indirectly increase the childbearing 
desires through the improvement of their perceived health. Findings of Kipp et al in Uganda, 
showed that although HIV-infected individuals were more likely to want more children than 
their counterparts not yet treated, this difference was not statistically significant (18.2% on 
HAART vs. 10.7% not on HAART, p = 0.131)(180). Conversely, according to findings of Cooper 
et al in South African, being on ART is a determinant of positive desire of childbearing, 
particularly for women(181). The odds of intending to have a child in the near future, 
increased significantly among HIV-infected women on ART compared to those not yet on 
treatment (aOR: 2.41; 95%IC: 1.28–4.54). 
Moreover, although it has been suggested that fertility intentions and desires of having a 
child might varies over time since a positive diagnosis, within this review only one 
longitudinal study aiming at analyzing the trends of the desire for children over the time 
among HIV-infected women of reproductive age.  
This study conducted by Homsy et al among a cohort of 711 HIV-infected Ugandan women 
of reproductive age initiating ART,  accounting for 2.4 years of follow-up and showed that 
fertility desires changes significantly over the time for HIV-infected women.  
 
 
 
 
 
 
 
 
Figure 20. Desire for children and incidence of pregnancy among HBAC women on ART. 
90 
 
As shown in figure 20, the desire for children increased significantly over follow-up for both 
women (p<0.004) and their partners (P=0.0001), but remained under 7% for the women and 
under 26% for their partners throughout follow-up(209)  
9.3.2. Psycho-social factors associated with the desire of procreation 
among people living with HIV  
In the literature an important number of psycho-social and cultural factors have been 
identified as predictors of the desire of procreation and fertility intentions among people 
living with HIV in sub-Saharan Africa. There are individual factors, factors associated with 
couple dynamics and factors more related to health providers. The following section 
presents several of them, explaining in part the mechanism of their association with the 
desire of procreation. 
Several studies point out that men are often reporting higher desires of child bear than 
women (180, 181, 205, 207, 210). It is suspected that this increased male desire of child bear 
obeys to cultural and social gender norms (211, 212). According to qualitative research, the 
drivers of fertility desires may also differ according to gender perceptions of men and 
women and this is regardless serological status.  
In many cultures, having children is a major requirement for both men and women 
identity(212). Assuring the continuity of the lineage and their kin is men responsibility and a 
major masculine driver of reproductive decision (210, 212). In addition, men possessing 
knowledge of benefits of antiretroviral treatment on preventing mother–to-child 
transmission were more favorable towards having children in the future, this is regardless 
their knowledge on availability of these treatments in their setting (213, 214). Differently, for 
women the knowledge of the existence of PMTCT does not influence their fertility intentions 
unless they are sure about availability of ART, pointing out the fact that preventing children’s 
infection is as important as maintaining their own health in order to subsequently be able to 
take care of children(213-215) 
Although HIV-infected women are more concerned about the potential repercussions of 
pregnancy on their own health, the future of the orphaned children, motherhood grants 
them an identity and respect in the African societies(212, 216).  
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Thus men and women would rather prefer to face risks of HIV transmission to their partners 
or their children than be tagged as infertile, in order to fit within African gender norms(212).  
9.3.2.1. Reproductive decisions within couple dynamics 
Firstly, for HIV-infected men and women, having a current partner within a former 
relationship is associated with a positive desire of childbearing regardless partner’s 
serological status (203, 205). In addition, it appeared that for HIV-infected women, being in a 
relationship for at least five years increased significantly the odds of desiring to child bear 
(205, 207). Among African HIV-infected women, marriage has been identified as a potential 
predictor of future intentions of childbearing (181, 202). Frequently, some women’s desires 
of not having children is strongly outweighed by partner and family expectations or societal 
norms regarding fertility and family formation (213, 216). In many African societies, 
motherhood is considered a major social and cultural defining feature of women’s adult live 
(217, 218). 
For married women or those intending marriage, exercising their right of choosing not to 
procreate is very difficult regardless of their HIV status. Conversely, family and societal 
expectations exert less pressure on men regarding parenthood (212, 213, 216). These 
differences emphasize the gender power imbalances in intimate relationships between men 
and women and the less powerful position occupied by women in the society (212, 213) 
However, findings of qualitative assessments conducted among HIV-affected couples point 
out that child bear under a HIV-positive diagnosis becomes an important dilemma, 
particularly for serodiscordant couples(219). Among the most common challenges reported 
by serodiscordant couples willing to procreate findings underscored: 1) Dealing with the 
emotional and sexual impact of HIV on the relationship and the fear of transmitting the 
infection to partner and child; 2) disclosing serological status to partner, family and friends; 
3) confronting reproductive decisions and the lack of negotiating power for safer sex of 
uninfected partner (this happen more often among female partners); 4) The limited capacity 
of health system in offering safe methods of reproduction and (219, 220). 
In order to avoid HIV-related stigma, women who had not disclosed their status are 
pressured to have children to avoid raising community suspicions regarding their HIV 
status(213). However, for women and men who had already disclosed their status, seeking 
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to have children is socially unacceptable(221). The expressed desire of child bearing among 
HIV-affected couples is highly stigmatized. These attitudes exert an important pressure on 
women, and become a major constraint to disclose their HIV positive status(213) 
Secondly, according to several studies, having few or not having children with current 
partner is a third important factor associated with a positive desire to procreate (181, 201, 
204, 205). The desire for procreation decreases significantly with the number of living 
children for HIV-infected women and men (181). This decrease is slightly more important 
when the living children were conceived within the current couple (204). For several 
childless men and women, living with HIV strengthened their desire for children through the 
fact that having a child give them “hope and happiness” and brings somehow “normality” to 
their lives(213). For some serodiscordant disclosed couples the desire of a child goes beyond 
their perception of risk of acquiring HIV infection (206, 219, 222). Findings of Beyeza-
Kasheya et al in Uganda revealed that for some negative partners engaging in serodiscordant 
relationships, the desire of procreation is so strong that they are ready to risk acquiring HIV 
infection at the expense of getting children(219). 
However this attitude seems to change when individuals have already experience the loss of 
a child to AIDS. Although the desire to have another child to replace one they had lost 
already is present in a few individuals, according to cooper et al, the predominant effect was 
to deter women and men from further childbearing(213). 
9.3.2.2. Health care workers attitudes towards childbearing 
The attitudes of Health care providers towards childbearing desires exert an important 
influence on reproductive decisions of HIV-infected individuals. Although women are 
encouraged to discuss their procreation plans with health care providers, an open discussion 
on this subject is often a great source of anxiety, particularly for HIV-infected women. Fears 
of facing judgmental attitudes regarding their reproductive options seems to be a major 
hurdle for HIV-infected women to start an open discussion with health care providers about 
reproductive intentions (213, 219). 
Despite that health care workers seem open to discussions of pregnancy  plans, scientific 
evidence suggests that their attitudes are often unsupportive and disapproving, dissuading 
HIV-infected women who express a positive desire of becoming pregnant to stop 
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childbearing (213, 215). This conflicting result may be explained by the expectations in terms 
of their professional role of guiding women’s reproductive choices, while at the same time 
they are confronted to their own fears around the future of the baby and the mother(215).  
Clients who discuss with health care provides about their reproductive decisions and future 
desires of child bear were three times more likely to use condoms consistently(215). The 
attitudes of health care providers towards ceasing childbearing after an HIV positive 
diagnosis are understood as a preventive message in order to reduce the risk of transmitting 
or acquiring HIV infection and reducing the number of HIV orphans(215). 
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9.2. Incidence of pregnancy among HIV-infected women on ART 
9.2.1. Epidemiological trends of incidence rate of pregnancy following ART 
initiation 
As seen before, a positive diagnosis of HIV might modify but it does not eliminate the 
broader desire of childbearing among HIV-infected adults. Owed to the reduced life 
expectancy of HIV-infected women before ART era, pregnancy was not a very common event 
after a positive diagnosis of HIV. The rapid progression of untreated HIV disease threatened 
reproductive functions of HIV-infected women, reducing considerably the probability of 
becoming pregnant.  
Notwithstanding, scientific evidence analyzed in the previous chapter suggest that the 
introduction of antiretroviral treatment have had an important influence in reproductive 
decisions of HIV-infected individuals. Indeed, the outstanding improvement of health status 
and self-health perception provided by antiretroviral treatment has made HIV-infected 
individuals reconsider the possibility of childbearing.  
Besides the expressed growing desire of procreation, the increasing rates of pregnancy after 
initiating antiretroviral treatment corroborate this statement. Current estimations point out 
that with the advent of antiretroviral treatment, pregnancy became a more frequent event 
among HIV-infected women, suggesting a more biologic hypothesis explaining the effect of 
antiretroviral drugs on reproductive functions. This hypothesis set out that besides the 
recognized benefit of antiretroviral treatment on restoring health status of HIV-infected 
individuals; these drugs may also have a positive effect on the biology of reproductive 
functions. In order to better understand to what extent existing scientific evidence underpin 
this hypothesis we explored the estimations of the incidence rate of pregnancy among 
African HIV-infected women on antiretroviral treatment.  
Pregnancy is a well-known transmission path of HIV infection from HIV-infected mothers to 
their child. Moreover, pregnancy is a reliable indicator of unprotected sexual intercourses 
which may lead to an increased risk of HIV infection. Thus, I believe that characterizing the 
epidemiology of reproduction among HIV infected population, estimating incidence rates of 
pregnancy and its determinants, is one major priority in terms of public health. This 
information would help stakeholders in designing evidence-based strategies to correctly 
address reproductive needs of HIV-infected population.  
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In these regards, I conducted a literature review aiming at compiling existing epidemiologic 
scientific research studies estimating incidence rates of pregnancy among HIV-infected 
women. These estimations could have been reported as a primary outcome or as an 
additional secondary outcome of these studies. Within this literature review, I also looked at 
the factors associated with the incidence rate of pregnancy, the direction and the 
significance of their association. Only studies conducted in sub-Saharan Africa and published 
after the year 2000 were retained within this literature review. 
9.2.2. Incidence of pregnancy among HIV-infected women in sub-Saharan 
Africa 
Sixteen studies meeting inclusion criteria were retained within this literature review (table 1 
and table 2). In Burkina Faso, Nebie, Y. et al estimated an incidence rate of pregnancy which 
was of 12.3 pregnancies per 100/women-year and Desgées-du Lou, A. et al in Côte d’Ivoire 
estimated 16.5 pregnancies per 100/women-years(223, 224). Although lower than former 
estimations, Bussman et al found in Botswana an incidence rate of pregnancy of 7.9 per 100 
women-year (225).  
Later in time, observational cohort studies started to produce this epidemiological indicator 
and incidence rates of pregnancy varied importantly. Indeed, estimations of incidence rates 
of pregnancy among HIV-infected women after ART initiation varied between 5.2 
pregnancies per 100 women-years to 24.6 pregnancies per 100 women-years. Westreich et 
al, estimated incidence rate of pregnancy within an observational clinical cohort of patients 
on antiretroviral treatment in South-Africa and findings showed an incidence rate of 
pregnancy of 5.2 pregnancies per 100 women-years (95%IC: 4.8 - 5.5)(226). Estimations of 
incidence rate of pregnancy of studies conducted on similar contexts and under comparable 
methodological designs were very similar (209, 227-230).  
On the other hand, findings of cohort studies axed on reproductive health outcomes showed 
higher incidence rates of pregnancy. A study conducted by Heffron et al in four Eastern-
Africa countries (Zambia, Kenya, Rwanda, Tanzania and Uganda) using data from Partners in 
Prevention HSV/HIV Transmission Study, a randomized, placebo-controlled, HIV-1 
prevention trial of daily acyclovir for herpes simplex virus Type 2 (HSV-2) suppression 
provided to HIV-1/HSV-2 dually infected members within heterosexual HIV-1 serodiscordant 
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couples found out an incidence rate of pregnancy among HIV-infected women on ART of 
16.3 pregnancies per 100 women-year (95%CI: 14.9-17.7)(231). Although slightly lower, 
estimations of incidence rates of pregnancy post-ART initiation in other studies conducted in 
Malawi found out similar incidence rates. Hoffman et al and Taulo et al estimated an 
incident rate of pregnancy among HIV-infected women of 14.5 pregnancies per 100 woman-
years and 13.9 per 100 woman-years respectively within a prospective cohort studies both 
conducted in Malawi (232, 233). 
 Finally, high incidences rates of pregnancy were reported by two studies, one conducted in 
South-Africa and the other in Uganda. In South-Africa, within a cohort study aiming at 
measuring fertility intentions and reproductive outcomes among HIV-infected women; 
Schwartz et al estimate an incidence rate of pregnancy of 21.6 pregnancies per 100 women-
years (95%CI: 18.5-25.2) following ART initiation (234). Similarly, within an observational 
cohort of HIV-infected individuals on ART follow-up in Uganda the incidence rate of 
pregnancy as high as 24.6 pregnancies per 100 women-years (95%CI 18.1, 32.6) (235).  
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Table 1. List of research studies reviewed estimating the incidence rate of pregnancy among HIV-infected women. 
Author Setting Type of study crude incidence rate of pregnancy incidence rate at last year of follow-up  
Nebie et al, 2001 Burkina Faso 
Prospective cohort of women on 
ART 12.3 pregnancies per 100 person-years 
1st year: 4 per 100 person-years  
3rd year: 18 per 100 person-years  
Hoffman et al, 2008 Malawi Prospective cohort of HIV-infected women 14.5 per 100 women-years N/A 
Taulo et al, 2009 Malawi Prospective cohort of HIV-infected and uninfected women 
Overall estimated pregnancy rate: 14.9 
per 100 person-years (95% CI: 13.0–
16.8). 
Pregnancy rates HIV infected: 13.9 per 
100 person-years  
uninfected: 14.2 per 100 person-years  
(P = 0.94). 
N/A 
Heffron et al, 2010 
South Africa -
Zambia, Kenya, 
Rwanda, Tanzania, 
Uganda  
Randomized Control Trial 
Partners in Prevention HSV/HIV 
Transmission Study. 
Prospective cohort of HIV-
infected and uninfected women 
in heterosexual serodiscordant 
couples 
HIV-infected incidence rate of pregnancy: 
16.3 per 100 women-years (95% CI, 14.9-
17.7) 
HIV uninfected: 15.6 (95% CI, 13.6-17.6) 
per 100 person-years 
N/A 
Desgrées du loup et 
al, 2002 Côte d'Ivoire 
Randomized Control Trial ANRS 
049 DITRAME 16.5 per 100 women-years N/R 
Schwartz et al, 2012 South Africa Prospective cohort of HIV-infected women on ART 
21.6 per 100 women-years (95%IC: 18.5-
25.2) 
cumulative incidence of pregnancy  
1st year 23.9 per 100 women-year  [95% CI 16.4–
34.1] 
2nd year 15.9 per 100 women-year [95% CI 12.0–
20.8] 
>2 years 21.0 per 100 women-year [16.8–26.1] 
Makumbi et al, 2011 Uganda 
Observational cohort of HIV-
infected women pre-ART and on 
ART 
 
pre-ART: 13.1 per 100 women-year 
(95%IC: 10.14 - 16.75) 
post-ART: 24.6 per 100 women-year 
(95%IC: 18.1, 32.6) 
The cumulative probability of incident pregnancy 
increased overtime and was higher among 
women with CD4 count ≥100+ compared to those 
with CD4 counts level of less than 100 cells/mm3, 
but this difference was not statistically significant 
(log rank χ2 = 2.32; p = 0.3133). 
Karim et al, 2011 South Africa Prospective cohort of HIV-infected women 
16.6 per 100 women-years  (rural) 
22.4 per 100 women-years(urban) N/R 
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Table 2. List of research studies reviewed estimating the incidence rate of pregnancy among HIV-infected women. 
Author Setting Type of study crude incidence rate of pregnancy incidence rate at last year of follow-up on ART 
Gibb et al, 2012 Uganda/Zimbabwe RCT 4.4/100 woman-years [95% CI 4.0-4.9] N/R 
Westreich et al., 
2012 South Africa Observational cohort 5.2 per 100 women-years. [95%IC: 4.8, 5.5] 
Cumulative incidence of first pregnancy by six years 22.9 
per 100 women-year(95% CL 20.6%, 25.4%).  
Myer et al, 2010 Multicountry  (Sub-Saharan Africa) Observational cohort 
Overall rate of pregnancy 7.7 per 100 women-
years. 
Pre-ART rate of pregnancy: 6.51 per 100 women-
years; (95% CI 5.73–7.38) 
Post-ART rate of pregnancy: 9.03 per 100 women-
years; (95% CI 8.13–10.03) 
Cumulative incidence: 
1st year: 6.8 per 100 women-year 
2nd year: 9.9 per 100 women-year 
3rd year: 10.5 per 100 women-year 
4th year: 13.7 per 100 women-year 
Bussman et al, 
2007 Botswana 
Prospective cohort of 
women on ART 7.9 per 100 person-years N/R 
Homsy et al, 2009 Uganda Prospective cohort of women on ART 8.2 per 100 women-years 
Cumulative incidence: 
1st quarter of time of follow-up: 3.5 per 100 women-year 
5th quarter of time of follow-up: 11.7 per 100 women-year 
Tweya et al, 2012 Malawi Retrospective cohort study 9.3 per 100 women-years 
cumulative incidence: 
6 months: 2% (95% CI 1.31–2.19) 
12 months: 7% (95% CI 5.89–7.66) 
24 months: 17% (95% 15.64–18.67) 
36 months: 25% (95% CI 23.69–27.97) 
Kaida et al, 2013 Uganda 
Prospective cohort of HIV-
positive individuals 
initiating ART  
Uganda AIDS Rural 
Treatment Outcomes 
(UARTO) 
9.4 per 100 women-years (95% CI: 7.68, 11.4) 
Incidence of first pregnancy peaked between 6–12 months 
after ART initiation (15.2 pregnancies per 100 WYS (95% CI: 
9.53, 23.0), declined and stabilized between 12–36 months, 
then decreased sharply 36 months after ART initiation.  
 
Guthrie et al, 
2011 Kenya 
Prospective cohort of 
women on serodiscordant 
couples 
10.0 per 100 women-years 
Cumulative incidence for women reporting a positive 
desire of procreation: 
- 6-month cumulative incidence of 10.4% (95% CI, 6.9–
15.6%)  
- 1-year incidence of 17.4% (95% CI, 12.5–24.0%)  
Cumulative incidence for women not reporting a positive 
desire of procreation: 
- 6-month incidence of 2.1% (95% CI, 0.9–5.0%)  
- 1-year incidence of 3.7% (95% CI, 1.9–7.4%)  
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9.2.3. Predicting factors of pregnancy incidence among HIV-infected 
women 
9.2.3.1. Association of antiretroviral treatment with the incidence of 
pregnancy 
It has been hypothesized that antiretroviral treatment may has an effect on fertility 
functions and several studies have addressed this issue comparing the incidence rates of 
pregnancy among women before and after ART initiation. In a multi-country cohort study 
conducted in seven sub-Saharan Africa countries, findings of Myers et al showed that the 
incidence rate of pregnancy was lower during the period prior to ART initiation, increasing 
significantly after ART initiation (6.5 per 100 women-years vs. 9.0 per 100 women-
years)(227). As showed in figure 21, it appeared, that prior to ART, incidence rate of 
pregnancy was lower but also relatively constant, peaking discretely just before the third 
year on clinical follow-up. In contrast, following ART initiation, the risk of becoming pregnant 
increased proportionally to time on follow-up.  
 
Similarly, in Uganda, Makumbi et al have conducted a study aiming at comparing 
reproductive outcomes among HIV-infected women according to ART status. Findings of this 
study  showed that incidence rate of pregnancy among women on ART was almost two times 
Figure 21. A) Instantaneous hazard of pregnancy during the pre-ART period by duration of follow-up, 
with 95% CIs.; B) Instantaneous hazard of pregnancy during the on-ART period by duration 
of follow-up, with 95% CIs. Source: Myers et al. PLoS Med, 2010. 
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higher (24.6 per 100 women-years) than among ART-naïve women on clinical follow-up (13.1 
per 100 women-year)(235). To explain this differences Makumbi et al proposed a behavioral 
hypothesis which suggest that rapid and progressive improvement of health status and well-
being favored by ART may increase hopefulness about the future and improve mental 
health. This improved health status may lead to a reevaluation of their intentions and 
decisions regarding childbearing; increasing sexual activity, particularly among women 
cohabiting in stable partnerships. However, whether or not the ART-related improvement of 
immunological functions, increases female fecundity and capacity to take pregnancy to term 
remains an unanswered question (227, 235).  
In addition, one important epidemiological phenomenon observed is how the risk of 
becoming pregnant increases proportionally to time on ART. Indeed, it has been almost 
systematically documented by the studies estimating incidence rate of pregnancy after ART 
initiation within more than 12 months of clinical follow-up.  The cumulative incidence rate 
estimated by several studies increase to more than 20% at 36 months comparing with 
around 2% during first year on ART follow-up (226, 228). Consistently with this increased 
cumulative incidence proportional to time on ART, other studies have suggested that the 
probability of becoming pregnant increases of roughly 30% after 36 months on ART follow-
up(229). In the study conducted by Myer et al, crude incidence rate of pregnancy among 
HIV-infected women was of 13.7 per 100 women-years at year four of ART follow-up, more 
than two times higher than what it was during first year (6.8 per 100 women-years)(227). 
Besides estimating the incidence rates and epidemiological trends of pregnancy, current 
scientific evidence has also documented associated factors of incident pregnancies among 
women on ART. Unsurprisingly, the most commonly cited are biological factors and chief 
among these is women biological age.  
It seems that high incidence rates of pregnancy are more common among young women <35 
years old. In addition, and consistently with this first finding, although incidence rate of 
pregnancy increases proportionally to time on ART,  the probability of becoming pregnant 
decreases with women’s biological age, peaking the higher rate among  women of <25 years 
old. Westreich et al estimated a probability of 52.2% of becoming pregnant among women 
who started ART between 18-25 years old when compared to peers starting ART at older 
ages regardless their CD4 cell count at ART initiation (Figure 22) (226).  
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One important associated factor increasing the risk of pregnancy among women on ART was 
the fact of having a current male partner. Although not statistically significant, being married 
or cohabiting with a male partner increased by 59% the risk of becoming pregnant after ART 
initiation (HR: 1.59; 95%IC: 0.94 – 2.69; p=0.08)(209). Additionally, if the HIV-infected 
women have disclosed her HIV status to current male partner the risk of becoming pregnant 
increased by more than two-folds (aHR: 2.45; 95%IC: 1.29 – 4.63) compared to those who 
haven’t disclosed their serological status(229).  
Other factors that found a statistically significant association with a higher risk of becoming 
pregnant were a high CD4 levels and WHO clinical stage. Women having higher levels of CD4 
and during early clinical stages of AIDS disease according to WHO classification had an 
increased risk of becoming pregnant after ART initiation(227, 228). These last findings seems 
to be consistent with the biological hypothesis suggesting that even after an HIV positive 
diagnosis, healthier HIV-infected women are probably more up to become pregnant and 
take a pregnancy to term. 
 
 
Figure 22. Cumulative incidence of first pregnancy among 5,996 women initiating HAART in 
Johannesburg, South Africa, from time of HAART initiation, by baseline age and baseline 
CD4 count: (a) ≤100 cells/mm3; (b) >100 cells/mm3. 
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9.3. Discussion on fertility intentions and pregnancy incidence 
among HIV-infected African women on ART 
9.3.1. Fertility intentions and desires 
Findings of studies within the present literature review suggest that a positive diagnosis of 
HIV does not eliminate the future desire of child bear among HIV infected individuals. 
Moreover, findings suggest as well that the introduction of ART could probably have a 
positive influence on reproductive decision making of HIV-infected women and men. This 
particular finding might be corroborating with the hypothesis that the improvement of 
health perceived status favored by ART might influence positively reproductive decision 
making. 
However, although studies suggest ART is a relevant factor increasing fertility desires among 
HIV-infected individuals, the same studies suggest that reproductive decisions among HIV-
infected individuals could probably be predicted by an important number of other biological 
and psychosocial factors.  
Biological age was found almost systematically associated with a positive desire of 
procreation. The desires of child bear decreased proportionally to women biological age. 
Younger women probably have not yet completed their reproductive goals, they are maybe 
more up to start or continue their procreation program, regardless of their serological 
status.  
Moreover, besides biological age, it appeared that there are gender-related differences in 
terms of desires to bear a child. According to several studies, HIV-infected men were more 
likely to express a positive desire to have a child in the future than women of same 
serological status. HIV-infected women are probably more concerned about the potential 
repercussions of pregnancy on their health status and therefore more sceptics about 
becoming pregnant and bearing a child. On the other hand men are probably more focused 
in the gender norms which dictate that keeping the family kin is man duty.  
In addition, for HIV-infected individuals the fact of being in couple is an important factor 
associated with a positive desire of child bear. Present findings point out that HIV-infected 
individuals in couple were more likely to express a positive desire of having children in the 
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future that their single counterparts. This finding suggests that couple dynamic may play a 
relevant role in terms of reproductive decision making.  
Similarly, for those HIV-infected individuals in couple, disclosing HIV status appeared to be 
an important determinant of reproductive decisions. Although not systematic, for 
serodiscordant couples, disclosing serological status within the couple appeared to be 
associated with an increased desire to cease childbearing. Disclosing the serological status 
within the couple may probably increase the awareness about the risk of HIV transmission 
and the potential repercussions of pregnancy in women health status and making therefore 
the couple reconsider their will of child bear.    
Moreover, among HIV-infected individuals engaging in couple relationships, the fact of 
having few or no child at all with current partner appeared to be significantly associated with 
a positive desire of childbearing. Within certain societies, parenthood grants men and 
women with an upgraded status, this is particularly true in African societies.  Choosing not to 
child bear in African societies is often source of stigma, discrimination and exclusion thus 
HIV-infected individuals choose to procreate regardless the risk associated with their 
serological status.     
Furthermore, the scientific evidence reviewed has explored as well the role of structural 
factors on reproductive decision making among HIV-infected individuals. According to 
findings, health care staff may play a relevant role on the way HIV-infected individuals make 
their reproductive choices. Current literature suggest that negative judgmental attitudes of 
health care staff about the HIV-infected individuals expressed will of child bear might 
influence their reproductive decisions, reducing the desires of child bear among this 
population. In one hand, judgmental attitudes of health care staff hinder effective 
communication on sexual and reproductive issues, becoming therefore probably a hurdle for 
an effective integration of sexual and reproductive programs within HIV care programs. 
However, although these findings constitute an important amount of sounding scientific 
evidence describing and trying to explain reproductive decision making process among HIV-
infected individuals, several methodological issues limit its interpretation. One major limit is 
the fact that the vast majority of these findings are outcomes of cross-sectional studies, and 
therefore causal and temporal relationships are difficult to stablish.  
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Fertility desires following a HIV positive diagnosis are suspected to experience important 
variations across time and cross-sectional designs are unable to capture the potentially 
changing pattern of these desires. Longitudinal designs are more appropriate to explain 
causality and capture changing patterns of procreation desires across the time. Among the 
reviewed studies, only one was conducted under a longitudinal prospective design(209).  
Moreover, it is important to underscore the fact that desires and intentions of procreation 
are relative concepts but not exactly the same and therefore not necessarily measured by 
the same indicators. Several reviewed studies described clearly the outcome measure 
whereas this outcome was unclear in several others. In addition, it is worth to note that 
owed to the large variety of data collection tools used to capture the concepts of desire and 
intention of procreation among different studies, it is difficult to compare or extrapolate 
findings across the different settings. 
Similarly, as the measure of fertility desires might be subject of sensitive personal 
information, information bias cannot be excluded. This bias could be related to the concept 
of social desirability as women answers are consistent with societal expectations from them 
as future mothers, regardless their knowledge on the repercussion on their health status.  
According to findings of this literature review, the vast majority of studies aiming at 
measuring child bearing desires in sub-Saharan Africa have been mostly conducted in 
southern and eastern Africa. Besides two quantitative studies conducted in Nigeria and one 
qualitative study conducted in Côte d’Ivoire, data on this concern is scarce in West Africa. 
This fact may limit interpretation of current findings and current findings may not be 
representative of the whole sub-Saharan region. 
Finally, although the present literature review is maybe not fulfilling all methodological 
criteria to be labeled as systematic, a large number of studies responding to inclusion criteria 
are included thus we believe present findings are a fair representation of current status of 
this subject in scientific literature.  
A positive desire of procreation persists among HIV-infected women and men and it is 
modify by a set of biological and psychosocial factors. Measuring and reporting the desires 
of procreation of HIV-infected individuals is one major input in order to provide this 
population with an appropriate reproductive health services. Assessing procreation desires 
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of HIV-infected individuals at diagnosis, at the initiation of antiretroviral treatment and 
periodically during clinical follow-up could undoubtedly health care service to address more 
correctly their needs in terms of family planning and therefore prevent risky unintended 
pregnancies among HIV-infected women.  
9.3.2. Incidence of pregnancy 
Although lower than in general population, the incidence of pregnancy among HIV-infected 
women after initiating antiretroviral treatment is high. Moreover, current scientific evidence 
suggests that the incidence rate of pregnancy increases proportionally to time on 
antiretroviral treatment. Several biological and psychosocial factors appeared to be 
associated to the incident pregnancies among HIV-infected women on antiretroviral 
treatment.  
Unsurprisingly biological age appeared to be almost systematically associated with the 
incidence of pregnancy after antiretroviral treatment initiation. The incidence rate of 
pregnancy appeared to be higher among younger women (under 25 years old) compared to 
the incidence rate of pregnancy of their older counterparts. One study suggested that the 
effect of age remains regardless immunological status at antiretroviral treatment initiation. 
However, pregnancy appeared to be more frequent among HIV-infected women with 
improved immunological responses. In addition, the incidence rate of pregnancy was higher 
among HIV-infected women reporting being in couple, regardless the nature of this 
engagement. 
Notwithstanding, as the incidence rate of pregnancy among HIV-infected women observed a 
great variation across the different studies consulted, we supposed this large variation is 
probably owed to the method implemented to the pregnancy detection method. Indeed, as 
the incident rate of pregnancy of studies detecting pregnancy only by women-self report 
was lower, it could be induced that maybe an important number of pregnancies may have 
gone undetected. Pregnancy detection of studies implementing systematic-periodic urine or 
blood pregnancy test was more accurate and therefore maybe more exhaustive. It is 
suspected that the estimation of incidence of pregnancy through women-self report is 
probably an important source of information bias. In addition, several studies estimated the 
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incidence rate of pregnancy as a secondary outcome, not necessarily related to the principal 
objective of the study and thus detecting pregnancy was maybe not so rigorous.  
Moreover, the differences of the outcomes measured and reality depend in some extent to 
methodological design of the studies. Estimations of observational cohort studies are 
probably more close to comprehensive care services reality than randomized control trials. 
The strict measures of follow-up and data collection implemented are maybe incompatibles 
with conventional health care services functioning. However, missing data and uncontrolled 
confounders of retrospective cohort studies reduce quality and reliability of reported 
outcomes. 
The estimation of cumulative incidence rate of pregnancy within prospective cohorts varies 
according the number of person-years of follow-up, making difficult to compare different 
outcomes across studies with similar methodological designs. Health care-based clinical 
observational cohorts have in some extent large periods of follow-up and thus higher 
denominators in terms of person-year to calculate cumulative incidence. Larger periods of 
follow-up might induce a higher risk of loss to follow-up and therefore probably an 
underestimation of the incidence rate of pregnancy. On the other hand, prospective cohort 
studies conducted within a limited period of time, although accounting maybe for a lower 
risk of loss to follow-up; these studies account as well for a reduce number of person-year of 
follow-up and thus probably overestimating the incidence rate of pregnancy. 
Although probably less common than in the general population; pregnancy is a frequent 
event among women of reproductive age after a HIV positive diagnosis. Current scientific 
evidence suggests that the introduction of ART may have played a role in increasing the 
incidence rates of pregnancy among HIV-infected women. Moreover, epidemiologic trends 
point out that the incidence rate of pregnancy increases proportionally to time on ART, 
suggesting an exposure effect of these drugs on women’s fertility. However, whether this 
positive effect of ART on reproductive functions is due to a direct impact on women’s 
reproductive structures and physiology, indirectly due to the whole restoration of health 
status affecting women’s perception of her life after a positive diagnosis or both is not 
completely understood and merits further research.  
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IMPLEMENTATION AND OPERATIONAL RESEARCH: EPIDEMIOLOGY AND PREVENTION
Incidence of Pregnancy After Antiretroviral Therapy
Initiation andAssociated Factors in 8West AfricanCountries
Juan Burgos-Soto, MD, MPH,*† Eric Balestre, MPH,*† Albert Minga, MD, PhD,‡ Samuel Ajayi, MD,§
Adrien Sawadogo, MD,k Marcel D. Zannou, MD,¶ Valériane Leroy, MD, PhD,*†
Didier K. Ekouevi, MD, PhD,*†# François Dabis, MD, PhD,*† and Renaud Becquet, PhD,*†
IeDEA West Africa Collaboration
Introduction: This study aimed at estimating the incidence of
pregnancy after antiretroviral therapy (ART) initiation in 8 West
African countries over a 10-year period.
Methods: A retrospective analysis was conducted within the
international database of the IeDEA West Africa Collaboration.
All HIV-infected women aged ,50 years and starting ART for their
own health between 1998 and 2011 were eligible. Pregnancy after
ART initiation was the main outcome and was based on clinical
reporting. Poisson regression analysis accounting for country hetero-
geneity was computed to estimate ﬁrst pregnancy incidence post-
ART and to identify its associated factors. Pregnancy incidence rate
ratios were adjusted on country, baseline CD4 count and clinical
stage, hemoglobin, age, ﬁrst ART regimen, and calendar year.
Results: Overall, 29,425 HIV-infected women aged 33 years in median
(interquartile range, 28–38) contributed for 84,870 women-years of
follow-up to this analysis. The crude incidence of ﬁrst pregnancy
(2304 events) was 2.9 per 100 women-years [95% conﬁdence interval
(CI): 2.7 to 3.0], the highest rate being reported among women aged 25–
29 years: 4.7 per 100 women-years; 95% CI: 4.3 to 5.1. The overall
Kaplan–Meier probability of pregnancy occurrence by the fourth year on
ART was 10.9% (95% CI: 10.4 to 11.4) and as high as 28.4% (95% CI:
26.3 to 30.6) among women aged 20–29 years at ART initiation.
Conclusions: The rate of pregnancy occurrence after ART initiation
among HIV-infected women living in the West Africa region was
high. Family planning services tailored to procreation needs should be
provided to all HIV-infected women initiating ART and health
consequences carefully monitored in this part of the world.
Key Words: HIV, incident pregnancy, predicting factors, post-ART
initiation, Africa
(J Acquir Immune Deﬁc Syndr 2014;67:e45–e54)
INTRODUCTION
Women of reproductive age constitute the largest
population affected by HIV infection in sub-Saharan Africa.1
The wide availability of antiretroviral therapy (ART) in
African settings has considerably decreased morbidity and
mortality of many women living with HIV, reducing as well
the risk of mother-to-child transmission of HIV.1,2 We
hypothesize that this outstanding improvement of life expec-
tancy of women of childbearing age is positively associated
with the increasing procreation desires and fertility rates
observed after ART initiation in several settings.3–5 However,
safe motherhood needs are partially met for HIV-infected
women, since for instance the access to family planning,
antenatal, and postnatal care services of good quality are
not fully available in most settings.6–11 Several studies have
showed that fertility desire among childless HIV-affected
couples, even if lower than in the general population, is high,
especially among younger individuals.12,13 Indeed, the
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pregnancy rate among HIV-infected women increases signif-
icantly after ART initiation, and this increase seems propor-
tional to the duration of ART exposure, independently of the
use of contraceptive methods.12–15
The pregnancy occurrence among HIV-infected women
remains a major clinical and public health concern for the
following reasons. First, women starting ART for their own
health during pregnancy present a higher risk of virological
failure than women starting ART while not pregnant.16 More-
over, HIV infection has been pointed out as a leading indirect
cause of maternal death in sub-Saharan Africa,17–20 increasing
the risk of several maternal complications positively associated
with maternal death.21,22 Finally, the vertical risk of HIV trans-
mission has not been eliminated yet, especially in lower income
settings. This is primarily due to the failure to reach high levels
of linkage and retention throughout the cascade of HIV services
for all pregnant, delivering, and breastfeeding women.23
In West Africa, although the roll out of ART over the last
decade has been slower than elsewhere in the developing world,
it has considerably contributed to the overall improvement of
survival of HIV-infected women in a context of high fertility.
Available information about reproductive health patterns and
more speciﬁcally demographic trends of fertility among HIV-
infected women on ART remains poor in this region however.
In this context, the aim of this study was to estimate over
a 10-year period the incidence of pregnancy after ART initiation
on a large sample of ART-treated HIV-infected women of
reproductive age, and to identify the associated factors of
pregnancy occurrence after ART initiation in West Africa.
METHODS
The IeDEA West Africa Collaboration
The International epidemiological Database to Evaluate
AIDS (IeDEA) initiative (http://www.iedea-hiv.org) is a con-
sortium of leading clinicians and epidemiologists launched in
2006 that has been addressing high-priority research questions
and streamline HIV/AIDS research through large pooled
regional databases. Its African organization was extensively
described elsewhere.24 This cohort analysis was conducted
within the IeDEA West Africa Collaboration (http://mereva.
isped.u-bordeaux2.fr/iedea/Accueil.aspx). Fifteen HIV/AIDS
adult clinics located within 8 countries participated in this
report: Benin (n = 1), Burkina Faso (n = 2), Côte d’Ivoire
(n = 5), Gambia (n = 1), Guinea-Bissau (n = 1), Mali (n = 2),
Nigeria (n = 2), and Senegal (n = 1). Every 18 months, each
cohort submits information to the central coordinating center
based in Côte d’Ivoire, using a standardized data format. The
data collected capture demographic, clinical, biological, and
therapeutic information at baseline and during follow-up visits.
Inclusion/Exclusion Criteria and Study Sample
We conducted a retrospective analysis within the West
African cohort database among all HIV-infected women of
reproductive age (,50 years) and starting ART for their own
health between January 1998 and December 2011 according to
in-country ART protocols. Women not reporting any follow-up
visit were not retained for this analysis. Additionally, 1 clinic
participating to the consortium was not systematically reporting
pregnancies within its database and was therefore excluded
from this analysis. As we were interested in estimating the
incidence of pregnancy after ART initiation, HIV-infected
women starting ART for their own health while pregnant were
included for this analysis but were left censored 9 months after
ART initiation (any prevalent pregnancy that initiated before
ART initiation was thus not taken into account). The ﬂow
diagram of patients’ selection is detailed in Figure 1.
Data Collection and Outcome Definition
All eligible women started ART for their own health
fulﬁlling clinical eligibility criteria established by in-country
ART protocols. All of the participating clinics had the
capacity to perform CD4 cell counts, hematology, and
biochemistry. ART was provided free of charge by the
national treatment programs according to their individual
treatment algorithms. After entry into care, women were
typically followed every 6 months or were seen at in-between
visits for any intercurrent illness. CD4 cell counts were
measured every 6 months. Baseline CD4 was the measure
performed at the time of ART initiation or in the previous 6
months. Women not seen at least 6 months without any
transfer or death report were considered lost to follow-up.
Pregnancy diagnosis was considered based on the delay
of the last menstruation period according to the woman self-
FIGURE 1. Flowchart of women eligible for the pregnancy anal-
ysis. The IeDEA West Africa collaboration database, 1998–2011.
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report that was assessed at each follow-up visit. The main
outcome measure for this analysis was ever becoming
pregnant after ART initiation, as reported in the database.
Statistical Analysis
Baseline characteristics were described and compared
between pregnant and nonpregnant women using x2 test for
categorical and qualitative variables and Kruskal–Wallis non-
parametric test for continuous variables. Incidence rates of
pregnancy event including recurrences were calculated per
100 women-years of follow-up with their 95% conﬁdence
interval (CI). Poisson regression method was used to estimate
incident rate of ﬁrst pregnancy among women of reproductive
age starting ART as soon as January 15, 1998, until end point
date set at December 31, 2011. Each woman included con-
tributed to the denominator from time of ART initiation to
their date of pregnancy recording, their last visit or December
31, 2011. Women were right censored at the time of death or
loss to follow-up when these events occurred.
Considering pregnancy as a time-dependent event, the
probability of becoming pregnant according to the age at ART
initiation was estimated using Kaplan–Meier analysis. To iden-
tify associated factors of the ﬁrst pregnancy occurrence after
ART initiation, we ran univariable and multivariable Poisson
regression models performed with a manual backward selection
method, assuming signiﬁcant all associations with P values
,0.05. Maternal age was computed as a time-dependent vari-
able in Poisson regression models. ART history (pretreated or
naive) was considered as an explanatory variable. Statistical
analyses were generated using SAS software (version 9.2 for
Windows, Copyright 2013 for SAS Institute, Inc, Cary, NC).
RESULTS
Overall, 29,425 HIV-infected women accounted for the
present analysis, contributing a total of 84,870 women-years
of follow-up with 4.4% of death and 25.6% of loss to follow-
up across the study period.
Baseline characteristics according to pregnancy experi-
ence are detailed in Table 1. Women who reported a preg-
nancy were signiﬁcantly younger at ART initiation than those
who never reported such an event: 29.7 years in median ver-
sus 33.5 years (P , 0.001). Similarly, women who were
identiﬁed as pregnant started ART at higher median CD4 cell
count level (191 cells/mm3) than those who never reported
a pregnancy during the study period (172 cells/mm3) (P ,
0.001). Pregnancy was less frequent among women who
started ART with a clinical stage III/IV or AIDS compared
with those starting ART with a less-advanced stage of HIV
disease (19.6% vs. 24.5%) (P , 0.001). Hemoglobin level at
baseline among women becoming pregnant after ART initia-
tion was slightly higher in median than among those who
never became pregnant (10.2 vs. 10.1 g/dL; P = 0.01).
Pregnancy Occurrence
As detailed in Table 2, 2515 pregnancies were reported
among 2304 women during the course of follow-up: 2107
women had 1 pregnancy, 183 had 2 pregnancies, and 14
women reported 3 pregnancies. The crude incidence rate of
pregnancy was 2.96 pregnancies per 100 women-years (95%
CI: 2.85 to 3.08) (Table 2). The highest rate was reported in
Burkina–Faso (3.46 pregnancies per 100 women-years; 95%
CI: 3.11 to 3.81), followed by Nigeria (3.43 pregnancies per
100 women-years; 95% CI: 3.19 to 3.66) and Togo (3.35
pregnancies per 100 women-years; 95% CI: 2.57–4.13). For
the remaining 5 countries, the incidence rate of pregnancy
was below 3.0 pregnancies per 100 women-years.
Median time from ART initiation to the ﬁrst pregnancy
was 24.6 months [interquartile range (IQR), 12.1–43.1].
Among women reporting several pregnancies, the median
time between ﬁrst pregnancy and the second one was 19.7
months (IQR, 13.1–30.3) and 15.3 months (IQR, 14.1–22.1)
between the second and the third ones.
As shown also in Table 2, the incidence rate of ﬁrst
pregnancy was 2.85 per 100 women-years (95% CI: 2.74 to
2.97) during the ﬁrst 12 months after ART initiation and was
increasing thereafter. The incidence rate of pregnancy was
higher than 4 pregnancies per 100 women-years among
women aged between 20 and 34 years, especially among
those aged between 25 and 29 years peaking at 4.69 pregnan-
cies per 100 women-years (95% CI: 4.32 to 5.06). For age
groups 35–39 years old and 16–19 years old, incidence rate of
pregnancy was of 2.74 (95% CI: 2.50 to 2.97) and 1.95 (95%
CI: 0.60 to 3.30) pregnancies per 100 women-years, respec-
tively. The lowest incidence rate of pregnancy was estimated
in the age group of 40–49 years old [0.53 pregnancies per 100
women-years (95% CI: 0.43 to 0.62)].
As shown in Figure 2, the overall pregnancy probability
was 11% by the fourth year on ART; between 19% and 33%
among women aged ,30 years at ART initiation, around
18% among women aged 30–35 years, and much lower in
older women.
As presented in Table 2, incidence rate of ﬁrst preg-
nancy after ART initiation among women starting ART with
a clinical stage A, B/I, II was 3.20 per 100 women-year (95%
CI: 3.04 to 3.35), whereas this ﬁgure was lower among
women starting ART at more advanced stages of HIV disease.
Similarly, the incidence rate of ﬁrst pregnancy among women
starting ART with CD4 cells counts of $500 cells per cubic
millimeter was 3.72 per 100 women-years (95% CI: 3.05 to
4.38) and decreased proportionally to the severity of immune
deﬁciency at ART initiation. Although not statistically signif-
icant, pregnancy tended to be less frequent among women
starting ART with lower levels of hemoglobin (Table 2).
Factors Associated With
Pregnancy Occurrence
The following factors collected at ART initiation and
during follow-up were investigated in multivariable regression
analysis to estimate adjusted incidence risk ratios (aIRRs) of
the ﬁrst pregnancy: country, year of starting ART, age (time-
dependent variable), clinical stage, baseline CD4 cell count,
ART regimen, history of ART, and hemoglobin (Table 3).
When compared with women aged 40–49 years,
women aged 16–19, 20–24, 25–29, 30–34, and 35–39 years
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had an increased risk of becoming pregnant after ART initi-
ation (aIRR of 3.52, 7.12, 8.26, 7.64, and 5.11, respectively,
P , 0.001).
Starting ART at an advanced clinical stage of HIV
disease (CDC stage C or WHO stages III and IV) reduced
signiﬁcantly the likelihood of pregnancy after ART initiation
(aIRR: 0.83; 95% CI: 0.74 to 0.93). CD4 cell count at ART
initiation discriminated well the risk of ﬁrst pregnancy after
ART initiation: the higher the CD4 count at ART initiation, the
more frequent the subsequent occurrence of pregnancy. Indeed,
compared with women starting ART with a CD4 cell count less
than 50 cells per cubic millimeter, the aIRR of pregnancy post-
ART initiation was 1.14 (95% CI: 0.93 to 1.39), 1.25 (95% CI:
1.06 to 1.48), 1.38 (95% CI: 1.16 to 1.64), 1.35 (95% CI: 1.07
to 1.70), 1.41 (95% CI: 1.13 to 1.76), and 1.43 (95% CI: 1.13
to 1.81) for women starting with CD4 cell count between 50
and 99, 100–199, 200–299, 300–349, 350–499, and $500
cells per cubic millimeter, respectively.
Finally, when compared with those initiating ART with
a nevirapine-based regimen, HIV-infected women starting
ART with an efavirenz-based regimen had a signiﬁcantly
decreased aIRR (0.63, 95% CI: 0.56 to 0.71). The history of
Antiretrovirals use did not inﬂuence the pregnancy occur-
rence after ART initiation.
DISCUSSION
This study estimated the occurrence of pregnancy
among HIV-infected women after ART initiation at 15
clinical sites in 8 West African countries over a 10-year
period. To explain demographic trends of the incidence of
pregnancy in this population, we looked as well for
epidemiological, clinical, biological, and therapeutic charac-
teristics. According to our ﬁndings, the average crude
incidence rate of pregnancy after ART initiation was 2.9
pregnancies per 100 women-years. To the best of our
TABLE 1. Baseline Characteristics According to Women’s Experience of Pregnancy: the IeDEA West Africa Collaboration,
1998–2011
Characteristics at ART Initiation
Women Ever Becoming
Pregnant (N = 2304)
Women Never Becoming
Pregnant (N = 27,121) Total (N = 29,425) P
Age in yrs, median (IQR) 29.7 (26.5–32.9) 33.5 (28.9–39.3) 33.1 (28.6–38.8) ,0.0001*
Baseline CD4 count (cells/mL), median (IQR) 191 (108–285) 172 (84–271) 173 (86–272) ,0.0001*
Baseline CD4 count (cells/mL) (%) ,0.0001†
,50 194 (8.4) 3205 (11.8) 3399 (11.6)
50–99 193 (8.4) 2645 (9.8) 2838 (9.6)
100–199 527 (22.9) 5763 (21.3) 6290 (21.4)
200–299 430 (18.7) 4399 (16.2) 4829 (16.4)
300–349 117 (5.1) 1329 (4.9) 1446 (4.9)
350–499 143 (6.2) 1453 (5.4) 1596 (5.4)
$500 119 (5.2) 1201 (4.4) 1320 (4.5)
Missing 581 (25.2) 7126 (26.3) 7707 (26.2)
Hemoglobin (g/dL), median (IQR) 10.2 (9.0–11.4) 10.1 (8.9–11.3) 10.2 (8.9–11.3) 0.0130*
Baseline hemoglobin (g/dL) (%) 0.0028†
$12 217 (9.4) 2417 (8.9) 2634 (9.0)
10–12 629 (27.3) 6288 (23.2) 6917 (23.5)
8–10 455 (19.8) 5155 (19.0) 5610 (19.1)
,8 147 (6.4) 2070 (7.6) 2217 (7.5)
Missing 856 (37.2) 11,191 (41.3) 12,047 (40.9)
WHO or CDC clinical stage (%) ,0.0001†
A, B/I, II 1574 (68.3) 16,617 (61.3) 18,191 (61.8)
AIDS/III, IV 452 (19.6) 6648 (24.5) 7100 (24.1)
Missing 278 (12.1) 3856 (14.2) 4134 (14.0)
Regimen at ART initiation (%) ,0.0001†
2NRTIs + nevirapine 1665 (72.3) 16,584 (61.1) 18,249 (62.0)
2NRTIs + efavirenz 416 (18.1) 7692 (28.4) 8108 (27.6)
2NRTIs + PI 156 (6.8) 2115 (7.8) 2271 (7.7)
3NRTIs 25 (1.1) 359 (1.3) 384 (1.3)
Other regimens 42 (1.8) 371 (1.4) 413 (1.4)
History of ART (%) 0.3622†
Naive 2142 (93.0) 25,347 (93.5) 27,489 (93.4)
Pretreated 162 (7.0) 1774 (6.5) 1936 (6.6)
*Kruskal–Wallis test.
†x2 test.
CDC, US Centers for Disease Control.
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TABLE 2. Pregnancy Incidence According to Country and Women’s Baseline Characteristics: the IeDEA West Africa Collaboration,
1998–2011
Country No. Women (%)
No. First
Pregnancies
Incidence of First Pregnancy
per 100 Women-Years
(95% CI*)
Overall No.
Pregnancies
Pregnancy Incidence per
100 Women-Years
(95% CI)
Country
Côte d’Ivoire 10,107 (34.4) 777 2.52 (2.34–2.70) 887 2.71 (2.53–2.89)
Benin 1621 (5.5) 101 2.21 (1.78–2.64) 119 2.41 (1.98–2.84)
Burkina Faso 3685 (12.5) 341 3.33 (2.97–3.68) 379 3.46 (3.11–3.81)
Guinea-Bissau 1130 (3.8) 20 1.20 (0.68–1.73) 22 1.31 (0.76–1.85)
Mali 2447 (8.3) 187 2.45 (2.10–2.81) 202 2.53 (2.18–2.88)
Nigeria 8711 (29.6) 800 3.43 (3.19–3.67) 824 3.43 (3.19–3.66)
Senegal 287 (1.0) 10 2.40 (0.91–3.89) 11 2.51 (1.03–4.00)
Togo 1437 (4.9) 68 3.29 (2.51–4.07) 71 3.35 (2.57–4.13)
Follow-up post-ART (yrs)
First year on ART 7940 (27.0) 574 2.36 (2.16–2.55) 576 2.36 (2.16–2.55)
Second year on ART 5403 (18.4) 563 2.93 (2.69–3.17) 596 3.17 (2.91–3.42)
Third year on ART 4560 (15.5) 399 2.77 (2.50–3.04) 439 3.18 (2.89–3.48)
Fourth year on ART 3358 (11.4) 318 3.08 (2.74–3.41) 371 3.82 (3.43–4.21)
Fifth year on ART and more 8164 (27.8) 450 2.92 (2.65–3.19) 533 3.67 (3.36–3.99)
Age at pregnancy (yrs)
40–49 9232 (31.4) 118 0.53 (0.43–0.62) 128 0.57 (0.47–0.66)
35–39 6729 (22.9) 523 2.74 (2.50–2.97) 567 2.79 (2.56–3.02)
30–34 7298 (24.8) 896 4.17 (3.89–4.44) 991 4.29 (4.03–4.56)
25–29 4364 (14.8) 618 4.69 (4.32–5.06) 671 4.78 (4.42–5.15)
20–24 1170 (4.0) 141 4.01 (3.35–4.68) 150 4.11 (3.45–4.76)
16–19 126 (0.4) 8 1.95 (0.60–3.30) 8 1.92 (0.59–3.26)
Missing 506 (1.7) — —
Baseline clinical stage
A, B/I, II 18,191 (61.8) 1574 3.20 (3.04–3.35) 1712 3.30 (3.14–3.45)
C/III, IV 7100 (24.1) 452 2.33 (2.11–2.54) 500 2.45 (2.23–2.66)
Missing 4134 (14.1) 278 2.30 (2.03–2.57) 303 2.42 (2.15–2.69)
Baseline CD4 count (cells/mL)
,50 3399 (11.6) 194 2.24 (1.93–2.56) 215 2.39 (2.07–2.71)
50–99 2838 (9.6) 193 2.53 (2.17–2.88) 220 2.74 (2.38–3.10)
100–199 6290 (21.4) 527 3.01 (2.75–3.27) 574 3.10 (2.85–3.36)
200–299 4829 (16.4) 430 3.34 (3.02–3.66) 463 3.41 (3.10–3.72)
300–349 1446 (4.9) 117 3.38 (2.77–4.00) 120 3.31 (2.71–3.90)
350–499 1596 (5.4) 143 3.57 (2.99–4.16) 154 3.63 (3.06–4.21)
$500 1320 (4.5) 119 3.72 (3.05–4.38) 126 3.73 (3.08–4.38)
Missing 7707 (26.2) 581 2.48 (2.28–2.68) 643 2.62 (2.42–2.82)
First ART regimen
2NRTIs + NVP 18,249 (62.0) 1665 3.48 (3.31–3.65) 1795 3.56 (3.40–3.73)
2NRTIs + EFV 8108 (27.6) 416 1.75 (1.58–1.91) 468 1.88 (1.71–2.05)
2NRTIs + PI 2271 (7.7) 156 2.41 (2.03–2.79) 179 2.60 (2.22–2.98)
3NRTIs/others 797 (2.7) 67 2.57 (1.96–3.19) 73 2.67 (2.06–3.28)
History of ART
Naive 27,489 (93.4) 2142 2.86 (2.73–2.98) 2337 2.97 (2.85–3.09)
Pretreated 1936 (6.6) 162 2.82 (2.39–3.25) 178 2.93 (2.50–3.36)
Baseline hemoglobin (g/dL)
$12 2634 (9.0) 217 3.11 (2.69–3.52) 232 3.15 (2.75–3.56)
10–12 6917 (23.5) 629 3.28 (3.02–3.54) 698 3.45 (3.19–3.70)
8–10 5610 (19.1) 455 2.94 (2.67–3.21) 494 3.01 (2.75–3.28)
,8 2217 (7.5) 147 2.80 (2.35–3.26) 163 2.96 (2.50–3.41)
Missing 12,047 (40.9) 856 2.53 (2.36–2.70) 928 2.63 (2.46–2.80)
Total cohort 2304 2.85 (2.74–2.97) 2515 2.96 (2.85–3.08)
*95% Conﬁdence Interval.
EFV, efavirenz; NVP, nevirapine; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
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knowledge, it is the ﬁrst time that such a ﬁgure is reported in
this part of Africa known for its high-fertility patterns and
infrequent use of contraceptive methods. Although elevated,
the estimated pregnancy incidence we found in this popula-
tion living with HIV and in care in West Africa was lower
than among their uninfected counterparts in the region.
Indeed, according to the 2012 African health observatory
report, fertility rates across the countries we surveyed ranged
between 4 and 6 live births per 1000 women-years.25
Although this variation might be owed to methodological
differences, it may also suggest that fertility patterns are
somehow conditioned by HIV infection.
Similarly, it seemed that the incidence rate of pregnancy
within our study sample was lower than previous estimations in
other sub-Saharan African settings. In Southern Africa,
Bussmann et al26 reported a post-ART pregnancy rate of 7.9
per 100 women-years in Botswana, and Westreich et al15 re-
ported an incidence rate of pregnancies of 5.2 per 100 women-
years after ART initiation in a South African clinical cohort.
Furthermore, in rural Uganda, the incidence rate of pregnancy
was as high as 9.5 per 100 women-years 24 months after ART
initiation.13 Finally, a larger study conducted by Myer et al
reported an overall crude incidence rate of pregnancy after
ART initiation of 9.0 per 100 women-years in 7 African coun-
tries including Côte d’Ivoire. Although not fully detailed,
Myers et al estimation for Côte d’Ivoire appeared higher than
the one we found in our study. We suspect that this difference
might be owed to the fact that their study was conducted within
a network of women-centered clinics focusing on PMTCT of
HIV infection, thus, pregnancy was the main outcome measure
with probably more accurate and rigorous detection methods.14
We also suspect that differences in occurrence of
pregnancy after ART initiation between West Africa and
other African settings might be due to sociodemographic
speciﬁcities and HIV disease and care patterns. Methodolog-
ical variations across studies cannot however be fully
excluded. Although systematically conﬁrmed clinically, esti-
mations on incidence rate of pregnancy presented in our study
were initially based on women self-report of the last
menstruation period. Bearing in mind that miscarriages and
abortions are very frequent during the early months of
pregnancy27 and HIV infection has been pointed out as an
important cause,28 we suspect that a substantial number of
pregnancies may have gone undetected. The former and the
signiﬁcant proportion of dropouts contributed clearly to an
underestimation of the pregnancy incidence reported. Simi-
larly, in this context of large-scale public health program, the
data quality did not allow to document how patients break in
care in a standardized way across sites. Finally, the lack of
information on some potentially important confounding
variables (such as marital status, parity, or family planning
methods availability or use) limits somewhat the interpreta-
tion of our ﬁndings.
The incidence rate of pregnancy after ART initiation
increased slightly but progressively throughout years in care,
suggesting a positive effect of ART on fertility among women
of reproductive age, and this association was particularly
strong among younger women. This phenomenon is consis-
tent with studies conducted in other sub-Saharan African
settings, showing an increased cumulative incidence rate of
pregnancy post-ART initiation proportional to time on
clinical follow-up.14,15,26 This ﬁnding suggests that the global
FIGURE 2. Kaplan–Meier probability of preg-
nancy occurrence after ART initiation according
to age at ART initiation. The IeDEA West Africa
collaboration, 1998–2011.
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TABLE 3. Poisson Regression Univariable and Multivariable Model Estimating Associated Factors of the Incidence Rate of First
Pregnancy After ART Initiation (29,425 Women; 84,870 Person-Years): the IeDEA West Africa Collaboration, 1998–2011
Predicting Factors
No. Reported Pregnancies
(First Event)
Univariable Models Multivariable Model
Incidence Rate Ratio
(95% CI) P
Adjusted Incidence
Rate Ratio (95% CI) P
Country ,0.0001 0.0006
Côte d’Ivoire 777 Ref Ref
Benin 101 0.88 (0.71–1.08) 0.92 (0.74–1.14)
Burkina Faso 341 1.32 (1.16–1.50) 1.24 (1.09–1.42)
Guinea-Bissau 20 0.48 (0.31–0.75) 0.59 (0.38–0.93)
Mali 187 0.98 (0.83–1.15) 0.90 (0.76–1.08)
Nigeria 800 1.37 (1.24–1.51) 0.99 (0.89–1.11)
Senegal 10 0.96 (0.51–1.79) 1.01 (0.54–1.9)
Togo 68 1.30 (1.01–1.67) 0.83 (0.64–1.08)
Year of starting ART ,0.0001 ,0.0001
,2005 299 Ref Ref
2005–2006 722 1.24 (1.09–1.42) 0.89 (0.77–1.04)
2007–2008 760 1.83 (1.60–2.09) 1.34 (1.15–1.56)
2009–2011 523 2.16 (1.87–2.49) 1.58 (1.35–1.86)
Age (yrs, time dependant) ,0.0001 ,0.0001
40–49 118 Ref Ref
35–39 523 5.26 (4.31–6.42) 5.11 (4.19–6.24)
30–34 896 8.00 (6.60–9.69) 7.64 (6.30–9.26)
25–29 618 9.00 (7.39–10.96) 8.26 (6.77–10.07)
20–24 141 7.71 (6.04–9.85) 7.12 (5.57–9.11)
16–19 8 3.74 (1.83–7.66) 3.52 (1.72–7.20)
Clinical stage at ART initiation ,0.0001 ,0.0001
A, B/I, II 1574 Ref Ref
C/III, IV 452 0.73 (0.66–0.81) 0.83 (0.74–0.93)
Missing 278 0.72 (0.64–0.82) 0.78 (0.68–0.90)
CD4 count at ART initiation (cells/mL) ,0.0001 0.0032
,50 194 Ref Ref
50–99 193 1.13 (0.92–1.37) 1.14 (0.93–1.39)
100–199 527 1.34 (1.14–1.58) 1.25 (1.06–1.48)
200–299 430 1.48 (1.25–1.76) 1.38 (1.16–1.64)
300–349 117 1.50 (1.19–1.88) 1.35 (1.07–1.70)
350–499 143 1.58 (1.27–1.96) 1.41 (1.13–1.76)
$500 119 1.64 (1.31–2.06) 1.43 (1.13–1.81)
Missing 581 1.10 (0.94–1.30) 1.38 (1.15–1.66)
Regimen at ART initiation ,0.0001 ,0.0001
2NRTIs + NVP 1665 Ref Ref
2NRTIs + EFV 416 0.50 (0.45–0.56) 0.63 (0.56–0.71)
2NRTIs + PI 156 0.69 (0.59–0.81) 0.86 (0.72–1.02)
3NRTIs/others 67 0.74 (0.58–0.95) 0.96 (0.75–1.23)
Hemoglobin at ART initiation (g/dL) ,0.0001 0.0012
$12 217 Ref Ref
10–12 629 0.94 (0.80–1.11) 1.14 (0.97–1.35)
8–10 455 0.90 (0.73–1.11) 1.11 (0.90–1.38)
,8 147 1.05 (0.90–1.23) 1.15 (0.98–1.34)
Missing 856 0.81 (0.70–0.94) 0.90 (0.76–1.06)
ART history 0.8805
ART naive 2142 Ref —
Pretreated 162 0.99 (0.84–1.16) —
EFV, efavirenz; NVP, nevirapine; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
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restoration of health status favored by ART and measured by
CD4 cell recovery also boosted fertility functions among women
of reproductive age. It is also possible that immune restoration
owed to ART favored the onset of maternal fetus tolerance
mechanism increasing the probability to take a pregnancy to
term successfully. However, such a biological association
between post-ART health improvement and restoration of fertil-
ity functions requires further research to better understand the
underlying biological mechanisms and their association with
temporal changes in couple and family life experiences.
Additionally, our ﬁndings show that both age and
clinical/immunological parameters at ART initiation were
important predictors of reproductive patterns among HIV-
infected women in care. Consistently with other studies, the
incidence rate ratio of pregnancy after ART initiation was
signiﬁcantly higher among younger and healthier HIV-
infected women than among their older counterparts with
a poorer health status.13–15 However, the increase of the inci-
dence rate of pregnancy after ART initiation reached its peak
at 25–29 years old to decrease progressively afterward, sug-
gesting that although ART might have a positive effect on
fertility, it remains restricted to biological conditions, respect-
ing human reproductive cycle.
Healthier women at ART initiation were those having
the highest probability of becoming pregnant. This associa-
tion is explained by the fact that their improved health status
increases their reproductive ability but also by the fact that an
early exposure to ART might limit the HIV-associated risk of
miscarriage. This increased incidence risk of pregnancy
associated to higher CD4 levels at ART initiation should be
better taken into account in strategies such as treatment as
prevention promoting universal and early treatment initiation
regardless of CD4 levels.
Unintended pregnancy rates are high in sub-Saharan
Africa among women of reproductive age and raise major
public health concerns among younger women in these
settings.29 We hypothesize that besides the potential beneﬁts
of ART on restoring fertility functions, an important number
of these pregnancies is owed to the limited capacity of HIV-
infected women to manage their procreation desires. Indeed, the
unmet needs for family planning among West African women
irrespective of their HIV status are as high as 30%.9,30 It has
been pointed out that integrating family planning services into
HIV care is an important shortcoming to reduce unintended
pregnancy rates among HIV-infected women and eliminate
the vertical risk of HIV transmission.1,31,32
To conclude, this is one of the ﬁrst studies estimating
incidence rate of pregnancy among a large regional cohort of
about 30,000 HIV-infected women initiating ART for their
own health and accounting for about 75,000 women-years of
follow-up across 8 West African countries. Although lower
than in other African settings and probably underestimated,
the incidence rate of pregnancy increases proportionally after
ART initiation in West Africa. Moreover, pregnancy after
ART initiation remains an event, particularly for younger
women, with potentially important individual and public
health consequences. As universal access to ART has enabled
HIV-infected women of reproductive age to live longer and
with higher quality of life standards, childbearing is a growing
desire among this population. Understanding the dynamics of
fertility among women on ART is a key step to correctly ﬁt
the strategies of integrating family planning into HIV care and
to help HIV-infected women to correctly fulﬁll their pro-
creation trajectory through safe and adapted motherhoods
programs. This is one of the many challenges that HIV care
and treatment programs must address upfront now, especially
in West Africa.
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APPENDIX. The IeDEA WEST AFRICA
COLLABORATION STUDY GROUP
(AS OF NOVEMBER 2013)
Participating Sites (Members of the
Steering Committee)
Executive Committee
François Dabis (Principal Investigator, Bordeaux, France), Emmanuel
Bissagnene (Co-Principal Investigator, Abidjan, Côte d’Ivoire), Elise Arrivé
(Bordeaux, France), Patrick Cofﬁe (Abidjan, Côte d’Ivoire), Didier Ekouevi
(Abidjan, Côte d’Ivoire), Antoine Jaquet (Bordeaux, France), Valériane
Leroy (Bordeaux, France), Charlotte Lewden (Bordeaux, France), and Annie
J. Sasco (Bordeaux, France).
Benin, Cotonou. Adults: Djimon Marcel Zannou*, Carin Ahouada, Jocelyn
Akakpo, Christelle Ahomadegbé, Jules Bashi, Alice Gougounon-Houéto,
Angèle Azon-Kouanou, Fabien Houngbé, and Jean Sehonou (CNHU
Hubert Maga).
Pediatrics: Sikiratou Koumakpaï*§, Florence Alihonou, Marcelline
d’Almeida, Irvine Hodonou, Ghislaine Hounhoui, Gracien Sagbo, Leïla
Tossa-Bagnan, and Herman Adjide (CNHU Hubert Maga).
Burkina Faso. Adults: Joseph Drabo*, René Bognounou, Arnaud Dienderé,
Eliezer Traore, Lassane Zoungrana, Béatrice Zerbo (CHUYalgado, Ouagadougou),
Adrien Bruno Sawadogo*§, Jacques Zoungrana, Arsène Héma,
Ibrahim Soré, Guillaume Bado, and Achille Tapsoba (CHU Souro Sanou,
Bobo Dioulasso).
Pediatrics: Diarra Yé*, Fla Kouéta, Sylvie Ouedraogo, Rasmata
Ouédraogo, William Hiembo, and Mady Gansonré (CH Charles de Gaulle,
Ouagadougou).
Côte d’Ivoire, Abidjan. Adults: Eugène Messou*, Joachim Charles
Gnokoro, Mamadou Koné, Guillaume Martial Kouakou (ACONDA-CePReF);
Clarisse Amani Bosse*, Kouakou Brou, Achi Isidore Assi (ACONDA-MTCT-
Plus); Henri Chenal*, Denise Hawerlander, Franck Soppi (CIRBA); Albert
Minga*, Yao Abo, Jean-Michel Yoboue (CMSDS/CNTS); Serge Paul
Eholié*§, Mensah Deborah Noelly Amego, Viviane Andavi, Zelica Diallo,
Frédéric Ello, Aristophane Kofﬁ Tanon (SMIT, CHU de Treichville), Serge
Olivier Koule*, Kofﬁ Charles Anzan, and Calixte Guehi (USAC, CHU de
Treichville).
Pediatrics: Edmond Addi Aka*, Kofﬁ Ladji Issouf, Jean-Claude
Kouakou, Marie-Sylvie N’Gbeche (ACONDA-CePReF); Touré Pety*,
Divine Avit-Edi (ACONDA-MTCT-Plus); Kouadio Kouakou*, Magloire
Moh, Valérie Andoblé Yao (CIRBA); Madeleine Amorissani Folquet*,
Marie-Evelyne Dainguy, Cyrille Kouakou, Véronique Tanoh Méa-Assande,
Gladys Oka-Berete, Nathalie Zobo, Patrick Acquah, Marie-Berthe Kokora
(CHU Cocody); Tanoh François Eboua*, Marguerite Timité-Konan, Lucrèce
Diecket Ahoussou, Julie Kebé Assouan, Mabéa Flora Sami, and Clémence
Kouadio (CHU Yopougon).
Ghana, Accra. Pediatrics: Lorna Renner*§, Bamenla Goka, Jennifer
Welbeck, Adziri Sackey, and Seth Ntiri Owiafe (Korle Bu TH).
Guinea-Bissau. Adults: Christian Wejse*§, Zacarias José Da Silva*,
Joao Paulo (Bandim Health Project), The Bissau HIV cohort study group:
Amabelia Rodrigues (Bandim Health Project), David da Silva (National HIV
program Bissau), Candida Medina (Hospital National Simao Mendes,
Bissau), Ines Oliviera-Souto (Bandim Health Project), Lars Østergaard
(Department of Infectious Diseases, Aarhus University Hospital), Alex Laursen
(Department of Infectious Diseases, Aarhus University Hospital), Morten
Sodemann (Department of Infectious Diseases, Odense University Hospital),
Peter Aaby (Bandim Health Project), Anders Fomsgaard (Department of
Virology, Statens Serum Institute, Copenhagen), Christian Erikstrup (Depart-
ment of Clinical Immunology), and Jesper Eugen-Olsen (Department of Infec-
tious Diseases, Hvidovre Hospital, Copenhagen).
Mali, Bamako. Adults: Moussa Y. Maïga*§, Fatoumata Fofana Diakité,
Abdoulaye Kalle, Drissa Katile (CH Gabriel Toure), Hamar Alassane
Traore*, Daouda Minta*, Tidiani Cissé, Mamadou Dembelé, Mohammed
Doumbia, Mahamadou Fomba, Assétou Soukho Kaya, Abdoulaye M. Traoré,
Hamady Traoré, and Amadou Abathina Toure (CH Point G).
Pediatrics: Fatoumata Dicko*, Mariam Sylla, Alima Berthé, Hadiza-
tou Coulibaly Traoré, Anta Koïta, Niaboula Koné, Clémentine N’Diaye,
Saﬁatou Touré Coulibaly, Mamadou Traoré, Naïchata Traoré (CH Gabriel
Toure).
Nigeria. Adults: Man Charurat* (UMB/IHV), Samuel Ajayi*, Georgina
Alim, Stephen Dapiap, Otu (UATH, Abuja), Festus Igbinoba (National Hospital
Abuja), Okwara Benson*, Clément Adebamowo*, Jesse James, Obaseki, Philip
Osakede (UBTH, Benin City), and John Olasode (OATH, Ile-Ife).
Senegal, Dakar. Adults: Moussa Seydi*, Papa Salif Sow, Bernard Diop,
Noël Magloire Manga, Judicael Malick Tine§, Coumba Cissé Bassabi (SMIT,
CHU Fann).
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Pediatrics: Haby Signate Sy*, Abou Ba, Aida Diagne, Hélène Dior,
Malick Faye, Ramatoulaye Diagne Gueye, Aminata Diack Mbaye (CH Albert
Royer).
Togo, Lomé. Adults: Akessiwe Patassi*, Awèrou Kotosso, Benjamin
Goilibe Kariyare, Gafarou Gbadamassi, Agbo Komi, Kankoé Edem
Mensah-Zukong, and Pinuwe Pakpame (CHU Tokoin/Sylvanus Olympio).
Pediatrics: Koko Lawson-Evi*§, Yawo Atakouma, Elom Takassi,
Améyo Djeha, Ayoko Ephoévi-gah, and Sherifa El-Hadj Djibril (CHU
Tokoin/Sylvanus Olympio).
Operational and Statistical Team
Jean-Claude Azani (Abidjan, Côte d’Ivoire), Eric Balestre (Bordeaux,
France), Serge Bessekon (Abidjan, Côte d’Ivoire), Sophie Karcher (Bordeaux,
France), Jules Mahan Gonsan (Abidjan, Côte d’Ivoire), Jérôme Le Carrou
(Bordeaux, France), Séverin Lenaud (Abidjan, Côte d’Ivoire), Célestin Nchot
(Abidjan, Côte d’Ivoire), Karen Malateste (Bordeaux, France), and Amon
Roseamonde Yao (Abidjan, Côte d’Ivoire).
Administrative Team
Madikona Dosso (Abidjan, Côte d’Ivoire), Alexandra Doring§
(Bordeaux, France), Adrienne Kouakou (Abidjan, Côte d’Ivoire), Elodie
Rabourdin (Bordeaux, France), and Jean Rivenc (Pessac, France).
Consultants/Working Groups
Xavier Anglaret (Bordeaux, France), Boubacar Ba (Bamako, Mali),
Renaud Becquet (Bordeaux, France), Juan Burgos Soto (Bordeaux, France),
Jean Bosco Essanin (Abidjan), Andrea Ciaranello (Boston, MA), Sébastien
Datté (Abidjan, Côte d’Ivoire), Sophie Desmonde (Bordeaux, France), Jean-
Serge Elvis Diby (Abidjan, Côte d’Ivoire), Geoffrey S. Gottlieb* (Seattle,
WA), Apollinaire Gninlgninrin Horo (Abidjan, Côte d’Ivoire), Julie Jesson
(Bordeaux, France), Serge N’zoré Kangah (Abidjan, Côte d’Ivoire), David
Meless (Abidjan, Côte d’Ivoire), Aida Mounkaila-Harouna (Bordeaux,
France), Camille Ndondoki (Bordeaux, France), Caroline Shiboski (San
Francisco, CA), Boris Tchounga (Abidjan, Côte d’Ivoire), Rodolphe Thiébaut
(Bordeaux, France), and Gilles Wandeler (Dakar, Senegal).
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10. Repercussions of pregnancy on health status of HIV-
infected women of reproductive age 
10.1. Introduction 
As discussed in the previous chapter, an HIV diagnosis does not necessarily cease the desires 
of childbearing, and many HIV-infected women and men chose to procreate, particularly 
after starting ART. This persistent positive desire of childbearing expressed by HIV-infected 
individuals is somewhat reflected in the incidence rates of pregnancy observed in 
observational studies conducted within clinical cohorts of HIV infected individuals. Although 
incidence rate of pregnancy among HIV-infected women is probably lower than in general 
population, pregnancy is not an uncommon event among this population. Moreover, this 
incidence rate of pregnancy seems to increase proportionally to time on follow-up for 
women on antiretroviral treatment.  
Given that pregnancy is a major biological and psychosocial event in women life with 
potential repercussions on women health. Besides the risk of transmission of HIV infection 
during pregnancy from mothers to their babies, I hypothesized that pregnancy could be a 
major health challenge for HIV infected women and their babies. The increased metabolic 
demand occurring during pregnancy may probably have important repercussions on HIV-
infected women immune system, weakened already by HIV infection and, therefore 
probably accelerating HIV-disease progression. This potential negative effect on women’s 
immune response could probably provoke a higher susceptibility to opportunistic diseases 
threatening women and children lives.  
Current scientific literature points out as well that HIV infection is associated with a higher 
risk of maternal mortality. In settings with high HIV prevalence, an important fraction of 
maternal deaths are owed to the HIV infection. However, the mechanism explaining the 
association between HIV infection and the risk of maternal death is not fully understood. 
Current research is inconclusive in terms of whether pregnancy increases the risk of HIV-
disease progression or HIV-infection increase the risk of fatal maternal complications.  
The objective of the following section is to firstly present an epidemiologic update of 
maternal mortality, which is a major cause of death among women of reproductive age. 
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Within this epidemiologic update, I present current epidemiologic trends, geographic 
distribution and major maternal causes of death. Secondly, based on current scientific 
literature, I present a review of current scientific literature aiming at investigating whether 
or not HIV infection is associated with a higher risk of death during pregnancy or postpartum 
and the possible mechanisms explaining this association. Finally, I close this section with the 
third peer-reviewed article of this doctoral research framework aiming at estimating the risk 
of death, HIV-disease progression and/or loss to follow-up according to pregnancy 
occurrence among women on ART, conducted within the IeDEA West Africa observational 
cohort. 
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10.2. Epidemiologic background of maternal mortality 
Maternal mortality is defined as the death of a woman while pregnant or within 42 days of 
termination of pregnancy, irrespective of the duration and site of the pregnancy, from any 
cause related to or aggravated by the pregnancy or its management but not from accidental 
or incidental causes(236). 
Estimations from early nineties indicated that around 585,000 women died of maternal-
related causes worldwide(237). Moreover, desegregated data showed that a great disparity 
existed across regions and almost the totality (582,000) of overall maternal deaths were 
reported by low-and-middle resources settings(237). Alarmingly, around 40 per cent of all 
these deaths occurred in the African continent, setting where one women out of sixteen 
died of maternal causes(237, 238). 
These deaths were mostly due to pregnancy, delivery and postpartum complications which 
were not correctly managed(237, 238). The most of these maternal deaths can be averted if 
births are attended by skilled health personnel, have the proper equipment and supplies, 
and can refer women in a timely manner to emergency obstetric care when complications 
are diagnosed(237, 238). Complications require prompt access to quality obstetric services 
equipped with life-saving drugs, including antibiotics, and the ability to provide blood 
transfusions needed to perform Caesarean sections or other surgical interventions(237, 
238). Additional scientific evidence suggests as well that the reducing the gap in terms of 
unmet needs of family planning could avert a significantly high number of maternal deaths in 
low-and-middle resource settings(94). 
It is worth to note as well that maternal mortality rate was higher African settings than 
anywhere else worldwide and, particularly and strikingly higher in settings at the South of 
the Sahara. It was estimated that in certain sub-Saharan Africa regions one out of twelve 
women died of maternal causes (237, 238). At the end of past century, these alarming 
estimations raised great awareness within the global community and, taking action in order 
to reduce these estimations became one major public health priority. The reduction of 
maternal mortality by half from 1990 levels by the year 2000 was adopted as common goal 
of WHO and UNICEF(238).  
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As by the deadline year this goal remained unachieved, the global community set out this 
goal once again within the Millennium Declaration as a part of the eight Millennium 
Development Goals. Reduce by three quarters maternal mortality ratio worldwide by 2015, 
was the ambitious target set out within The Millennium Declaration. 
Since the reduction of maternal mortality ratio by three quarters by 2015 was embraced by 
the global community as one Millennium Development Goals target and the global action 
plan was rolled out; trends of maternal mortality have sensibly changed. Recent estimations 
point out that, although the goal will not be completely achieved worldwide by 2015 as 
expected, great progress has been achieved. 
10.3. Current global status 
Globally, the maternal mortality ratio decreased by 55 per cent over the last two decades, 
from 523 000 in 1990 to 289 000 in 2013(10, 53, 236, 238).Within this period the global rate 
of decline in the maternal mortality ratio is of 3.1 per cent per year, just over a half of what 
needed to achieve the Millennium Development Goal by 2015 (53, 236). As shown in figure 
23, although this decline was significant for all WHO regions in 2010, it happened at different 
rates. 
 
 Important disparities remain between developed and low-and middle income settings. Over 
800 women died every day from avoidable maternal causes and almost 99% (286 000) of 
these deaths occurred in developing countries(53, 238).  
Figure 23. Regional and global trends in maternal mortality ratio 1990 – 2010. (Source: WHO, 2013) 
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As shown in figure 24, in 2013 sub-Saharan Africa was the region reporting the highest 
maternal mortality ratio worldwide. Maternal mortality ratio (MMR) varies across the 
different sub-Saharan African sub-regions. Western Africa (540 000) and Central Africa 
(680 000) are the two regions reporting the highest Maternal Mortality Ratios (MMR) 
whereas, Eastern Africa (440 000) and Southern Africa (160 000) maternal mortality ratios 
are somewhat lower(236).  
Global and regional estimations tends to mask disparities within and among countries, more 
desegregated estimations point out that over half of all maternal deaths are reported by 
seven countries(238). Four out of these seven countries are located in sub-Saharan Africa, 
the other three in South-East Asia.  
Out of these seven countries, two countries accounted for 30 per cent of all maternal deaths 
worldwide: India with a maternal mortality ration of 50,000 maternal deaths and Nigeria 
with 40 000 accounted for 17 and 14 per cent respectively  (236, 238). Democratic Republic 
of the Congo (21 000, 7%); Ethiopia (13 000, 4%); Indonesia (8800, 3%); Pakistan (7900, 3%); 
United Republic of Tanzania (7900, 3%) are the remaining countries reporting the highest 
number of maternal deaths (figure 25)(236, 238). 
 
Figure 24. Maternal mortality ratio (maternal deaths per 100,000 live births in women aged 15 to 
49), 2013. (Source: UNICEF, 2013) 
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Additionally, the ranking of the highest maternal mortality ratios is leaded by ten sub-
Saharan African countries: Sierra Leone (1,100 per 100,000 live births), Chad (980,000), 
Central African Republic (880,000), Somalia (850,000), Burundi (740,000), Democratic 
Republic of the Congo (730,000), South Sudan (730,000), Côte d’Ivoire (720,000), Guinea 
(650,000) and Liberia (640,000) (236).  Only two countries outside the sub-Saharan African 
region had high MMR: Afghanistan (400,000) and Haiti (380,000) (236).  
Finally, according to current estimations lifetime risk of maternal death, which is a 
population indicator expressing the probability that a 15-year-old women will die eventually 
from a maternal cause, has observed an important reduction at a global level(237). Within 
ten years the lifetime risk of maternal death decreased of more than the half. In 1990, one 
woman out of 60 was at risk of dying of maternal causes whereas in 2013, it was of 1 woman 
out of 190 (237). However, this indicator observes important disparities across different 
world regions. 
In industrialized countries, the lifetime risk of maternal death is one in 3,700 whereas in 
least developed countries this risk is of one in 160 (237). Alarmingly, the estimated lifetime 
risk of dying of maternal causes for sub-Saharan African women is as high as one woman in 
38(237). Within the sub-Saharan region, Chad and Somalia had the highest life time risks of 
maternal mortality reporting at 1 in 15 and 1 in 18, respectively (237).  
Figure 25. Proportion of global maternal deaths in the seven countries with highest numbers of 
maternal deaths. (Source: UNICEF, 2013) 
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10.4. Progress towards achievement of the 5th MDG: Improve 
maternal health 
In order to track the progress of the achievement of 5th MDG, assessments of the mortality 
rate ratio are conducted periodically at all levels. To achieve a reduction of 75% of maternal 
mortality rates by 2015, it is expected that countries reduce their annual mortality rate ratio 
by 5.5%.  
According to recent estimations, the global annual rate of decline increased from 2.2% over 
the years 1990-2005 to 3.3% from 2005 to 2013. Regarding least developed countries, 
maternal mortality ratio declined from 2.9% between 1990 and 2005 to 3.9% between 2005 
and 2013. However, significant differences have been observed among regions (figure 26). 
  
 
South Asia leads with the highest annual declines of maternal mortality ratio. In this region 
the annual mortality rate ratio declined increased from 4.3 per cent between 1990 and 2005 
to 4.6 between 2005 and 2013. Latin America and the Caribbean, the annual decline 
decreased of 1.7 between 2005 and 2013. Sub-Saharan Africa, although far still from global 
target, maternal mortality ratio decline, increased of 1.1 per cent between 2005 and 2013 
(236, 238). 
 
Figure 26. Percentage annual rate of reduction in the maternal mortality ratio, by region. 
(Source: UNICEF, 2014) 
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At a country level, 19 countries have achieved The Millennium Development target by 2013: 
• African countries: Equatorial Guinea (81%); Eritrea (77%); Cabo Verde (77%); Rwanda 
(76%). 
• Asian countries: Maldives (93%); Bhutan (87%); Cambodia (86%); Lao People’s 
Democratic Republic (80%); Timor-Leste (78%); Nepal (76%). 
• Eastern and central Europe: Belarus (96% reduction in MMR); Poland (81%); 
Romania (80%); Bulgaria (78%); Estonia (78%); Latvia (77%); 
• Middle East: Israel (84%); Oman (77%); Lebanon (76%); 
Eleven countries among these are indicated as “On Track” to achieve MDG 5, 63 countries 
were categorized as “Making Progress” and 13 countries have made “insufficient progress”. 
To conclude, although during last ten years an impressive progress has been achieved in 
terms of reduction of maternal mortality worldwide, a great effort is still needed to fully 
achieve the global target of reducing maternal mortality of 75% by 2015. Low-and-middle 
income settings scores for the highest maternal mortality ratios when compared to 
industrialized settings. South-East Asia leads the score in terms of reduction of maternal 
mortality and is the world region more plausible of achieving this goal by the deadline set. 
Despite sub-Saharan Africa has reported important progress in achieving this goal, this 
region holds the highest maternal mortality rate and is the least plausible of achieving the 5th 
Millennium Goal of reducing maternal mortality by three-quarters by 2015. 
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10.5. Causes of maternal mortality 
According to the etiology and physiopathology, the World Health Organization (WHO) 
classifies the causes of maternal death into two categories: Direct and indirect causes(236). 
Direct maternal deaths are those resulting from obstetric complications of pregnant state, 
specific interventions, omissions, incorrect management or a succession of events resulting 
from any of the former situations(236). Hypertensive disorders, obstetric hemorrhage or 
complications of C-section surgery are examples of direct causes of maternal death (236).   
Indirect maternal deaths are those resulting from previously existing diseases, or from 
diseases that developed during pregnancy and that were not due to direct obstetric causes 
but aggravated by physiological effects of pregnancy(236). Deaths due to the aggravation of 
an existing cardiac or renal disease or chronic infections such as HIV are typical examples of 
indirect causes of maternal deaths(236).  
The concept of “death during pregnancy, childbirth and the puerperium” also called 
“pregnancy-related death” is an alternative concept related to maternal death, defined as 
any death temporal to pregnancy, childbirth or the postpartum period, even if it is due to 
accidental or incidental causes(236). This alternative classification allows the measurement 
of deaths that are related to pregnancy, even though they do not fulfill strictly the standard 
definition of maternal death. This alternative definition is particularly useful in settings 
where the causes of death cannot be accurately verified or are not available in medical 
certificates(236).  
The concept of pregnancy-related deaths are commonly used in population-based surveys, 
where respondent cannot provide precise information of the causes of deaths but they can 
provide information about the pregnancy status of the reproductive-aged sibling at the time 
of death (236). Rather than the measure of maternal death, these surveys provide the 
measure of pregnancy-related deaths. Although not fully reliable, this measure provides an 
approximation of maternal death, adapted to the methodological limits of these surveys 
(236). 
Furthermore, as complications of pregnancy and/or childbirth can lead to death beyond the 
six weeks postpartum period and; current technology and modern procedures enable 
women to survive adverse outcomes of pregnancy and delivery delaying death beyond 42 
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days postpartum (236). In certain routine civil registration forms, these deaths do not count 
as maternal death although they are owed to pregnancy-related event. In order to capture 
delayed maternal deaths occurring between six weeks and one year postpartum, several 
maternal deaths assessments use this definition. 
10.6. Epidemiology of maternal causes of death 
According to recent estimations, 73% of all maternal deaths between 2003 and 2009 were 
owed to direct obstetric causes whereas indirect causes were responsible of the remaining 
quart of all maternal deaths from known causes. Among the direct causes, hemorrhage has 
been the leading cause of maternal death worldwide over the last decade, representing 
almost one third of all maternal deaths (27.1%) in 2014(238-240). Postpartum hemorrhage 
was responsible of more than 60% of all reported cases of Hemorrhage (240). 
The second leading direct cause of maternal death worldwide was hypertension accounting 
for 14% of overall rate (239, 240). Sepsis, abortion and embolism together with other direct 
causes were responsible of 11%, 8% and 13% respectively of overall maternal deaths 
worldwide (figure 27)(240). Furthermore, obstructed labor and complications of delivery 
were responsible of 23% of all maternal deaths worldwide each (240). In figure 25, these two 
causes are included in “Other direct causes” category, which represented 10% of the total 
(238, 240). 
 
 
 
 
 
 
 
 Figure 27. Global distribution of the causes of maternal death. (Source: UNICEF, 2014) 
*Nearly 99% of abortion deaths are due to unsafe abortions. 
**This category includes deaths due to obstructed labor or anemia. 
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Geographic distribution of maternal deaths causes is importantly affected by the high 
epidemiologic burden of this phenomenon observed in sub-Saharan Africa and southern 
Asia, regions accounting for 84% of all maternal deaths(240). Desegregated data showed 
that embolism is an important cause of maternal death in developed regions compared to 
developing regions, where this condition is not commonly diagnosed and reported (240). 
Moreover, although hemorrhage is the leading cause of maternal death worldwide; the 
contribution of this condition to overall maternal deaths in northern Africa is of 36%, higher 
than anywhere else (240). Hypertensive disorders appeared to be a particularly important 
cause of maternal deaths in Latin America and the Caribbean, with a contribution of 22% to 
overall maternal deaths in this region (240). 
Concerning the indirect causes of maternal deaths, more than three thirds of these deaths 
were due to pre-existing disorders. These pre-existing disorders included HIV infection, 
which alone contributed with 5.5% to all maternal deaths dues to indirect causes worldwide 
(238, 240). Unsurprisingly, the contribution of HIV to the number of maternal deaths owed 
to indirect causes in settings with high prevalence rates of the infection was sensibly higher. 
The contribution of HIV infection to overall maternal deaths in sub-Saharan Africa is of 6.4%, 
higher than any other region worldwide (240). The contribution of HIV to maternal deaths in 
the remaining regions reached barely 5% (240). 
In sub-Saharan Africa, HIV infection is considered one major indirect cause of maternal 
mortality in this setting (5, 24, 241). Recent estimations pointed out that the risk of death 
among HIV-infected pregnant and postpartum women is eight times higher than their 
uninfected counterparts (24). These estimations predicted that roughly 24% of overall 
maternal deaths in sub-Saharan Africa are attributable to HIV-infection (24). 
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10.7. HIV infection and maternal mortality 
The underlying mechanism explaining the morbid association between HIV-infection and 
maternal mortality is not completely elucidated and is still subject of debate. On the one 
hand, it has been suggested that pregnancy itself, might accelerate HIV disease progression 
of HIV-infected women through interactions between the physiopathology of the viral 
infection and the pregnancy-related metabolic changes. On the other hand, it has been 
suspected that HIV-infection could be associated with an increased risk of developing lethal 
obstetric complications. The following sections will aim at presenting scientific evidence 
underpinning both mechanisms and then discussing the limitations of these findings.  
10.7.1. Association of pregnancy on HIV disease progression or death 
Pregnancy is considered a major health event in women’s lives, with potential harmful 
repercussions for HIV-infected women health. It has been widely recognized the major role 
played by HIV infection increasing the risk of maternal death in sub-Saharan Africa and 
several research studies aiming at explaining the causal mechanisms of this association has 
been conducted. 
These studies identified HIV disease progression as the diagnosis of any AIDS-defining 
condition following a positive pregnancy status. According to findings of Westreich et al, 
within an observational cohort of south African women on antiretroviral treatment, 
pregnancy was not associated with an increased risk of death or any AIDS-related morbid 
event (242). Indeed, findings of Westreich et al showed that the risk of death or progressing 
to a disease stage 4 for HIV-infected women who became pregnant following the initiation 
of antiretroviral treatment was of aHR: 0.87 (95%CI: 0.51-1.49). Consistently, a similar study 
conducted by Tai et al reported that the risk of AIDS disease progression decreased 
significantly of 60% among HIV-infected women who became pregnant after initiating 
antiretroviral treatment (aHR: 0.40; 95%CI:[0.21-0.76](243). Similar findings were reported 
by Kaplan et al. and Myer et al. in others South African cohorts of HIV-infected women(244, 
245). These findings are underpinned by a literature review on the subject which concluded 
not finding a significant association between pregnancy and an increased risk of HIV-disease 
progression among women on ART(246).  
However, it is worth to note that, within these cohort studies, , we believe there are major 
shortcomings to the reliability of these findings since pregnancy detection was based on 
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women self-report and thus probably not exhaustive, plus a high proportion of women were 
reported loss to follow-up . Moreover, as the risk period of these studies was unrestricted, 
we believe their estimations correspond more to a pregnancy-related risk of death rather 
than a risk of maternal mortality. 
On the light of such findings, it has been hypothesized that among HIV-infected women on 
ART, pregnancy might probably modify the immunological response to ART treatment. To 
explain this phenomenon and according to literature, three possible reasons were proposed: 
1) a potential immunologic boost associated with pregnancy; 2) A selection bias whereby 
women who are healthier (and thus less likely to have HIV disease progression) are more 
likely to become pregnant; 3) Adherence to HAART regimens during pregnancy may improve 
due to increased concern about the well-being of the fetus and/or due to increased contact 
with the healthcare system for prenatal care(246, 247). 
However, recent findings of Matthews et al. within a Ugandan cohort of HIV-infected women 
on ART tend to contradict the above-mentioned findings. Indeed, within this Ugandan 
cohort, pregnancy and postpartum periods appeared to be associated with an increased risk 
of mortality, (248). In addition, the risk of death associated with pregnancy and postpartum 
was outstandingly high during first year after ART initiation (aHR: 21.48, 95% CI: 3.73-
123.51), and decreased proportionally to time on ART (248).  
Moreover, within this Ugandan cohort the causes of death were mostly AIDS-related 
conditions (Tuberculosis, Cryptococcus meningitis and Kaposi sarcoma)(248). These findings 
suggest probably an important immunosuppression during pregnancy(249, 250) or an 
increased risk of immune reconstitution inflammatory syndrome (IRIS) owed to the reverse 
effect during postpartum of the relative immunosuppression provoked by pregnancy(251). 
Although these findings seems to be sounding, pregnancy detection was based on women 
self-report thus an unknown number of pregnancy may have gone undetected. In addition, 
according to authors, the post-partum period was not captured at the enrollment producing 
probably an information bias and therefore underestimating the time at risk.  
The repercussions of pregnancy on immune response have been also subject of several 
studies. Findings of studies on this concern conducted among ART-naïve women suggested 
that pregnancy might accelerate the progression of HIV disease through a more rapid 
depletion of immune system (252-254). However, the restricted number of participants (16 
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women)(252) and the particular heterogeneity of the study population (more than 50% of 
injecting drug users)(254), implies a careful interpretation of these findings. 
Findings from more recent studies, aiming at estimating the repercussions of pregnancy on 
immune status of HIV-infected women are somewhat different. According to these studies, 
CD4 cells declines during pregnancy are temporary and not sustained in postpartum period 
among ART-naïve women (255-257). Moreover, it appeared that immunological depletion 
after delivery was uncommon among ART naïve women who had relatively high CD4 cell 
counts during pregnancy (>500 cell/mm3)(258). Finally, it was underscored that ART naïve 
women with high initial CD4 count (>500 cells/mm3) had a protracted time (5-7 years) 
before they reach therapeutic thresholds after pregnancy (259). 
However, a study conducted by Westreich et al aiming at exploring the repercussion of 
pregnancy on a sustained viral suppression. According to the findings of this study pregnancy 
after initiating antiretroviral treatment was associated with a modest increase of viral 
failure(193). The risk of virologic failure among HIV-infected women becoming pregnant 
following initiation of antiretroviral treatment increased significantly of 35% compared to 
those who never became pregnant. This study suggests as well that an incident pregnancy 
following the initiation of antiretroviral treatment could increase significantly the risk of 
virologic failure of 6% by five years. 
10.7.2. Association of HIV with lethal direct obstetric complications 
HIV infection has been also associated to an increased risk of developing high deadly direct 
obstetric complications. In sub-Saharan Africa, were HIV-infection is highly prevalent this 
could be a major threat for women of reproductive age. There is a growing body of scientific 
evidence aiming at measuring the association of HIV infection and the risk of developing 
lethal obstetric complications and; understanding the underlying mechanisms probably 
explaining this phenomenon.  
According to a meta-analysis conducted by Calvert et al., HIV increases the risk of 
intrauterine infections during pregnancy, delivery or the postpartum. HIV-infected women 
had over three times the risk of a puerperal sepsis compared with uninfected women 
whether they delivered by C-section or vaginal(260). Additional findings of these meta-
analysis pointed out that this risk increased by roughly six times among studies only 
122 
 
including women who delivered by C-section(260). This finding is not surprising since HIV-
related immunosuppression may lead to an increased risk of infection among infected 
women(261). According to the 2005–2007 Saving Mothers report in South Africa, 71% of 
deaths due to pregnancy-related sepsis occurred in HIV-infected women(262). However, 
whether the excess risk of endometritis and puerperal sepsis in the intra- and postpartum 
period is directly attributable to the pregnancy or indirectly related to HIV or AIDS-
associated infections remains uncertain(260).   
HIV-infection has been also suggested to be associated with an increased risk of developing 
pre-eclampsia – severe metabolic syndrome of unknown etiology occurring during 
pregnancy, delivery or postpartum characterized by hypertension and proteinuria –, this 
association was particularly strong among women on ART. However, current scientific 
evidence is somewhat contradictory. 
On the one hand, within the systematic review and meta-analysis conducted by Calvert C et 
al, HIV infection was found positively associated with pregnancy-induced hypertension but 
not with pre-eclampsia and eclampsia(260). On the other hand, a study conducted by Suy et 
al within an European cohort of HIV-infected women, findings pointed out that HIV-infected 
women on ART who became pregnant have an increased risk of developing pre-eclampsia 
compared to their untreated counterparts (263). Similarly and consistently with this finding, 
Powis et al, found within Mma Bana study that, pregnant women with high levels of viral 
loads (>100 000 copies/mm3) have higher risk of developing pre-eclampsia(264).  
Although the mechanism explaining the onset of pre-eclamptic syndrome is not fully 
understood, it is suspected to be triggered by an autoimmune reaction(264). Thus, ART-
related immunologic restoration might be probably associated with a higher risk of 
developing pre-eclamptic syndrome (263).  
Finally, whilst HIV was associated with an increased risk of antepartum hemorrhage, there 
was no evidence of an increased risk of placenta praevia, placental abruption, postpartum 
hemorrhage or retained placenta(191). In addition, an association between HIV and both 
uterine rupture and prolonged labor was observed, but not between HIV and other 
complications of dystocia(191). 
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10.8. Discussion on maternal mortality in the context of HIV 
infection 
Maternal mortality remains one important cause of death among women of reproductive 
age worldwide. Since the goal of reducing maternal mortality ratio by three-quarters by 
2015 was embraced by the global community, great progress has been achieved worldwide 
towards achieving this goal. Although all regions have reported important achievements 
towards this goal, the progress is unequal. The highest maternal mortality rates have been 
estimated in low-and-middle income settings. Sub-Saharan Africa is the setting reporting the 
highest maternal mortality rate worldwide. No other region in the world as far as sub-
Saharan Africa of achieving the fifth Millennium Development Goal by 2015. 
The vast majority of maternal deaths are owed to direct causes which are responsible of 
roughly three-quarts of overall maternal mortality worldwide. Among the direct causes of 
maternal death, 27% are owed to hemorrhage which is leading direct cause of maternal 
death worldwide. Following hemorrhage, hypertensive disorders and sepsis are the second 
most frequently reported causes of maternal death. Among the indirect causes of maternal 
death, HIV infection is one leading cause responsible of roughly 5% of all maternal deaths 
worldwide. In high HIV prevalence levels, almost one quart of all maternal deaths is 
attributable to this infection.  Indeed, according to current estimations, HIV-infected 
pregnant women have a risk of death eight times higher than their uninfected counterparts. 
However, findings of current research aiming at estimating the pregnancy-related risk of 
death among HIV-infected women are somewhat contradicting. Findings of several research 
studies conducted in observational cohorts of HIV-infected women suggest that pregnancy is 
not associated with an increased risk of death whereas some others suggest an increased 
risk of death associated with pregnancy. Within the study we conducted in the IeDEA West 
Africa observational cohort, pregnancy was not associated with an increased risk of death 
among HIV-infected women.  
However, owed to different methodological limitations these studies are not conclusive. 
Firstly, as the detection of the outcome pregnancy is based on women self-report, it is not 
impossible that an important number of events could have gone undetected. Secondly, it is 
not uncommon that in observational clinical cohorts the event pregnancy is not fully 
documented. Finally, gestational age at time of pregnancy detection and the date of end of 
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pregnancy are not systematically documented limiting the correct estimation of the risk 
period. 
To summarize, maternal mortality is an important cause of death among women of 
reproductive age. HIV infection has been suggested one leading indirect cause of maternal 
death. HIV-infected women face a higher risk of dying of maternal causes than their 
uninfected peers and an important fraction of maternal death rates in settings with high HIV 
prevalence is owed to the infection. Although current scientific evidence is not conclusive in 
demonstrating the association of pregnancy with a higher risk of death among HIV-infected 
women on treatment, a potential association is suspected. Similarly, current research 
suggests as well that pregnancy may have repercussions in terms of immune response of 
HIV-infected women on antiretroviral treatment.  
Although more research is needed to clearly understand the association of HIV infection 
with the risk of maternal mortality and its underlying mechanisms, current findings are of 
major public health concern. As pregnancy is not an uncommon event among HIV-infected 
women on antiretroviral treatment, more clinical scientific knowledge is needed to correctly 
manage pregnancy under these circumstances, preventing potential risk for children and 
mothers. This knowledge is a key input to the successful achievement of the targets set out 
in the global plan of elimination of new HIV pediatric infections and keeping the mothers 
alive. 
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Box 4. Estimation of Maternal Mortality. Concepts review. 
 
In order to better understand the concepts utilized to measure and compare levels of maternal 
mortality around the world it is important to understand the different concepts used to define this 
topic. According to WHO Health Metrics and Evaluation System, Following measures are the standard 
measures used to present maternal mortality: 
• Maternal death: Is the death of a woman while pregnant or within the 42 days of termination 
of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to 
or aggravated by the pregnancy or its management but not from accidental or incidental 
causes. 
 
• Pregnancy-related deaths: The death of a woman while pregnant or within 42 days of 
termination of pregnancy, irrespective of the cause of death. 
 
• Late maternal death: the death of a woman from direct or indirect cause, more than 42 days 
but less than one year after termination of pregnancy. 
Measures of maternal mortality 
The measure of maternal mortality in a population is essentially estimated using two principal factors: 
1) The risk of death in a single pregnancy or a single live birth; 2) The fertility level (the number of 
pregnancies or births that are experienced by women of reproductive age. These two parameters 
allow the estimation of three main indicators that yield approximately the number of maternal deaths: 
• Maternal Mortality Ratio (MMR): defined as the number of maternal deaths during a given 
time period per 100,000 live births during the same period. This concept captures essentially 
the risk of death in a single pregnancy or single live birth. 
 
• Maternal Mortality Rate (MMRate): defined as the number of maternal deaths in a given 
period per 1000 women of reproductive age during the same time period. 
 
• Adult lifetime risk of maternal death: is the probability that a 15-year-old women will die 
eventually from a maternal cause. 
 
 
• Proportion of deaths among women of reproductive age that are due to maternal causes: is 
the number of maternal deaths in a given time period divided by the total deaths among 
women aged 15-49 years. 
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Abstract 
Objective: The objective of this study was to determine whether pregnancy has an impact on the 
long-term clinical outcomes among women becoming pregnant post-ART initiation in West Africa. 
Design: This cohort analysis was conducted within the IeDEA West Africa collaboration. All HIV-
infected women aged <50 years old, starting ART for their own health in 9 West-African countries. 
The effect of pregnancy (time dependent variable) on loss to follow-up (LTFU), progression to AIDS 
and death 48 months after ART initiation was estimated by adjusted Cox regression models. For the 
second analysis, the mean gain of CD4 cells in the first 24 months following ART initiation was 
estimated in multivariable linear mixed models.  
Results: The first analysis accounted for 12,851 HIV-infected women on ART, from which 1,102 
reported at least one pregnancy. After adjustment, pregnancy reduced the risk of AIDS or death 
(aHR=0.61; 95%CI: 0.40-0.92) and the risk of becoming LTFU at M48 (aHR=0.74; 95%CI: 0.60-0.92). 
Overall 20,408 HIV-infected women accounted for the second analysis. The mean gain of CD4 cells 
between ART initiation and M24 was significantly higher among women who experienced a 
pregnancy in the first six months following ART initiation, compared to those with no pregnancy. 
Conclusion: In West Africa, pregnancy post-ART initiation is a common event and reduces by roughly 
one third the risk of AIDS or death and the risk of LTFU. Moreover, pregnancy post-ART initiation had 
no deleterious impact on immune response of women initiating ART for their own health.  
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Introduction 
HIV infection has been pointed out as one leading indirect cause of maternal mortality in the 
developing world, responsible of 90% of all maternal deaths in sub-Saharan Africa(24, 191, 265-267). 
The probability of developing potentially fatal HIV-comorbidities increases importantly during 
pregnancy (9, 18, 268) and the risk of mortality due to maternal causes is eight times higher among 
HIV-infected pregnant women compared to their uninfected counterparts (24). Additionally, 
according to several studies pregnancy is not an uncommon event after antiretroviral therapy (ART) 
initiation and its occurrence increases steadily and proportionally to time on ART, suggesting that the 
outstanding improvement of health status owed to ART, might also restore fertility functions among 
HIV-infected women(209, 226, 227, 269). 
Current evidence on the relationship between pregnancy and the health status of HIV-infected 
women on ART is somewhat contradictory. Becoming pregnant after ART initiation was associated 
with a decreased risk of death or AIDS-related clinical events among South African women (242), 
contrasting with findings in Uganda where pregnancy and postpartum period were independent risk 
factors for death among HIV-infected women initiating ART, particularly during the early ART 
period(248).  
As fetal tissues might be highly antigenic, pregnancy is considered a major challenge for maternal 
immune system. Thus in order to successfully take the pregnancy to full-term, maternal immune 
system must provide a maternal-fetal tolerance state which is characterized by important central and 
peripheral changes of maternal immunity(270-273). Thus, in order to control the production of new 
potentially fetus-reactive T cells, maternal thymus reduces its size and changes its histological 
structure(274). Additionally, maternal tolerance system is completed by a subtle balance of cytokines 
Th1-Th2, favored by former histological changes (275, 276). Recent evidence points out that 
pregnancy do not affect adversely the immunologic course of HIV infection (273). However, we can 
hypothesize that the time when pregnancy occurs might influence long-term immunological recovery 
of HIV-infected women on ART and the clinical course of HIV disease once in care. 
While the increasing incidence rate of pregnancy post-ART initiation in sub-Saharan Africa, scientific 
evidence is well documented the impact of pregnancy on mother’s HIV-infection while on ART is less 
well investigated, particularly in West-Africa. We aimed at estimating the pregnancy related-risk of 
AIDS-disease progression, death or loss to follow-up among HIV-infected women of reproductive age 
on ART in eight West-African countries. We aimed at estimating the gain of CD4 cells according to 
time of pregnancy after ART initiation within the same population. 
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Methods 
The IeDEA West Africa collaboration 
The International epidemiological Database to Evaluate AIDS (IeDEA) initiative (http://www.iedea-
hiv.org) is a consortium of leading clinicians and epidemiologists launched in 2006 that has been 
addressing high priority research questions and streamline HIV/AIDS research through large pooled 
regional databases. Its African organization was extensively described elsewhere (277). This cohort 
analysis was conducted within the IeDEA West Africa Collaboration (http://mereva.isped.u-
bordeaux2.fr/iedea/Accueil.aspx). Fifteen HIV/AIDS adult clinics located within eight countries were 
eligible for in this analysis: Benin (n=1), Burkina Faso (n=2), Côte d'Ivoire (n=5), Gambia (n=1), Guinea 
Bissau (n=1), Mali (n=2), Nigeria (n=2) and Senegal (n=1). The data collected capture demographic, 
clinical, biological and therapeutic information at baseline and during follow-up visits. Every 18 
months, each cohort submits information to the central coordinating center, using a standardized 
data format. 
Inclusion/exclusion criteria and study sample 
We conducted a retrospective analysis within the West-African cohort database among all HIV-
infected women of reproductive age (<50 years old), ART-naïve and starting ART between January 
1998 and December 2011 under the clinical criteria established by the in-country ART protocols. 
Women meeting following criteria were not retained for the main analyses: 1) All women reported as 
previously exposed to ART for prophylaxis purposes (prevention of MTCT); 2) All women with a 
positive pregnancy status at ART start even if they were meeting clinical criteria to start treatment 
and; 3) All women not reporting any follow-up visit after ART initiation. Finally, one clinic 
participating of the consortium was not documenting pregnancies systematically within its database 
and therefore was not taken into account. 
Statistical analysis 
Baseline characteristics of study population were described and compared using Kruskal-Wallis test 
and Chi square test for continuous and categorical variables respectively. In order to address our 
research questions two different methods used.  
Pregnancy related-risk of AIDS-disease progression, death or loss to follow-up  
The risk of AIDS disease progression, death and loss to follow-up over 24 months of follow-up was 
estimated using Cox regression models were pregnancy was considered as a time-dependent 
variable. To estimate the pregnancy-associated risk two models were proposed: 1) the first model 
considered that the pregnancy-associated risk period was of 15 months from pregnancy detection; 2) 
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The second model considered the pregnancy-associated risk period since pregnancy detection and 
for the following 24 months. In order to control the potential confusion bias, women starting ART at 
AIDS clinical stage III or IV were excluded from this analysis.  
We also ran three additional models to test sensitivity of previous survival analyses: In the first of 
them, all women starting ART at an advanced AIDS clinical stage were withdrawn; in the second one, 
besides withdrawing women starting ART at an advanced AIDS clinical stage, we included all women 
starting ART while pregnant. Finally, one last sensitivity model was conducted were all women were 
taken into account, regardless of their health or pregnancy status at ART initiation. 
Estimation of the gain of CD4 cells according to time of pregnancy after ART initiation  
Immunologic response to ART was modeled with linear mixed models (LMM). CD4 cell count change 
was modeled within a 24 months period starting at ART initiation. The LMM had no intercept and 
two slopes, the first slope within the first 6 months after starting ART and the second slope between 
6 and 24 months after ART initiation. The LMM was adjusted for initial CD4 count, pregnancy, age at 
ART initiation, first ART regimen, and calendar year of ART initiation, Body Mass Index (BMI), baseline 
hemoglobin and country. For this analysis, only women having a documented CD4 cell count at ART 
start were retained. To take into account intra-individual correlation of the repeated CD4 count 
measures, we performed random effects on the two slopes with a diagonal variance-covariance 
matrix structure. To verify the adequacy of the multivariable LMM, residual homoscedasticity and 
normality of the random effect were graphically verified. 
Results 
Retention in care and risk AIDS-disease progression or death 
Study sample 
As shown in figure 1, overall 12,851 (8.6%) HIV-infected women on ART accounted for the survival 
analysis out of who 1,102 women reported at least one pregnancy after ART initiation. As shown in 
table 1, women who became pregnant after ART initiation were significantly younger at ART start 
than women who did not (29.5 years old, IQR:[26.5-32.8] Vs. 33.4 years old, IQR:[28.8-39.2]; 
p<0.001).  
Median CD4 cell count at ART initiation among women who became pregnant was significantly lower 
compared to those who never became pregnant during this period (199, IQR:[122-307] Vs. 189, 
IQR:[105-285], p<0.001); 38,2% of women who became pregnant after ART initiation started ART 
with CD4 levels >200 cells and 34.0% of the other group (p=0.01). Although median hemoglobin at 
ART initiation was not significantly different among the two groups of women, women becoming 
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pregnant after ART start had more frequently higher levels of hemoglobin at ART initiation than 
those who didn’t (p=0.004). 
Pregnancy was more frequent among women who started ART with a Nevirapine-based regimen 
than among those starting with a different ART regimen (82.6% Vs. 70.1%; p: <0.001). Although not 
statistically significant, death rate was significantly lower among women who did not report any 
pregnancy after ART start compared to those who reported a pregnancy after ART initiation(1.5% Vs. 
2.3%; p: 0.06).  
After adjustment on baseline CD4 cell count, age, BMI, hemoglobin at ART initiation, initial ART 
regimen, calendar year at ART start and country, the first model restricting pregnancy-associated 
hazard risk period at 15 months from pregnancy detection, even if not statistically significant, the 
fact of becoming pregnant after ART initiation didn’t increase the risk of progressing to AIDS and/or 
to clinical stages III,IV or dying (aHR: 0.61, 95% confidence interval:  [0.40 – 0.92], p: 0.01). Similarly, 
the risk of becoming lost to follow-up was lower in case of pregnancy after ART initiation (aHR: 0.74, 
95% Confidence interval: [0.60 – 0.92], p<0.001). Finally, becoming pregnant after ART initiation 
reduced the risk of all three outcomes combined (aHR: 0.74, 95% Confidence Interval: [0.61-0.90], 
p=0.003). (Table 2) 
In the second model, considering pregnancy-related hazard risk period at 24 months since pregnancy 
detection were similar to first model. After adjusting on the same variables, the risk of AIDS disease 
progression and/or clinical stages III,IV or death was lower in case of pregnancy (aHR: 0.63, 95% 
Confidence Interval: [0.42 – 0.96], p=0.03). As the first model, the risk of becoming lost to follow-up 
at 24 months was lower for women who reported a pregnancy after ART initiation (aHR: 0.73, 95% 
Confidence Interval: [0.59 – 0.91], p<0.001). Finally, pregnancy post-ART initiation lowered the risk of 
all three outcomes combined at 24 months (aHR: 0.70, 95% confidence interval: [0.58 – 0.86], 
p<0.001) (Table 2) 
 
Sensitivity analyses 
In order to ascertain results of main survival analyses, we ran three sensitivity survival models 
(results not shown). Firstly, we ran the same models excluding all women starting ART already at an 
advanced clinical stage (stages C/III, IV), it appeared that whether the pregnancy-related risk period 
was restricted to 15 months after pregnancy detection or beyond; pregnancy remained associated to 
a reduced risk of death, AIDS disease progression and becoming lost to follow-up. Compared to the 
main survival model, the hazard ratios observed a slightly decrease but all of them reached a 
statistically significant threshold. Additionally, we ran a second model on the same population as the 
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former one, but this time including all women with a positive pregnancy status at ART initiation and 
pregnancy remained positively and significantly associated with a reduced hazard risk of AIDS disease 
progression, LTFU or both outcomes combined when the risk period was of 24 months. Although 
pregnancy remained associated with a reduced hazard risk for all three outcomes at 15 months, the 
association with AIDS-disease progression lost it significance. Finally, we ran a model taking into 
account all women of reproductive age regardless neither their clinical stage nor their pregnancy 
status at ART initiation. The results of this last sensitivity analysis appeared to be similar to the main 
survival models, pregnancy remained associated with a reduced risk of death, AIDS disease 
progression or becoming loss to follow-up.  
Immune response according to time of pregnancy after ART initiation  
Study sample 
As shown in figure 2; overall, 20,408 HIV-infected women on ART accounted for the linear mixed 
model analysis. Within this population sample, 1,615 women reported at least one pregnancy post-
ART initiation during the period analyzed. Women becoming pregnant were significantly younger at 
ART initiation than those who did not (29.5 years old, IQR:[26.3 – 32.7) Vs. 33.4 years old, IQR:[28.8-
39.4], P<0.001).  
Among women becoming pregnant, median CD4 levels at ART initiation were significantly higher 
than among those who never became pregnant (189 cells/mm3, IQR: 105-282) Vs. 169 cells/ mm3, 
IQR:[82 – 264, p<0.001). Likewise, women becoming pregnant appeared to have better clinical HIV 
status at ART start and those who never became pregnant during the period of the study were more 
likely to be at clinical stages C/III,IV (24.5% Vs. 18.7%).  
Median hemoglobin level was slightly different between the two groups of women (10.2 gr/dl, IQR: 
[9.0-11.4] Vs. 10.1 gr/dl, IQR:[8.8-11.3], p0.007). Similarly, women becoming pregnant were more 
likely to start treatment with a Nevirapine-based regimen than those who never became pregnant 
(74.7% Vs 64.0%, p<0.001). Finally, death rate was significantly higher among women who never 
became pregnant than among those becoming pregnant (1.5% Vs. 4.3, P<0.001). (Table 3) 
The fully adjusted model showed that mean gain of CD4 cells among women becoming pregnant 
within the first six months was significantly higher than among those who didn’t. Even if not 
statistically different this gain remains slightly higher among those who became pregnant six months 
and 12 months after ART initiation. Finally at 24 months, our estimations pointed out a higher mean 
gain of CD4 cells for women who became pregnant during the first six months after ART initiation 
and this gain is statistically significant (Table 4). 
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Discussion 
According to our findings, pregnancy after ART initiation seems to be associated to a lower risk of 
death or AIDS disease progression at 24 months among HIV-infected west-African women. Although 
this association appeared not to be statistically significant when the risk period was restricted to 15 
months from pregnancy detection; at 48 months, this protective association finds statistical 
significance. Our findings showed as well that the risk of becoming lost to follow-up decreased 
significantly among women who became pregnant post ART initiation whether the risk period is of 15 
months or 48 months after pregnancy detection. 
To our knowledge this is the first study estimating pregnancy-related risk of death, AIDS disease 
progression or loss to follow-up in west-Africa. In contrast with our findings, Matthews L et al(248) 
reported recently that among HIV-infected Ugandan women, the pregnancy-related risk of dying 
after ART initiation was high during pregnancy and postpartum (aHR: 21.48, 95% CI: 3.73–123.51), 
although decreasing proportionally to the time on ART follow-up, it remained positively associated 
and statistically significant. On the other hand, our findings remain consistent with those of 
Westreich et al(242) in South Africa, suggesting that besides pregnancy post-ART initiation is not 
associated with a higher risk of disease progression or death; it might be a protective factor for HIV-
infected women.  
A major strength of our findings is the fact that IeDEA West Africa dataset contains socio-
demographic and clinical information of a large number of HIV-infected patients on ART, followed-up 
for over ten year across eight West-African countries. As our analyses were conducted on a 
retrospective dataset, we were only able to control a limited number of potential confounders. This 
applies particularly to plasma viral load, marker of treatment adherence and response. 
As pregnancy is not systematically detected during clinical visits we suspect an important number of 
pregnancies have gone unnoticed. In addition, variables enabling to accurately estimate a pregnancy-
related risk period such as gestational age at pregnancy detection, delivery date and pregnancy 
outcome are frequently unavailable. As we believe it is important to differentiate crude and maternal 
mortality, we estimated our hazard ratios on a shorter risk period (15 months) as a proxy of maternal 
mortality risk and a longer one (24 months), although still short, as a proxy of overall mortality.  
Of note, within our dataset an important number of women are declared lost to follow-up but as the 
verification of vital status of these women is not exhaustive and some of them might have passed 
away or just transferred to another health facility, we believe that the death rate estimation within 
our sample might be biased, we decided therefore to estimate the risk of a combined outcome death 
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and AIDS disease progression. Furthermore, we conducted several sensitivity analyses which 
remained consistent with our primary findings.  
Regarding CD4 cells count evolution over the time, our findings point out that the CD4 cells gain at 24 
months after ART initiation was significantly higher among women becoming pregnant during the 
first six months after ART initiation compared to those never becoming pregnant or those who 
became pregnant later. We hypothesize first that pregnancy-related peripheral T cells expansion 
might concern CD4 cells which, among women becoming pregnant during early ART initiation (<6 
months), coincide with rapid CD4 cells release of CD4 cells stocked in the thymus, characteristic of 
early post-ART period. Moreover, pregnancy during early ART might be an extra stimulation of this 
rapid release, taking women who became pregnant during early post ART to a higher sustained 
plateau level of CD4 cells, lead to a higher long-term gain of CD4 cells. However, as women who 
became pregnant had an improved health status at ART initiation when compared to those who 
never did, higher CD4 cell count at ART initiation might have favored a higher gain of CD4 cell counts 
at the end of the study period. 
Our second hypothesis is behavioral and suggests that these three groups of women might have 
different adherence profiles. Adherence to ART among HIV-infected women becoming pregnant 
during early stages after ART initiation might be more optimal owed to the recent exposure to 
therapeutic education provided more frequently and intensively in conjunction with prenatal clinical 
visits. Moreover, HIV-infected women becoming pregnant during early stages after ART initiation are 
maybe more exposed to therapeutic education underlying the importance of adherence not just for 
her health but to prevent mother to child transmission as well.  
This second analysis was conducted on immunological response within a large sample of HIV-infected 
women, meeting strict inclusion criteria and relying on an important number of CD4 cell measures. 
We were able to control on an important number of variables to limit confounders. Also, the 
robustness of linear mixed model method allowed to control on missing data. However, whether 
these variations of immunological response are due to biological factors, behavioral factors or a 
combination of both, merits further research. Moreover, we restrained our analyses to a 24 months 
period because of data availability but we suspect that pregnancy might have an impact on immune 
response beyond this period and this merits further research.  Although not definitive, these findings 
suggest that pregnancy post ART initiation may play a role on immune recovery dynamics, leading 
possibly to important clinical consequences. 
In summary, according to our findings, becoming pregnant after ART initiation was associated with 
lower risk of death or HIV disease progression among HIV-infected West-African women of 
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reproductive age. Additionally, pregnancy after ART start appeared to be associated to a reduced risk 
of becoming lost to follow-up. Our findings are consistent with those from other observational 
cohorts in other sub-Saharan African settings. Finally, immunological response might be mediated by 
a combination of biological and behavioral factors; metabolic changes yielded by hormonal activity 
during pregnancy and adherence to ART during this period might have repercussions on CD4 cells 
evolution of HIV-infected women on ART. In order to better manage pregnancy post-ART initiation 
more research is needed to fully understand the role of pregnancy in the CD4 cell evolution dynamics 
and its determinants. 
In conclusion, HIV-infection has been pointed out as one major indirect cause of maternal mortality 
and it is indeed a very challenging event for maternal immune system, the correct management of 
HIV-infected pregnant women in order to assure mother’s health is of high clinical and public health 
concern.  
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Tables & Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart survival analysis – the IeDEA West Africa collaboration 
Collaboration IeDEA West Africa Adult 
4th Merger. End date: 12/31/2011 
N= 59,093 
Pregnancies reported (14 clinics) 
N= 52,455 
 
Pregnancies not reported 
SMIT CHU Treichville 
N=6,638 
 
Male 
N= 18,393 
 
Female 
N= 34,141 
Age <50 
N= 31,513 
 
Age >50 at entry 
N= 2,549 
 
ART-naive women 
N= 29,451 
 
ART-pretreated women 
N= 2,062 
 
No follow-up visit 
N= 1,962 
 
Eligible women 
N= 27,489 
 
Clinical status documented 
N= 13,211 
 
No clinical status available 
N= 14,278 
 
Not pregnant at ART initiation 
N= 12,851 
 
Pregnant at ART initiation 
N= 360 
 
137 
 
 
 
 
g      y        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow chart linear mixed model – the IeDEA West Africa collaboration 
Collaboration IeDEA West Africa Adult 
N= 59,093 
4th Merger. End date: 12/31/2011 
Pregnancies reported (14 clinics) 
N= 52,455 
 
Pregnancies not reported 
SMIT CHU Treichville 
N=6,638 
 
Male 
N= 18,393 
 
Female 
N= 34,141 
Age <50 
N= 31,513 
 
Age >50 at entry 
N= 2,549 
 
ART-naive women 
N= 29,451 
 
ART-pretreated women 
N= 2,062 
 
No follow-up visit 
N= 1,962 
 At least 1 follow-up visit 
N= 27,489 
 
At least one CD4 cell count measure 
N= 25,195 
 
No CD4 cell count measure 
available 
N= 2,294 
 
Eligible women 
N= 20,408 
 
No CD4 cell count at ART 
initiation available 
N= 4,787 
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Table 1. Baseline characteristics of eligible women for survival analysis  (n=12,851). IeDEA West Africa 
Collaboration.   
 
Variables Pregnant 
women 
(n=1,102) 
Not pregnant 
women 
(n=11,749) 
Total 
(n=12,851) 
p-value 
Median age in years (IQR*) 29.5 (26.5;32.8) 33.4 (28.8;39.2) 32.9 (28.5;38.6) <0.0001** 
Median CD4 count in cells/µl (IQR) 199 (122;307) 189 (105;285) 190 (106;287) 0.0011** 
CD4 count in categories (%):    0.0116£ 
<50 cells/µl 78 (7.1) 1,003 (8.5) 1,081 (8.4)  
50-99 cells/µl 81 (7.4) 1,010 (8.6) 1,091 (8.5)  
100-199 cells/µl 263 (23.9) 2,574 (21.9) 2,837 (22.1)  
200-349 cells/µl 268 (24.3) 2,717 (23.1) 2,985 (23.2)  
>349 cells/µl 153 (13.9) 1,275 (10.9) 1,428 (11.1)  
Missing 259 (23.5) 3,170 (27.0) 3,429 (26.7)  
Median hemoglobin in g/dl (IQR) 10.5 (9.4;11.5) 10.5 (9.2;11.6) 10.5 (9.2;11.6) 0.2416** 
Hemoglobin in categories (%):    0.0046£ 
<7.5 g/dl 30 (2.7) 419 (3.6) 449 (3.5)  
7.5-10 g/dl 210 (19.1) 2,071 (17.6) 1,311 (10.2)  
10-12 g/dl 343 (31.1) 2,742 (23.3) 3,085 (24.0)  
≥12 g/dl 117 (10.6) 1,194 (10.2) 2,281 (17.8)  
Missing 402 (36.5) 5,323 (45.3) 5,725 (44.6)  
First ART regimen (%)    <0.0001£ 
2NRTIs†+nevirapine 910 (82.6) 8,241 (70.1) 9,151 (71.2)  
2NRTIs+efavirenz 101 (9.2) 2,477 (21.1) 2,578 (20.1)  
2NRTIs+PI‡ 61 (5.5) 726 (6.2) 787 (6.1)  
3NRTIs 13 (1.2) 170 (1.5) 183 (1.4)  
Others 17 (1.5) 135 (1.2) 152 (1.2)  
Deaths 5 years after ART (%) 16 (1.5) 273 (2.3) 289 (2.3) 0.0620£ 
*IQR: Interquartile Range 
† NRTI: Nucleoside Reverse Transcriptase Inhibitor 
‡ PI: Protease Inhibitor 
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Table 2. Effect of pregnancy (time dependent variable) on loss to follow-up, AIDS progression and    
death at 48 months after ART initiation, estimated by adjusted Cox regression model 
(N=12,851). IeDEA West Africa Collaboration.   
 Adjusted Hazard 
Ratio† 
95% CI p-value 
Model 1: Restricted risk period *    
AIDS or death 0.61 [0.40-0.92] 0.01 
Lost to follow-up 0.74 [0.60-0.92] 0.006 
Both 0.74 [0.61-0;90] 0.003 
      
Model 2: Unrestricted risk period **    
AIDS or death 0.63 [0.42-0.96] 0.03 
Lost to follow-up 0.73 [0.59-0.91] <0.001 
Both 0.70 [0.58-0.86] <0.001 
* Restricted risk period: risk period starts at pregnancy reporting date and goes until 15 months after 
pregnancy detection.  
** Unrestricted risk period: risk period starts at pregnancy reporting date and goes endpoint date 
(e.g. maximum 48 months after ART initiation). 
† Adjusted on CD4 count at baseline; age, Body Mass Index (BMI) and hemoglobin at ART initiation; 
initial ART regimen; calendar year of starting ART and country. 
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Table 3. Baseline characteristics of eligible women for linear mixed models for CD4 trayectory. IeDEA    
West Africa Collaboration (n=20,408) 
 
Variables Pregnant 
women 
(n=1,615) 
Not pregnant 
women 
(n=18,793) 
Total 
(n=20,408) 
p-value 
Median age in years (IQR*) 29.5 (26.3;32.7) 33.4 (28.8;39.4) 33.0 (28.5;38.8) <0.0001** 
Median CD4 count in cells/µl (IQR) 189 (105;282) 169 (82;264) 170 (84;266) <0.0001** 
CD4 count in categories (%):    <0.0001£ 
<50 cells/µl 186 (11.5) 3,082 (16.4) 3,268 (16.0)  
50-99 cells/µl 187 (11.6) 2,534 (13.5) 2,721 (13.3)  
100-199 cells/µl 495 (30.7) 5,491 (29.2) 5,986 (29.3)  
200-349 cells/µl 512 (31.7) 5,412 (28.8) 5,924 (29.0)  
>349 cells/µl 235 (14.6) 2,274 (12.1) 2,509 (12.3)  
Clinical stage (%):    <0.0001£ 
A,B/I,II 1,146 (71.0) 11,920 (63.4) 13,066 (64.0)  
C/III,IV 302 (18.7) 4,597 (24.5) 4,899 (24.0)  
missing 167 (10.3) 2,276 (12.1) 2,443 (12.0)  
Median hemoglobin in g/dl (IQR) 10.2 (9.0;11.4) 10.1 (8.8;11.3) 10.1 (8.9;11.3) 0.0073** 
Hemoglobin in categories (%):    0.0016£ 
<7.5 g/dl 85 (5.3) 1,281 (6.8) 1,366 (6.7)  
7.5-10 g/dl 477 (29.5) 5,453 (29.0) 5,930 (29.1)  
10-12 g/dl 583 (36.1) 5,724 (30.5) 6,307 (30.9)  
≥12 g/dl 191 (11.8) 2,107 (11.2) 2,298 (11.3)  
Missing 279 (17.3) 4,228 (22.5) 4,507 (22.1)  
First ART regimen (%)    <0.0001£ 
2NRTIs†+nevirapine 1,207 (74.7) 12,019 (64.0) 13,226 (64.8)  
2NRTIs+efavirenz 266 (16.5) 5,097 (27.1) 5,363 (26.3)  
2NRTIs+PI‡ 97 (6.0) 1,225 (6.5) 1,322 (6.5)  
3NRTIs 14 (0.9) 218 (1.2) 232 (1.1)  
Others 31 (1.9) 234 (1.3) 265 (1.3)  
Deaths 5 years after ART (%) 24 (1.5) 811 (4.3) 835 (4.1) <0.0001£ 
*IQR: Interquartile Range 
† NRTI: Nucleoside Reverse Transcriptase Inhibitor 
‡ PI: Protease Inhibitor 
£ Global P-value 
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Table 4. CD4 count cells gain in the first 24 months following antiretroviral therapy (ART) initiation 
estimated by adjusted* linear mixed models (n=20,408). IeDEA West Africa Collaboration 
 
 
Mean CD4 count slope 
between  ART initiation  
and M6 (cells/µl gained 
per month) 
Mean CD4 count slope 
between  M6 and M24 
(cells/µl gained per 
month) 
Mean CD4 count gain 
between ART initiation 
and M24 (cells/µl)* 
Variables 
Adjusted 
estimate** 
(95%CI) 
p-value 
Adjusted 
estimate** 
(95%CI) 
p-value 
Adjusted 
estimate** 
(95%CI) 
p-value 
No pregnancy +29.9 
(26.6;33.3) Ref +5.6 (2.5;8.7) Ref 
+280 
(227;333) Ref 
Pregnancy in the first 
6 months after ART 
initiation 
+35.5 
(31.6;39.4) <0.0001 +5.7 (2.5;8.8) 0.7839 
+315 
(260;370) <0.0001 
Pregnancy beyond 6 
months after ART 
initiation 
- - +5.7 (2.5;8.8) 0.7839 +281 (227;335) 0.7839 
* Linear mixed models adjusted for CD4 count at baseline; age, Body Mass Index (BMI) and 
hemoglobin at ART initiation; initial ART regimen; calendar year of starting ART and country.  
** For the reference group: baseline CD4 count <50 cells/µl, 16-24 years old women treated with 
nevirapine, starting ART in 2011, with BMI=18.5;25kg/m², baseline hemoglobin<7.5g/dl and 
followed-up in Côte d’Ivoire.  
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11. Final discussion 
The original research included within this doctoral research framework is probably among 
the firsts addressing the subject of reproductive health among HIV-infected women on 
antiretroviral treatment in West Africa under a multidisciplinary quantitative approach. 
Studying the subject of reproductive health among HIV-infected women on antiretroviral 
treatment under a psychosocial, epidemiologic and clinical approach, is an important 
strength of the present doctoral research framework.  
Moreover, as the vast majority of similar existing scientific evidence on reproductive health 
of HIV-infected women on antiretroviral treatment belongs mostly to East and Southern 
Africa, the present original scientific research fulfills important scientific knowledge gaps 
about this subject in the West African region. It is worth to note that during my literature 
search it seemed to me that the existing epidemiologic information of the West-African’s 
HIV epidemic is somewhat dearth. Anyhow, even if available epidemiologic information 
suggests that the West African HIV epidemic presents a less aggressive profile compared to 
other sub-Saharan Africa regions hosting epidemics of greater magnitude, it followed the 
same gender trend. Similarly to other sub-Saharan Africa regions, in West Africa, women and 
girls hold the higher HIV epidemic burden. 
In addition, and concerning more specifically the different approaches I found several 
strengths. Although intimate partner physical and sexual violence is considered a 
psychosocial phenomenon associated to important negative health outcomes for HIV-
infected women, it has been scarcely studied in West Africa. The study aiming at estimating 
the prevalence rate of intimate partner physical and sexual violence among HIV-infected 
women in clinical care and its associated factors in Togo, presented within this doctoral 
research framework is amongst the first conducted in the region. 
The findings of this study showed that the prevalence rate of intimate partner physical and 
sexual violence was globally high but it was strikingly higher among HIV-infected Togolese 
compared to their uninfected peers. According to our findings for example almost seven out 
of ten of the HIV-infected Togolese women of our sample were victim of sexual violence 
perpetrated by her intimate partner. Moreover, our findings showed as well that intimate 
partner violence has important negative physical consequences for this population. 
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Concerning the epidemiologic approach, the literature review I conducted suggests that 
pregnancy is not an uncommon event among HIV-infected women on antiretroviral 
treatment in sub-Saharan Africa and, probably having important repercussions on HIV-
infected women health. Estimations of the incidence rate of pregnancy following the 
initiation of antiretroviral treatment have been produced by almost every region in sub-
Saharan Africa as it is considered an important public health indicator. In West Africa the 
incidence rate of pregnancy among HIV-infected women on antiretroviral treatment have 
been scarcely documented.  
The second study presented within this doctoral framework is probably the larger aiming at 
estimating the incidence rate of pregnancy following the initiation of antiretroviral 
treatment in West Africa. According to our findings, the crude global incidence rate of 
pregnancy among HIV-infected women on antiretroviral treatment is of 2.96 pregnancies per 
100 women-years (95%CI: 2.85 - 3.08), increasing proportionally to time on clinical follow-
up. Although these estimations are probably lower than those reported by other sub-
Saharan African regions, it remains consistent with their epidemiological trend.  
Finally, under a more clinical perspective, I aimed at estimating the pregnancy-related risk of 
death, HIV-disease progression and loss to follow-up among HIV-infected women on 
antiretroviral treatment. In sub-Saharan Africa, this particular risk has been estimated within 
Eastern and Southern African clinical cohorts of HIV-infected women. To my knowledge this 
is the first study aiming at estimating these outcomes within a large observational cohort of 
HIV-infected west-African women. 
According to our findings, for HIV-infected women, becoming pregnant after starting 
antiretroviral treatment is not associated with a risk of death or HIV-disease progression. 
Moreover, our findings point out as well that pregnancy after antiretroviral treatment 
initiation is associated with a lower risk of loss to follow-up. These findings appeared to be 
consistent with findings of a similar study conducted in South Africa(242). However, recent 
findings from a study conducted in Uganda suggest an association in the opposite direction 
(248). Anyhow, as pregnancy has been associated with impaired virological outcomes among 
HIV-infected women on treatment(242) and recent research point out HIV-infection as one 
major indirect cause of maternal death(24), more research is needed to clarify if whether or 
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not pregnancy is associated with a higher risk of death among HIV-infected women on 
antiretroviral treatment. 
It is noteworthy that, an important additional strength of the studies presented within this 
research framework is possibility of exploiting a large regional database. IeDEA West Africa 
observational database encompass sociodemographic and clinical information of a large 
number of HIV-infected patients on clinical follow-up over a long period of time across nine 
West African countries.  
However, it is important to underscore that even if IeDEA West Africa data base contains a 
huge amount of clinical information of people living with HIV/AIDS on antiretroviral 
treatment, these data should maybe be considered of moderate quality. The important 
number of missing data within this data base limits the analysis, interpretation and 
extrapolation of findings. Moreover, reproductive health outcomes of HIV-infected women 
are poorly documented within IeDEA West Africa datasets. Pregnancy is not systematically 
cataloged within datasets and when cataloged not fully documented. Finally, as IeDEA West 
Africa observational cohort is more interested in epidemiologic and clinical outcomes, 
psychosocial data is unavailable.  
On the other hand and more related to the major scientific conceptual frameworks several 
methodological limitations must be disclosed. Although the literature review of the subject 
was not conducted under a strictly rigorous systematic methodology, I believe that within 
this research framework I included a large sample of the most recent, sounding and solid 
scientific evidence on reproductive health and HIV infection in sub-Saharan Africa. 
Moreover, in order to enrich the view point of my research, in some cases I expanded my 
search to research studies conducted in industrialized settings. However, I recognize that 
owed to this methodological limit, I could have missed probably important and sounding 
scientific evidence not cited within the present scientific framework. 
It is worth to note as well that, besides the scientific literature reviewed, I reviewed and 
included within the present document an important amount of global political statements, 
strategic frameworks and global action plans which served to frame my research, adding 
consistency to current global health priorities. 
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Finally, I believe that the research conducted within this doctoral framework is consistent 
with the current knowledge needs set out by the global action plans aiming at  putting an 
end to HIV pandemic, particularly those of the global plan of Elimination of New HIV 
Pediatric Infections and Keeping the Mothers Alive released by UNAIDS in 2011. This 
consistency with larger global framework, I believe add a special value to the present 
research and probably makes of its findings key public health inputs for the West African 
region. 
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12. Final Conclusion 
During last decade, paramount goals have been achieved worldwide in terms of rolling back 
HIV epidemic. However, I believe that HIV epidemic among women has not been probably 
correctly addressed and the magnitude of the epidemic among this population was maybe 
underestimated. The first global action plans lacked probably of more solid, clear and 
objective gender-based strategies and intervention addressing HIV epidemic among women 
and girls. This was probably a reason explaining why it took so long to detect the rapid 
spread of HIV epidemic among women. 
Women and girls are at the crossroads of HIV transmission pathways, more vulnerable to 
acquire HIV infection through sexual intercourses and to transmit the virus to their children 
through vertical mechanism during pregnancy and/or postpartum. I believe that this 
particular situation justify the need of more specific public health strategies to prevent the 
spread of HIV infection among this population. I believe that the design and implementation 
of women-specific preventive and care strategies might be indeed one important step 
towards the end of HIV epidemic. 
I believe that the higher vulnerability of women to acquire HIV infection is owed to a 
combination of women-specific biological factors and context-dependent psychosocial 
factors, interwoven within a dynamic association that needs to be tackled at a structural, 
societal and individual level. In order to effectively reduce the high epidemic burden of HIV 
among women, more women-specific preventive interventions addressed at each one of 
these levels are urgently needed.    
The outstanding improvement of health status and life expectancy owed to antiretroviral 
treatment more HIV-infected women chose to child bear. This is corroborated by the 
persistent desire of procreation expressed by HIV-infected women and the growing 
incidence rates of pregnancy estimated following the initiation of antiretroviral treatment. In 
addition, although HIV-infection has been pointed out as a major cause of maternal death, 
the pregnancy-related health risks among HIV-infected women are not fully elucidated yet. 
I believe that an HIV positive diagnosis is not anymore a contraindication to procreate. 
However, more scientific evidence is needed to correctly help women living with HIV/AIDS to 
fulfill their reproductive needs, reducing the associated health risks this could take with for 
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themselves and their families. Further research must provide with sounding knowledge to 
design and implement effective motherhood programs for HIV-infected women. These safe 
motherhood programs should be able to provide assistance on how to prepare the future 
reproductive program of HIV-infected women desiring to child bear, reducing the risk of 
sexual transmission; how manage correctly a HIV-positive pregnancy and its associated risks, 
not only the risk of transmission but the health risks for women themselves. I believe this is 
one important public health challenge the global community will have to face in a near 
future.  
13. Perspectives 
As since the advent of antiretroviral treatment HIV is considered more as chronic 
manageable disease and pregnancy is not an uncommon event among HIV-infected women 
on antiretroviral treatment. I believe that there are still important scientific gaps to fully 
understand the repercussions of pregnancy on health status of HIV-infected women 
therefore further research on these concerns are of major public health interest. 
The fulfilment of these gaps will allow HIV-care programs to correctly address reproductive 
needs of people living with HIV/AIDS, reduce the potential pregnancy-related risks for HIV-
infected women and help HIV-infected individuals desiring to procreate complete their 
reproductive program reducing the potential associated risks. 
Following this thesis of science and in line with my previous work, I expect joining the WADA 
Women & Mothers initiative, which is a research initiative nested in IeDEA West Africa 
Observational Cohort. The aim of this initiative is to study the epidemiologic, clinical and 
psychosocial aspects associated with reproductive health of HIV-infected women on 
antiretroviral treatment in West Africa.  
The research program of this initiative is based on two principal objectives. The first 
objective is to study the relationship between pregnancies following ART initiation and the 
health outcomes of HIV-infected women of reproductive age through a multicountry 
retrospective approach. The second objective is to evaluate the sexual and reproductive 
health indicators of HIV-infected women on antiretroviral treatment through the design and 
implementation of a prospective observational cohort (Annex 1).  
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I believe that the scientific knowledge this initiative will provide will be a key public health 
input to guide the effective integration of reproductive health services into HIV care services 
in sub-Saharan Africa.  Moreover, I expect as well that this further research will contribute to 
constitute the foundation of safe motherhood programs for HIV-infected women desiring to 
child bear as a part of future scale up of HIV comprehensive care services. 
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1. Scientific background 
 
An estimated 287,000 maternal deaths occurred in 2010 worldwide and 56% of these deaths 
accounted for sub-Saharan Africa 1. Moreover, HIV infection is highly prevalent in sub-Saharan Africa, 
mostly among women in reproductive age. Hence, sub-Saharan Africa is the region with the largest 
proportion of maternal deaths attributed to HIV infection with 91% of all AIDS-related indirect 
maternal deaths worldwide occurring in this region, placing HIV-infected pregnant and postpartum 
women at a risk eight times higher of pregnancy-related death compared to their uninfected 
counterparts 1-3. AIDS-related maternal mortality is therefore a major public health concern in sub-
Saharan Africa, hindering the achievement of the Millennium Development Goal 4 and 5 by 2015 1, 4, 
5. 
 
Over the last ten years, the generalization of ART implementation has favored a striking 
improvement of health status among HIV-infected individuals in this region. This outstanding fact, 
has progressively led to the awakening of childbearing will among HIV-affected couple, increasing 
procreation desires. Pregnancy after ART initiation is therefore becoming a more and more common 
event 6-8. Indeed, several studies have showed that the incidence of pregnancy after ART initiation 
increases proportionally to years on ART 6, 9, 10.  
 
However, HIV-infected pregnant or postpartum women have a higher risk of pregnancy 
complications than their uninfected counterparts, such as preeclampsia which is one of the leading 
direct causes of maternal and fetal deaths 11, 12. Moreover, HIV-infected pregnant women are 
particularly more vulnerable to several highly deathful AIDS-related co-morbidities such as bacterial 
pneumonias, bacterial sepsis and cryptococal meningitis 13. The risk of developing active tuberculosis, 
which is the foremost cause of death among HIV-infected individuals, is around ten times higher 
among HIV-infected pregnant women than among the HIV-uninfected ones 4. In addition, there is a 
growing body of evidence that pregnancy after ART initiation has a deleterious impact on maternal 
immunological response. It has been recently shown in South Africa that pregnancy was associated 
with a hazard ratio of 1.34 (95% CI 1.02, 1.78), and an estimated absolute 6% increase in virologic 
failure by five years of follow-up 14.  
 
Such findings suggest detrimental repercussions of pregnancy on HIV-infected women’s health, but 
they are not entirely conclusive. One major limitation of these findings is that they are mostly based 
on retrospective datasets and/or inadequately powered population samples limiting interpretation. 
In addition, an important number of pregnancies may go undetected mostly due to unreported 
miscarriages and abortions, underestimating the real incidence of pregnancy  among HIV-infected 
African women 2, 15, 16. Similarly, the estimation of the “real” fraction of HIV attributable to maternal 
deaths is limited by the ineffective linkage between HIV and maternal care services and the 
subsequent high proportion of loss to follow-up women 2, 16-18.  
 
For the first time, the current global strategy to eliminate HIV mother-to-child transmission (eMTCT) 
addresses punctually the reduction of maternal mortality as major goal 5. Past strategies to prevent 
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HIV transmission from mothers to children focused principally on child health outcomes while HIV is 
a leading cause of maternal mortality in high prevalence settings. This is an unprecedented 
opportunity to create safer motherhood programs for HIV-infected women, aimed at keeping them 
healthy and alive while assuring a new HIV-free generation. Thus definitely, more research is now 
urgently needed to precisely estimate key strategic indicators on maternal health that will help 
defining safe motherhood public health policies. This is especially true in west-Africa where both 
pregnancy incidence and health outcomes among HIV-infected women and mothers are scarcely 
described. Such crucial information will undoubtedly contribute to the scale-up of eMTCT global 
plans and to the successful achievement of its main goals within this region. 
 
2. Objectives 
 
We propose the creation of the WADA Women & Mothers cohort nested within the IeDEA west-
Africa collaboration aimed at answering to the following objectives among HIV-infected women in 
reproductive age after ART initiation: 
 Investigate fertility intentions and identify predicting factors; 
 Estimate the incidence and associated factors of pregnancy; 
 Estimate the incidence and associated factors of pregnancy complications; 
 Investigate the evolution of the immunological response according to incident pregnancies; 
 Investigate the association of incident pregnancies with adverse health outcomes: loss to 
follow-up, AIDS disease progression and maternal mortality.  
 
3. Methodology: Study population, study sites and main outcome measures 
 
Besides standard clinical care data collected within the IeDEA West Africa collaboration, the WADA 
Women & Mothers cohort will prospectively and systematically collect standardized information on 
women reproductive health and maternal health issues, primarily based on the main outcome 
measures detailed below. At this stage, it is not possible to adequately answer to the objectives of 
this proposal using the data routinely collected. We have indeed analyzed in 2013 the data available 
to estimate pregnancy incidence and understand the association of pregnancy with health outcomes 
among IeDEA West Africa HIV-infected women (Burgos-Soto et al. Personal communication 
submitted to CROI 2014, Sept. 2013). These analyses showed a wide variability of pregnancy 
reporting procedures according to sites leading to underreported and biased estimates. Moreover, 
key variables like for instance gestational age or pregnancy complications were not collected.  
 
a. Study population 
 
We will constitute a prospective cohort based on both women already in care and women initiating 
ART:  
• All existing HIV-infected women in reproductive age (<49 years) and having initiated ART 
over the previous two years at the selected clinical sites will be systematically included; 
• All pregnant and non-pregnant women newly diagnosed with HIV infection within the 
selected IeDEA clinical sites and initiating ART (for their own health or as part of a universal 
ART strategy to prevent mother-to-child transmission of HIV) will be systematically included.  
 
b. Study sites 
 
The WADA Women & Mothers cohort will be progressively implemented at five clinical sites of the 
IeDEA West-Africa collaboration: Ivory Coast (3 clinical sites), Burkina Faso (1 clinical site) and Togo (1 
clinical site). Recruitment will take place in two distinct phases over the years 2014 and 2015. 
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First, recruitment will start in Côte d’Ivoire between January and December 2014. Our choice was 
based on the fact that Cote d’Ivoire is the country accounting for the largest population of women on 
ART and the setting with the most developed structural capacity in terms of clinical management and 
research within the IeDEA West-Africa Consortium. The WADA Women & Mothers cohort will be 
implemented at three clinical sites in the three mostly densely populated districts of Abidjan: the 
CNTS clinical site in Treichville district, the CEPREF clinical site in the Yopougon district and the 
Avocatier clinical site in the Abobo district. On the basis of previous estimations of annual 
recruitment capacities in 2011 and 2012 of the selected clinical sites in Cote d’Ivoire, expected cohort 
size for its first year is presented in Table 1. 
 
Table 1.  Estimated size of the WADA Women & Mothers cohort at the end of 2014.  
 
  
Women initiating ART 
in 2012-2013 
Women initiating ART in 
2014 
Total cohort size at 
the end of 2014 
Côte d’Ivoire - CNTS 286 143 429 
Côte d’Ivoire - Cepref 402 201 603 
Côte d’Ivoire - Avocatier 156 78 234 
Total in Côte d’Ivoire 844 422 1,266 
 
Second, recruitment will continue in Côte d’Ivoire and start in Burkina Faso and Togo between 
January and December 2015. The WADA Women & Mothers cohort will be progressively 
implemented at two additional clinical sites in rural Burkina Faso (CHU Souro Sanou in Bobo 
Dioulasso) and urban Togo (CHU Olympo).  On the basis of previous estimations of annual 
recruitment capacities in 2011 and 2012 of the selected clinical sites in Cote d’Ivoire, Burkina Faso 
and Togo, expected cohort size at the end of its second year is presented in Table 2. 
 
Table 2.  Estimated size of the WADA Women & Mothers cohort at the end of 2015.  
 
  
Women initiating ART 
in 2013-2014 
Women initiating ART 
in 2015 
Total cohort size at 
the end of 2015 
Cote d'Ivoire (3 sites)   1,266 * 422 1,688 
Burkina Faso (1 site) 640 320 960 
Togo (1 site) 1,048 524 1,572 
Total in the 3 countries 2,954 1,266 4,220 
 
* Women initiating ART in 2012-2014 for Côte d’Ivoire where recruitment will start one year earlier. 
 
 
c. Main outcome measures 
 
Fertility intentions (objective #1) 
 
At the time of enrolment, all women will be asked to fulfill a quantitative survey addressing issues 
related to fertility intentions, unplanned pregnancies and lifetime and current use of contraception 
methods. An adapted version of the London Measure of Unplanned Pregnancies 19 will be used to 
assess fertility intentions. This will be completed with qualitative interviews and focus-group 
discussions on this topic. Moreover, additional socio-demographic, economic, anthropometric 
(height and weight), family-related and women empowerment characteristics of participating 
women will be systematically collected in order to complete women’s profile characteristics. Family 
planning counseling will be proposed systematically to all women willing to prevent, stop or space 
pregnancies and appropriate methods will be proposed according to their will.  
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Incidence of pregnancy (objective #2) 
 
Incident pregnancies will be detected according to the two following methods: 
1. The usual women self-report of pregnancy during clinical follow-up. Every self-report will be 
confirmed by a urinary or a blood pregnancy test (depending on whether a laboratory 
assessment was planned for this visit).  
2. An anonymous uncorrelated pregnancy urine test will be performed on a 3-monthly basis to 
every included woman. Urine samples collected to monitor clinical outcomes will be used. 
Certain non-identifying information will be extracted from the patient's clinical record onto a 
study form and anonymously linked to each woman. This strategy will produce gold-standard 
pregnancy incidence values for each study site. This will then enable us to estimate to what 
extent the usual detection method underestimates the actual pregnancy incidence.  
Gestational age at pregnancy detection will be systematically assessed on the basis of dates of last 
menstrual period and/or symphysis-fundal palpation and confirmed through ultrasound 
 
Incidence of pregnancy complications (objective #3) 
 
A control group of women from the general population (e.g. mostly HIV-uninfected given the 
relatively low prevalence in these countries) will be recruited within maternity wards in each of the 
three countries to describe epidemiological trends and clinical profile of pregnancy and postpartum 
complications. For this purpose, every woman from the control group will be matched by age and 
gestational age to each newly pregnant HIV-infected women of the WADA Women & Mothers 
cohort. 
 
Ultrasound monitoring will be systematically offered for each reported pregnancy to detect 
anatomical and/or physiological abnormalities of the fetus, placenta, uterus or amniotic sac. 
Maternal pregnancy complications will be detected through a complete pregnancy evaluation at 
each antenatal visit and through blood and urine tests systematically performed as soon as the 
pregnancy is diagnosed, just before delivery and during the early postpartum period.  
 
Hemorrhage is the leading cause of maternal death in developing world and number one in sub-
Saharan Africa, accounting for one third of all causes of maternal deaths in this region 17. The etiology 
of maternal bleeding is multifactorial and associated causes will depend on the gestational period as 
shown in the Annex (Figure 1). 
 
All women recruited in the WADA Women & Mothers cohort presenting hemorrhage during 
gestational period are going to be evaluated and treated according to the type of bleeding. Medical 
staff will report a detailed diagnosis of bleeding and final outcome after management. Severity of 
bleeding and associated signs and symptoms will be described for each case.  
 
Hypertensive disorders during pregnancy are the second most important contributor to maternal 
mortality in developing countries, accounting for roughly 9% of all causes of maternal death in sub-
Saharan Africa 17. Amongst all hypertensive disorders associated to pregnancy, pre-eclampsia is one 
of the deadliest and HIV-infected women on ART are at higher risk to develop this syndrome. Pre-
eclampsia is a syndrome characterized by hypertension and renal function impairment 20. The signs 
and symptoms characteristics of pre-eclampsia and eclampsia are detailed in the Annex (Figure 2). 
 
Blood pressure will be systematically monitored and documented at every antenatal care visit for all 
women becoming pregnant during the course of the study. In order to detect the renal function 
impairment, urine samples will be collected and analyzed (proteinuria and creatinine excretion)at 
every antenatal visit, during labor and postpartum visits to complete pre-eclampsia screening. 
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Immunological response and incidence of adverse health outcomes (objectives #3 & 4)   
 
HIV-specific clinical and biological information will be exhaustively collected. CD4 cell 
counts/percentage (and viral load if available) will be performed following national clinical care 
protocols. All AIDS-defining events will be systematically reported by midwives at every routine 
clinical visit. Finally all reported deaths will be verified by midwives, emphasis will be placed to 
precisely collect the date and circumstances of death through family interviews. An autopsy will be 
systematically offered to the family of every woman deceasing during the course of the study. Causes 
of death will primarily rely on this autopsy, or if not performed, on the usual information available.  
 
3. Cohort organization 
 
In order to coordinate logistic aspects, data collection and context-related methodological issues of 
cohort management, a team of local midwives will be recruited. Owing a vast useful knowledge of 
local motherhood programs, midwives are key clinical care personnel to participate in the conceptual 
design of data collection tool adapted to local context specificities and to facilitate the articulation of 
such a cohort with local maternal health services. One midwife per site will be needed. Additionally, 
a senior research nurse will be recruited to act as the field project coordinator to ensure 
standardization of procedures across sites and to be in charge of data quality management. A local 
data-manager/web-developer will be recruited to create and manage on a day-to-day basis the new 
data-base specifically dedicated to this cohort. He will also be in charge of progressively 
implementing a web-based data-collection system for this cohort. Finally, consultancies of 
gynecologists (for objective #3) and of a social scientist (for objective #1) will also be needed.  
 
Cohort team: 
 
Principal investigators 
Renaud BECQUET, Inserm U897, Bordeaux, France 
Albert MINGA, CNTS, Abidjan, Côte d’Ivoire 
 
Project Leader 
Juan BURGOS-SOTO, Inserm U897, Bordeaux, France 
 
Field project coordinator 
Angèle YAHO, PAC-CI program, Abidjan, Cote d’Ivoire 
 
Consultants 
Patricia DUMAZERT (social scientist), Inserm U897, Bordeaux, France 
Apollinaire HORO (gynecologist), CHU de Yopougon, Abidjan, Côte d’Ivoire 
To be identified (gynecologist), CHU de Souro Sano, Bobo Dioulasso, Burkina Faso 
To be identified (gynecologist), CHU Olympo, Lomé, Togo 
 
Associated investigators 
Patrick COFFIE, PAC-CI program, Abidjan, Cote d’Ivoire 
Eugène MESSOU, CEPREF, Abidjan, Côte d’Ivoire 
Clarisse AMANI-BOSSE, Abidjan, Côte d’Ivoire 
Didier EKOUEVI, Faculté de médecine, Lomé, Togo 
Adrien SAWADOGO, CHU de Souro Sano, Bobo Dioulasso, Burkina Faso 
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4. Expected results 
 
With the creation of this women-centered prospective cohort on reproductive health issues, we 
expect to estimate more precise, bias-less and standardized through sites incidence rate of 
pregnancy among HIV-infected women in the west-African context. Additionally, identifying region-
specific predictors of pregnancy, estimated through reliable methods, will guide political decisions 
within the west-African region.  
 
Furthermore, on the basis of a prospective follow-up method, we expect to better understand the 
repercussions of pregnancy on the evolution of immune-virological response among HIV-infected 
women on ART. We believe that measuring the impact of pregnancy on AIDS disease progression and 
mortality among HIV-infected women on ART is definitely a major public health priority that is to 
date not clearly elucidated and scarcely documented within the west-African region. Such an 
approach also coincides with eMTCT global plan goals. 
 
Moreover, although HIV infection is currently considered one major cause of maternal death in sub-
Saharan Africa, more research is needed to understand its role as a direct and indirect cause of 
maternal death. We expect our results shed more light on this fact, fully describing the 
epidemiological profile of maternal deaths occurring in this west-African cohort. 
 
Finally, assessing fertility intentions will indubitably become a key input to better address family 
planning needs among HIV-infected women in reproductive age in West-African region. In this 
context, the WADA Women & Mothers cohort is tailored to enlarging safety motherhood programs 
for HIV-infected women upon the West-African region  
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Annex 
 
Figure 1.  Principal causes of hemorrhage according to gestational period [IMPAC] 20.  
 
Early pregnancy Hemorrhage Antepartum Hemorrhage postpartum Hemorrhage 
• Threatened abortion 
• Ectopic pregnancy 
• Complete abortion 
• Inevitable abortion 
• Incomplete abortion 
• Molar pregnancy 
• Abruptio placentae 
• Ruptured uterus 
• Placenta praevia 
• Atonic uterus 
• Tears of cervix, vagina or 
perineum 
• Retained placenta 
• Retained placental fragments 
• Inverted uterus 
• Delayed PPH 
• Ruptured uterus 
 
 
Figure 2.  Signs and symptoms of pre-eclampsia and eclampsia according to severity (IMPAC) 20. 
 
 
Mild pre-eclampsia 
 
Severe pre-eclampsia 
 
Eclampsia 
• Two readings of diastolic blood 
pressure 90–110 mm Hg 4 hours 
apart after 20th week Gestation 
• Proteinuria up to 2+ 
 
• Diastolic blood pressure 110 
mmHg or more after 20th week 
gestation 
• Proteinuria 3+ or more 
• Headache (increasing frequency, 
unrelieved by regular analgesics) 
• Blurred vision 
• Oliguria (passing less than 400 
mL urine in 24 hours) 
• Upper abdominal pain (epigastric 
pain or pain in right upper 
quadrant) 
• Pulmonary edema 
 
• Convulsions  
• Diastolic blood pressure 
90mmHg or more after 20th week 
gestation 
• Proteinuria 2+ or more 
• Coma (unconscious) 
• Other symptoms and signs of 
severe pre-eclampsia 
 
 
 
 
